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ABSTRACT 
In disease and senescence, the balance between cells and the 
surrounding interstitium is altered. Cell injury and inflammation induce 
fibrosis, with collagen deposition leading to expansion of the interstitium. 
When diffuse, this expansion can affect the structure and function of the 
whole organ. Examples of diffuse fibrosis include liver cirrhosis and 
myocardial fibrosis, which are becoming more prevalent as the population 
ages. Traditional assessment of such diseases involves invasive biopsy, 
but for many tissues, biopsy is poorly tolerated and carries a significant 
complication risk. 
Recently our group has developed a new technique (equilibrium imaging) 
that utilises the extracellular contrast agents employed widely in MRI and 
CT to quantify tissue fractional extracellular volume (ECV). Early work 
demonstrated a significant elevation in myocardial ECV in hypertrophic 
cardiomyopathy and aortic stenosis. Equilibrium contrast imaging 
potentially offers a powerful new non-invasive tissue biomarker for 
‘extracellular disease’, and promises new insights into the biology of these 
conditions. 
In this thesis I develop the equilibrium imaging technique, beginning with 
an evaluation of the basic principles of extracellular volume estimation by 
EQ-MRI - using a 3-dimensional engineered tissue model. I show an 
association between ECV quantified during construction of six engineered 
models with ECV measured using EQ-MRI (R2=0.77, p=0.02). I then 
explore the use of equilibrium imaging in quantifying two disease 
processes that alter the extracellular volume – diffuse fibrosis and 
amyloidosis. EQ-MRI is used in systemic amyloidosis to demonstrate 
significant elevation in ECV within the liver (0.32) and spleen (0.39) 
compared with healthy volunteers (p<0.01). I then translate the basic EQ 
method to a new modality – computed tomography, a potentially simpler  
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and more widely available imaging platform. EQ-CT is used to show an 
association between ECV and a histological comparator in cardiac valve 
disease (r=0.71); and in liver cirrhosis (r=0.64). EQ-MRI is also used as a 
reference test to investigate diffuse 99mTc-DPD skeletal muscle uptake in 
systemic ATTR amyloidosis. Using a novel scoring system to quantify 
uptake, I show that skeletal muscle ECV increases with 99mTc-DPD soft 
tissue score (R2=0.34) - suggesting that skeletal muscle is a significant 
target organ for amyloid deposition. 
Technical development of the CT technique required the optimisation of 
image acquisition and processing for quantitative attenuation 
measurement within tissues, and advancement of the contrast protocol to 
allow rapid ECV estimation using a bolus only dynamic equilibrium 
technique.  
In summary, this research thesis presents methological development and 
validation of EQ imaging for tissue extracellular volume fraction 
quantification. 
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1 INTRODUCTION 
1.1 Thesis Overview 
As complex multicellular organisms, humans are composed of a host of 
metabolically active cells, supported within a protein framework. In health, 
this structure provides the medium through which cells exchange 
components necessary for intra cellular metabolism, allowing them to 
contribute physically and metabolically to the function of their constituent 
tissue. 
In disease and senescence, the delicate relationship between cells and 
their surrounding framework can be disrupted. Cell injury and inflammation 
leads to fibrosis with expansion of the interstitium and reduction in 
cellularity. This fibrosis can occur focally leading to ‘scar’ or diffusely 
affecting whole organs. Familiar examples of diffuse fibrosis that ultimately 
lead to organ failure include pulmonary fibrosis and liver cirrhosis. 
As we better understand the role the interstitium plays in disease, it is 
clear that diffuse interstitial dysfunction frequently plays a more significant 
and previously unrecognised role in disease. In the heart, pathologists 
already identify disease states such as ‘idiopathic myocardial fibrosis’ that 
are virtually unrecognised clinically.   Yet in the heart, diffuse fibrosis is 
very likely to play as significant a role as in other organs such as the liver, 
and may be associated with adverse outcomes including heart failure, 
arrhythmia and death. 
One of the principle reasons for our limited understanding of the 
importance of interstitial disease has been an inability to reliably and 
accurately interrogate the interstitium. The current reference standard of 
invasive tissue biopsy is limited by its technical difficulty, complication rate, 
and sampling error. This has led to the development of a number of non-
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invasive tests, including serum biomarkers and tissue elastography, 
although these are frequently organ specific or suffer from similar sampling 
error. 
Recently, equilibrium contrast imaging has been developed to non-
invasively quantify diffuse interstitial expansion in a range of organs. This 
technique potentially offers a new tissue biomarker for ‘extracellular 
disease’, and promises new insights into the biology of these conditions. 
This thesis broadly aims to develop the equilibrium imaging technique into 
a robust and validated clinical test that can be used to quantify 
extracellular volume (ECV) in a range of tissues and diseases.  
The manuscript comprises 13 chapters, with experimental chapters 
summarised below. Unless otherwise stated, all work is that of the author. 
Peer-reviewed publications related to each chapter are summarised in 
Appendix 1. 
Chapter 1 provides a background to the thesis and starts by exploring 
current understanding of the structure and function of the interstitial space, 
and the specific proteins and other elements that occupy its volume.  
Pathological process which lead to expansion of the extracellular volume 
are then described with specific reference to diffuse fibrosis within the 
heart and liver; and systemic amyloidosis.  Section (ii) describes existing 
techniques used to assess the extracellular volume and extracellular 
expansion in disease – laying out the justification for development of new 
methods. Section (iii) then gives a background of the contrast techniques 
that led to the first use of equilibrium contrast imaging to quantify the 
extracellular volume, followed by a more detailed description of the 
underlying theory. 
In chapter 2 the overall research hypothesis is set out, with the specific 
aims and objectives to be addressed with the subsequent chapters.   
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Chapter 3 provides a technical description of methods utilised in the 
development of EQ imaging, including comparative biomarkers, imaging 
technologies, data processing and statistical methods. 
In Chapter 4 the basic principle of extracellular volume measurement by 
equilibrium imaging are tested using EQ-MRI and an engineered 3 
dimensional tissue model.   
In Chapter 5 the equilibrium cardiac MRI methodology developed by 
colleagues at UCLH and the Institute of Cardiovascular Science is applied 
to the liver and spleen of patients with systemic Amyloidosis to assess 
disease burden. Measurements are validated by comparison with the 
current reference standard of Serum Amyloid P component scintigraphy.  
Chapter 6 describes the translation of the equilibrium imaging technique 
from MRI to a computed tomography imaging platform, with development 
of an iodinated contrast equilibrium protocol. The contrast protocol is 
verified by CT in a group of healthy volunteers and CT based myocardial 
ECV measurement validated by comparison with MRI in a group of 
patients with aortic stenosis. 
In chapter 7 use of the technique is extended by application to 
measurement of diffuse fibrosis within the liver. Patients with viral hepatitis 
and a range of parenchymal disease severity - from no fibrosis to cirrhosis 
- are evaluated with equilibrium CT and comparison is made with the 
reference histological standard and an existing plasma biomarker panel.  
Development of equilibrium contrast CT is extended further in chapters 8 
and 9 with evaluation of the artefacts behind error in tissue attenuation 
measurement, and optimisation of the iodinated contrast protocol to refine 
the technique into a practical and clinically applicable test.  
Finally, in chapter 10 equilibrium MRI is used to investigate skeletal 
muscle amyloid deposition in systemic Amyloidosis, and to corroborate 
soft tissue uptake seen on DPD scintigraphy.  
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1.2 Ethical Approval 
At the outset of this project I made an application to the London Queens 
Square Research Ethics Committee and was granted approval (Ref: 
09/H0716/75) for the experiments described. Major amendments were 
made to allow recruitment of additional patients with aortic stenosis 
undergoing surgery; to perform scans at a second centre and thirdly to 
recruit an additional cohort of patients with systemic amyloidosis. I made a 
final forth major amendment in May 2015 to allow a reduction in the renal 
function threshold for recruitment exclusion – mirroring clinical 
departmental and Royal College of Radiologist’ policy. 
Ethical approval for equilibrium MRI (EQ-MRI) in aortic stenosis and 
amyloidosis was obtained from the UCL/UCLH research ethics committee 
by Dr. Andrew Flett (Ref: 07/H0715/101) with a substantial amendment by 
Dr. Daniel Sado to allow collection of EQ-MRI data in a group of healthy 
volunteers (n=100). 
1.3 Background 
1.3.1 Composition, structure and function of the interstitium 
The vertebrate extracellular space is filled with an intricate network of 
macromolecules. This extracellular matrix (ECM) was once considered an 
inert structural scaffold, simply providing mechanical support for the cells 
within a tissue. Many decades later we appreciate the ECM as a complex 
dynamic structure, playing a central role in modulating biochemical and 
biomechanical cues that are a crucial part of tissue morphogenesis, 
differentiation and homeostasis. This importance is highlighted by the 
range of conditions arising from monogenic disorders of ECM 
components, which include osteogenesis imperfect, Ehlers-Danlos and 
Marfan’s syndrome (1). 
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Although essentially composed of water, polysaccharides and proteins, 
the extracellular matrix within each tissue has a unique composition and 
topology, adapted to the functional requirements of the particular tissue. 
The matrix can become calcified, forming the rock like structure of bone 
and teeth, can have large amounts of linearly arranged fibrous elements 
with enormous tensile strength as seen in tendons, and can form the 
transparent matrix of the cornea. However this phenotype is not static. A 
constant interplay between the matrix and cells allows dynamic 
remodelling of the ECM, and alteration of tissue properties and function in 
response to physiological and pathological cues. This is mediated by a 
number of mechanism including chemical signalling, transmembrane 
mechanical coupling and cell surface receptors (2). 
The ECM is generally composed of two main classes of macromolecules. 
The insoluble fibrous proteins, which provide the structural elements are 
the collagens, elastins, fibronectins and laminins. The second group, 
soluble proteoglycans (PG) make up the ground substance; a hydrated 
gel, which occupies the majority of the extracellular volume. 
I will consider some of these major components in detail before discussing 
their role in extracellular expansion and resultant tissue dysfunction. 
1.3.2 Structural interstitial proteins 
Collagens are the most abundant protein within the ECM, comprising up to 
30% of the total protein mass of a multicellular animal and are chiefly 
responsible for maintaining its structural integrity. Collagens provide 
tensile strength; regulate cell adhesion and support chemotaxis and 
migration.  
The collagens typically comprise of long, stiff, triple-stranded helical 
molecules of three collagen chains (chains) wound into a rope like 
superhelix  (Figure 1.1). These chains are rich in proline and glycine - 
proline stabilises the helical conformation and being the smallest amino 
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acid, allows tight packing of the chains. Approximately 25 distinct 
chains have so far been identified, with expression of various 
combinations producing the 20 or so collagen molecules that have been 
found so far.  The most abundant collagen within the body is Type I, which 
forms the principle collagen in skin, fascia, tendons and scar. Type III co-
polymerises with type I within the wall of blood vessels and bowel. Type II 
collagen occurs within the cornea and vitreous body of the eye and within 
cartilage. Types V and XI are minor components found co-polymerised 
with Types I and II (3). Once synthesized by fibroblasts or related cells 
specific to the tissue type e.g. chondroblasts, myofibroblasts or 
osteoblasts –  chains assemble in the extracellular space to form 
procollagen. Cleavage of terminal procollagen peptides by specific 
procollagen metalloproteinases produces collagen molecules that are able 
to assembly into higher-order collagen fibrils, stabilised by covalent cross-
linking between residues that dramatically increases the tensile strength of 
the fibril. The alignment and organisation of fibres is dependent on tissue 
function, for example in tendons, fibres are aligned along the long axis or 
rotate into this axis on loading, thus providing the greatest resistance to 
strain. 
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Figure 1.1 Collagen α chain and molecule 
From ‘Molecular Biology of the Cell. 4th edition. Alberts B, Johnson A, Lewis J, et al. 
New York: Garland Science; 2002. (A) A single collagen αchain arranged as a left-
handed helix, with three amino acids per turn and glycine as every third amino acid. 
(B) Part of a collagen molecule in which three αchains are wrapped around each 
other forming a triple-stranded helical rod. 
Elastin is a highly hydrophobic protein, rich in proline and glycine, which 
forms the main component of the elastic fibres that give tissues their 
elasticity. This property is crucial for tissues such as the lungs and artery 
walls – allowing them to stretch and recoil. By intertwining elastin fibres 
with collagen fibrils, tissues acquire resilience and can limit the amount of 
stretching. Soluble tropoelastin is secreted into the extracellular space and 
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assembles into elastic fibres, which becoming extensively cross-linked. 
There is controversy over the structural conformation that accounts for the 
elasticity, however the leading view is one of a loose random coil, rich in 
hydrophobic residues and cross linked with covalent bonds that can 
stretch and contract (2). The elastin core is covered with a sheath of 
microfibrils, composed of a number of distinct glycoproteins, including 
fibrillin, which bind elastin and are essential for integrity of the fibre. 
Mutations in fibrillin result in Marfan’s syndrome, a relatively common 
condition with affected individuals being prone to aortic dilatation and 
rupture. 
Fibronectin is a member of a group of molecules that typically have 
multiple domains with specific binding sites for other matrix 
macromolecules and for cell surface receptors. This group is intimately 
involved in the organisation of the extracellular matrix and attachment of 
cells to it, and is essential for cell migration and cellular differentiation. The 
fibronectin molecule can be stretched, exposing cryptic binding sites within 
the molecule, which mediate pleiotrophic change in cellular behaviour 
(adhesion, migration etc).   
1.3.3 Proteoglycans 
Proteoglycan (PG) molecules within the extracellular space form a highly 
hydrated, gel-like ground substance into which the fibrous structural 
proteins are embedded. The volume of this gel allows the matrix to resist 
compressive forces while permitting the diffusion of a range of substances 
– including metabolites, nutrients and hormones – between cells and the 
blood. PGs are composed of glycosaminoglycan (GAG) chains, covalently 
joined to a specific protein core (with the exception of hyaluronic acid) and 
are classified by core protein, localisation and GAG composition. There 
are three main families, small leucine-rich proteoglycans (SLRPs), 
modular proteoglycans and cell-surface proteoglycans (3,4). By definition, 
at least one sugar side chain of a proteoglycan must be a GAG, but unlike 
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other glycoproteins, proteoglycans can be huge, containing as much as 
95% carbohydrate by weight, in the form of long unbranched GAG chains. 
Glycosaminoglycans are unbranched polysaccharide chains of repeating 
disaccharide units, with one of the two sugars always being an amino 
sugar (N-acetylglucosamine or N-acetylgalactosamine) and the second 
usually a uronic acid (glucuronic or iduronic). Sulfate or carboxyl groups on 
most of these sugars make GAGs highly negatively charged – a key 
property making GAGs the most anionic molecules produced by animal 
cells. This makes the molecules extremely hydrophilic. Negative charges 
attract a cloud of cations, notably Na+ that are osmotically active, causing 
large amounts of water to be drawn in. The polysaccharide chains are also 
stiff and resistant to folding into the globular structure typically adopted by 
polypeptide chains. GAGs therefore form highly extended conformations, 
occupying a huge volume relative to their mass, and will form a hydrated 
gel even at very low concentrations. The osmotic swelling pressure, or 
turgor thus produced provides mechanical support and allows the matrix to 
withstand large compressive forces.  
Hyaluronan, or Hyaluronic acid (HA) is the simplest of the 
glycosaminoglycans, consisting only of a repeating sequence of 
disaccharide units. Unlike the other GAGs, HA contains no sulphated 
sugars, and has an enormous chain length of thousands of monomers that 
are not generally linked to any core protein. HA is at the extreme end of 
the GAG spectrum, but its structure and chemical properties are illustrative 
of the group and have been extensively studied. In the early 1950s, 
Ogston and Stainer (5) described how the polyanion behaved 
hydrodynamically like a large solvated sphere containing a thousand times 
more water than organic material. Further investigation demonstrated a 
stiff random coil conformation to the molecule (6). HA acting as a network 
forming and space-filling component fulfils a wide range of roles, acting to 
create space for cell migration during embryonic development, in wound 
healing and within articular cartilage and synovial fluid.  
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Aggrecan, the major proteoglycan in cartilage, assembles with HA to form 
aggregates with over 100 GAG chains creating a large osmotic swelling 
pressure, occupying a volume of approximately 2 × 10-12 cm3 – i.e. as 
large as a bacterium (Figure 1.2). The water swollen Aggrecan matrix is 
critical to the biomechanical properties of cartilage.  Combining with 
collagen also makes the cartilage matrix network stiff and resistant to 
deformation, and fluid flow. Cartilage is then viscoelastic – both stiff and 
elastic – and can resist sudden impact loading and show inelastic 
deformation with sustained loads (7). 
 
 
Figure 1.2 Electron micrograph of an aggrecan aggregate 
From ‘Molecular Biology of the Cell. 4th edition. Alberts B, Johnson A, Lewis J, et al. 
New York: Garland Science; 2002. (A) A single collagen αchain arranged as a left-
handed helix, with three amino acids per turn and glycine as every third amino acid. 
(B) Part of a collagen molecule in which three αchains are wrapped around each 
other forming a triple-stranded helical rod. 
 
 
The extracellular space is then composed of a number of different 
contributing matrix elements – the main elements being collagen, 
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proteoglycans and water. In this thesis I will consider various indirect 
methods to quantify this extracellular volume. These techniques focus only 
on one or two of the main elements (usually collagen or water), with 
quantity or volume acting as a surrogate for the EQ volume as a whole. A 
true measure of the extracellular volume should encompass all of the 
extracellular space elements, although a reliable method to quantify this 
space has yet to be devised. The seemingly obvious solution would be 
direct visualisation and measurement of the fractional cellular or 
extracellular volume within a tissue, using microscopy. However, the 
majority of microscopy preparation techniques result in some physical 
disruption of tissue, cellular hypoxia and swelling. Water-soluble molecules 
are also washed out of the extracellular matrix when tissue sections are 
exposed to aqueous fixations solutions, and changes in pH, ionic, or 
osmotic conditions can drastically matrix protein conformation. Thus, 
indirect methods must be used. 
1.3.4 Interstitial expansion in disease 
The basic constituents of the interstitium are essentially the same in all 
tissues, although their relative quantities vary enormously. Rather than a 
static structure, the interstitium is in a constant state of turnover - growing, 
repairing and remodelling. This dynamic process is controlled by a host of 
cytokines, growth factors, enzymes, hormones and cell-to-cell signalling 
which allows tissues to adapt to changes in their physical and chemical 
environment. 
However certain diseases will exhaust cellular adaptation and interstitial 
homeostasis - leading to an accumulation of disorganised proteins with 
consequent effects on tissue functions. The main disease processes in 
which this occurs are (i) diffuse fibrosis and (ii) amyloidosis.  
 36 
1.3.5 Diffuse fibrosis in the heart  
Focal fibrosis within the heart resulting from myocardial infarction remains 
a leading worldwide cause of cause of heart failure – and considerable 
emphasis has been placed over the past 4 decades on understanding its 
pathophysiology, treatment and prevention. Diffuse myocardial fibrosis has 
also been recognised for some time (8) but its importance in diseases 
such as myocarditis, cardiomyopathy (9) and valve disease has only 
recently been appreciated. The pathological remodeling of the 
myocardium associated with diffuse fibrosis leads to ventricular systolic 
and diastolic dysfunction, and eventual heart failure, but this pathway is 
potentially reversible (10). 
Myocardial remodelling is a complex process involving genome 
expression, molecular, cellular, as well as interstitial changes. Early work 
examining interstitial changes showed that increasing skeletal (11) or 
myocardial (12) workload results in an increase in protocollagen proline 
hydroxylase (PPH) production, an enzyme participating in collagen 
biosynthesis. The increase in PPH is followed by an increase in 
extracellular collagen components, with an increase in larger diameter 
type I collagen fibres relative to other subtypes, and higher degree of fibre 
cross linking by lysyl oxidase (LOX). These changes are required to 
support the accompanying increase in myocyte mass, thus facilitating 
muscle growth and augmented muscular force. Weber et al. described a 
second ‘physiologic’ phase of this work-induced hypertrophy (12) wherein 
remodelling of these new elements occurs. Removal of the increased 
loading during this phase however causes the myocardium to remodel and 
revert back to normal. Progressive loading beyond this point leads to a 
maladaptive ‘pathologic’ phase, where alterations in collagen subtype 
proportions occurs; fibril arrangement and binding become disordered and 
matrix remodelling may become irreversible. Here the balance between 
structural and maintenance proteins is lost and there is accumulation of 
disordered ineffective matrix – Figure 1.3. These changes, coupled with 
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myocyte degeneration results in a drop in contractility indices, leading 
clinically to myocardial failure (10). 
 
 
Figure 1.3 Stained electron microscopy image 
Electron microscopy image with Fibronectin stained red and myocyte nuclei blue. (A) 
normal myocardium with fine septa between unstained myocytes. (B) severe fibrosis 
with few myocytes. From Hein et al. Circulation 2003 
A disproportionate accumulation of interstitial collagen is a characteristic 
feature of sustained arterial hypertension and is responsible for 
progressive abnormalities of diastolic relaxation, filling and ultimately 
systolic dysfunction. Associated left ventricular hypertrophy is an 
adaptation to these changes and is known to be a risk factor for 
arrhythmias, cardiac failure and sudden death. Hein et al. investigated the 
relationship between cardiac function and myocardial morphology in 
patients with aortic stenosis – demonstrating worsening fibrosis and 
myocyte degeneration with increasing left ventricular end diastolic 
pressure (LVEDP) and later falling ejection fraction (EF). A low grade 
inflammation was present with leukocytes and macrophages - the likely 
mediators of cytokine production such as ACE and TFG-β1 leading to 
reactive fibrosis (13). TFG-β1 regulates the turnover of collagen by 
myocardial fibroblasts, and abnormal persistence of myofibroblasts is seen 
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as a hallmark of fibrotic disease. TFG-β1in turn is controlled by angiotensin 
II synthesised locally by ACE. Increased expression and activity of ACE 
leading to upregulation of collagen mRNA is seen in aortic stenosis, 
cardiomyopathy, and also near an infarct scar. Proteins such as 
transforming growth factor (TGF), endothelin-1, angiotensin II (Ang II), 
connective tissue growth factor (CCN2/CTGF), and platelet-derived growth 
factor (PDGF) act in a network that contributes to myofibroblast 
differentiation and persistence. 
Invasive tissue sampling has shown that myocardial fibrosis is likely to 
play a crucial role in adverse myocardial remodelling, but the scarcity of 
human data has prevented assessment of the clinical importance of this 
process in terms of morbidity and mortality. Wider evaluation of the 
population significance will require development of non-invasive methods 
of assessment. These techniques could enable appropriate patient risk 
stratification, and allow evaluation of drugs and interventions targeting 
myocardial fibrosis.  
 
1.3.6 Diffuse fibrosis in the liver 
Diffuse fibrosis and derangement of the extracellular environment leading 
to organ dysfunction is the hallmark of chronic liver disease, and is a major 
cause of worldwide morbidity and mortality. In 2004, the direct cost of 
chronic liver diseases in the United States was estimated at $2.5bn; with 
indirect costs adding an additional $10.6 billion to this value (14,15).  
Diffuse liver fibrosis can occur as a rapidly progressive process over 
weeks or months as a result of drug injury or hepatitis C infection after 
transplantation, but it is the sustained activation that accompanies chronic 
liver diseases which allows for significant accumulation of fibrosis. This 
chronicity compared with diffuse fibrosis in other organs such as the 
kidneys or lungs is likely a reflection of the liver’s unique regenerative 
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capacity. In the normal liver, fibrous interstitial elements are quantitative 
small compared with other organs; however small changes in the EC 
matrix can affect liver function.  
In the healthy liver, collagen types I, III, and V, the major constituents of 
fibrillar collagen, are confined mainly to the portal tract and central vein 
wall, while type IV collagen, in association with laminin and entactin-
nidogen, form a low-density basement membrane-like material along the 
sinusoid wall (a true basement membrane is usually absent). The low 
density of this basement membrane-like structure is critical for allowing 
easy diffusion between blood and liver cells. 
Despite the diversity of agents that are noxious toward the liver (viruses, 
drugs, alcohol, autoantibodies, iron, etc.), the liver responds via a 
standardized pathway. The most prevalent diseases, including - viral 
hepatitis, alcoholic steatohepatitis (ASH), and non-alcoholic steatohepatitis 
(NASH) are characterised by an inflammatory response with leukocyte 
infiltration that produces high levels of profibrinogenic cytokines such as 
transforming factor beta (TGF-β), metalloprotease (MMP2), and tissue 
inhibitor of matrix metalloprotease 1 (TIMP1), which can be detected in the 
blood plasma. Metabolic diseases such as haemochromatosis however 
also induce diffuse fibrosis and lead to cirrhosis, but lack an inflammatory 
cell infiltrate, demonstrating multiple routes for activation of this standard 
pathway. One potential set of common mediators are the reactive oxygen 
species. These unstable compounds, which include superoxide and 
hydroxyl radicals and hydrogen peroxide are generated through lipid 
peroxidation in hepatocytes, macrophages and Hepatic Stellate Cells 
(HSCs) (16). Production is enhanced by ethanol and fatty acids, leading to 
cell injury. 
The mechanism of liver fibrogenesis is complex and incompletely 
understood, however human and animal studies suggest that 
hepatocellular damage is followed by a signaling response which leads to 
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activation of the innate immune system, hepatic stellate cell activation and 
EC matrix deposition. Some authors have suggested that in the case of 
viral hepatitis, an immune response to antigens normally sequestered 
within the EC matrix is the cause of the necroinflammation and 
subsequent fibrosis. Tumour necrosis factor (TNF) appears to be key a 
cytokine, responsible in health for normal hepatocyte proliferation during 
liver regeneration, HSC activation and for apoptosis of damaged cells 
though the TNF receptor 1. Tarrats et al. showed that specific knock out of 
the TNF receptor 1 in bile duct ligated mice led to a significant reduction in 
HSC proliferation and fibrogenesis (17).  
The pattern of accumulation of extracellular matrix components leading to 
cirrhosis varies with disease. Fibrosis due to viral hepatitis begins in the 
portal triads and manifests initially as fibrous expansion of the portal triads. 
Stellate fibrous septa then extend from the portal triads into the 
surrounding hepatic parenchyma, lengthening and thickening to eventually 
form fibrous bridges (bridging fibrosis) that link adjacent portal triads and 
central veins. As the injury continues, the bridges enlarge and coalesce, 
dividing the liver into cellular islands of dense hepatocytes – regenerative 
nodules – surrounded by bands of highly disorganised and loosely 
arranged fibrosis tissue which expand the extracellular space. These 
fibrotic bands carve through the liver parenchyma. Architectural distortion 
also follows as liver cell regeneration occurs around these fibrous septa – 
these regenerative nodules are the hallmark or cirrhosis. Advanced 
disease is also associated with an angiogenic reaction that leads 
vascularisation of the fibrotic tissue and redistribution of the normal 
vascularisation within the liver lobule. 
In contrast, fibrosis due to non-alcoholic fatty liver disease (NAFLD) and in 
alcohol liver disease begins adjacent to the central veins. Fibrotic matrix is 
deposited in a peri-sinusoidal pattern (chicken-wire fibrosis) with elements 
surrounding individual hepatocytes (18). With disease progression the 
fibrosis extends to the portal tracts, producing fibrotic tracts which when 
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extensive becoming indistinguishable from cirrhosis secondary to viral 
hepatitis. 
The traditional view of diffuse liver fibrosis as an irreversible process has 
been dispelled, with studies now showing that once identified, even 
advanced fibrosis can be reversed. Removal of the causative agent is the 
most effective treatment and spontaneous resolution of liver injury can 
occur following successful treatment of an underlying disease process e.g. 
alcohol induced liver injury, viral hepatitis, haemachromatosis and 
autoimmune hepatitis. Treatment of chronic hepatitis C viral infection has 
been studied extensively, with viral clearance using IFN-alpha plus 
Ribavirin resulting in nearly half of patients with cirrhosis demonstrating 
significant improvement of fibrosis. For patients with end stage cirrhosis 
with complications resulting from organ failure and portal hypertension, 
transplantation is currently the only shown to improve survival and quality 
of life.  
Various strategies for blocking or reversing progression of liver fibrosis 
have been evaluated in experimental animal models and small clinical 
trials with some success. These include the use of anti-inflammatory 
agents, modulators of HSC activation; antioxidants and disruptors of TGF-
beta synthesis. Inhibition of the renin-angiotensin system has also been 
evaluated. There however remains no standard therapy for liver fibrosis, 
with translation and evaluation in humans slowed by the need for serial 
biopsy and long-term follow-up.  
1.3.7 Systemic amyloidosis 
The amyloidoses are a group of disorders in which a misfolded pathogenic 
protein aggregates into insoluble fibrils that accumulate in the extracellular 
space, leading to disruption of tissue structure and function. Biochemical 
and environmental factors allow the normally soluble protein to adopt 
partially folded states leading to self-association and formation of a cross-
  structure and protofilaments measuring 2-5 nm in diameter which either 
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coil together or adhere to form fibrils. Amyloid fibrils differ from other 
protein aggregates as they show apple green birefringence when stained 
by Congo red and viewed by microscope under polarized light. This 
method of Amyloid identification, although technically challenging and 
requiring a long staining process has been the reference standard since 
the 1950s.  
The amyloidoses form a heterogeneous group of clinical conditions, 
involving one or more organs – including the heart, kidneys, liver, and 
nervous system. In its localised form the disease largely affects the organ 
of the precursor protein synthesis, and can cause intra and extracellular 
protein synthesis - examples include neurodegenerative disorders such as 
Parkinson’s, Alzheimer’s, and Huntington’s disease. In contrast all the 
systemic amyloidoses are extracellular, with precursor protein secreted at 
a site distinct from the major sites of deposition.  
Systemic amyloidosis is the quintessential extracellular disease; it is a 
relatively rare multisystem condition in which amyloid protein deposition 
occurs in various tissues and organs, causing organ dysfunction through 
interstitial expansion. It may present to almost any specialty with non-
specific symptoms including fatigue, weakness, loss of appetite, and 
weight loss, frequently leading to delayed diagnosis. There are several 
different types of systemic amyloidosis.  
Key indicators to the diagnosis of possible systemic amyloidosis include: 
nephrotic syndrome, autonomic neuropathy (postural hypotension, 
diarrhoea), soft tissue infiltration (macroglossia, carpal tunnel syndrome), 
cutaneous bleeding (periorbital, gastrointestinal), malnutrition/cachexia 
and genetic predisposition (family history/ethnicity).  Other organ 
involvement, particularly in AL amyloidosis, may cloud the cardiac 
presentation (nephrotic syndrome, autonomic neuropathy, pulmonary or 
bronchial involvement). Table 1.4 gives an outline of the clinical phenotype 
of the common amyloid subtypes. 
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Transthyretin (TTR) is a homotetrameric protein that transports thyroxine 
and binds retinol. Extracellular amyloid deposition of TTR is associated 
with two types of amyloidosis, familial amyloidotic polyneuropathy (FAP; or 
ATTR amyloidosis, an autosomal dominant disease) with deposits formed 
by TTR point mutants, and systemic senile amyloidosis (SSA) with wild-
type (wt) TTR deposits (19). Wild type transthyretin (TTR) amyloid 
deposits, which predominantly accumulate in the heart, are very common 
at autopsy in the elderly. Whilst the associated clinical syndrome known as 
senile systemic amyloidosis is diagnosed rarely in life, there is increasing 
evidence that this disorder is much under-diagnosed. With increasing 
longevity and improved diagnostic methods, it may be identified as a 
substantial public health problem.   
Light chain amyloidosis (AL) is the most commonly diagnosed systemic 
amyloidosis in the Western world, with an incidence of 10 patients per 
million per year (19). It is a fatal progressive disease characterized by 
extracellular deposition of light chains into insoluble fibrillar aggregates. 
Most AL amyloidosis patients are more than 45 years old with an average 
age of 67 years old. AL amyloidosis patients have a median survival of 
12–40 months after diagnosis (19). AL amyloidosis is caused by an 
abnormal proliferation of monoclonal plasma cells that secrete a high 
amount of free light chains into the bloodstream. These light chains self-
assemble and deposit as insoluble amyloid fibrils in various organs, 
ultimately causing organ failure and death. Current treatments target the 
plasma cell population and are not curative. Although this deposition can 
occur almost anywhere in the body, the most frequent sites of AL 
amyloidosis deposition are the kidneys, heart, peripheral nerves, 
gastrointestinal tract, and liver. Patients with clinical cardiac involvement 
have the worst prognosis with a median survival of less than a year. The 
variation in pattern of tissue deposition is poorly understood. 
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All amyloid deposits contain the non-fibrillar glycoprotein amyloid P 
component, which is derived from and identical to serum amyloid P 
component (SAP). SAP labelled with radioactive iodine can be used as a 
specific tracer to determine the distribution and extent of AL amyloid 
deposition.  Tissue retention of SAP scintigraphy may be related to 
survival in patients with systemic disease. Jager et al. showed that 
patients with greater than 60% extravascular retention of labelled SAP 
corresponded to a mean survival of just 4 month, compared with 23 month 
for those with <60%.  
Therapeutic options are limited in systemic AL amyloidosis, but cytotoxic 
chemotherapy has been employed to suppress the underlying pathogenic 
B-cell or plasma cell clone. This is however often limited by dysfunction of 
amyloid infiltrated organs. Recent work by Richards et al. has 
demonstrated impressive clearance of amyloid from the liver and other 
tissues by targeting with a therapeutic IgG anti-SAP antibody. SAP 
scintigraphy was used to qualitatively demonstrate marked reduction in 
hepatic amyloid load.  
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Amyloid 
type 
Precursor 
protein 
Typical  
onset 
Other organ 
involvement 
Treatment Prognosis 
(median 
survival) 
Primary (AL) 
Amyloidosis 
Monoclonal 
light chain 
6th  to 7th 
decade 
(but can be 
any) 
Heart, 
kidney, liver, 
soft tissue, 
neuropathy 
Chemother
apy or 
ASCT                      
48 months 
(8m 
advanced 
stage 
disease.  
Transthyreti
n 
Amyloidosis 
ATTR 
(V30M) 
Variant TTR 3rd or 4th 
decade  
Peripheral 
and 
autonomic 
neuropathy 
Liver 
transplantat
ion  
Good with 
liver 
transplant 
for V30M  
ATTR 
(T60A) 
Variant TTR 6th decade  Heart, 
Peripheral 
and 
autonomic 
neuropathy 
Liver 
transplant 
possible in 
selected 
Variable 
with liver 
transplant 
Wild Type 
ATTR 
Wild-type 
TTR 
70 years  Heart, carpal 
tunnel 
syndrome 
Supportive 
 
7-8 years  
ATTR Ile 
122 
Variant TTR 6th – 7th 
decade  
Heart, carpal 
tunnel 
syndrome 
Supportive 7-8 years 
Apolipoprote
in A1 
(ApoA1) 
Variant 
apolipoprote
in 
6th– 7th 
decade 
Predominantl
y renal 
Renal (+/- 
liver) 
transplant 
Usually 
slowly 
progressive 
(yrs) 
Secondary 
(AA) 
amyloidosis 
Serum 
amyloid A 
(SAA) 
Any Renal, liver Treat 
underlying 
condition 
Good 
Atrial 
natriuretic 
peptide 
(ANP) 
ANP 70 years or 
older 
Heart Not needed  
 
Table 1.4 Summary of clinical phenotype by amyloidosis type 
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1.4 Evaluating interstitial expansion 
Current methods to evaluate diseases that cause alteration in the 
extracellular environment focus on quantifying secondary extracellular 
disease specific processes (e.g. collagen deposition in fibrosis); resultant 
tissue property changes (e.g. tissue shear wave propagation) or systemic 
overspill of disease related components (e.g. plasma biomarkers). These 
methods provide useful surrogate markers of disease and are used as 
comparators in this thesis. 
The volume of the extracellular space and its relationship with disease has 
yet to systematically explored. Methods that interrogate ECV already exist, 
but are not widely used - largely as a result of their complexity. Global 
ECV measures have been studied in relation to sodium disturbances, 
diabetes and hypertension; and simpler schemes for measurement 
proposed (20). More recently extracellular tracers have allowed focussed 
assessment of tissue ECV, but these techniques are again complex. 
The main existing techniques for evaluating extracellular disease and 
measuring extracellular volume will be discussed further.  
1.4.1 Histological analysis 
Tissue sampling and histological analysis is currently the ‘reference 
standard’ technique for evaluation of the interstitium and diffuse fibrosis. 
Although it plays an important role in the current management of a host of 
diseases, it is far from an idea test, suffering a number of technical and 
methodological limitations. 
Collecting tissue for histological analysis frequently involves technically 
difficult and invasive procedures with an associated complication risk. In 
the liver, percutaneous biopsy carries a significant risk of haemorrhage. 
An audit of liver biopsies performed in district general hospitals in the UK 
found a mortality rate from haemorrhage of between 0.13 and 0.33% (21). 
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The use of image guidance, and centralisation of liver services to high 
volume specialist centres may help reduce these risks. 
Depending on aetiology, diffuse fibrosis is also commonly a non-
homogenous process. Biopsy of organs such as the liver where only 
1/50000th of the organ is sampled, suffers significant sampling error. 
Bedossa et al. illustrated this by comparing fibrosis staging in large 
surgical specimens with 25mm long virtual biopsy samples and found a 
25% rate of discordance (22) between the two. 
Although fibrosis within the liver is a continuous process – following the 
patterns previously described, a variety of semiquantitative 
histopathological scoring systems have been used to classify or stage the 
progression of disease to cirrhosis. The first systematic scoring system 
was described by Knodell et al (23) in 1981 and used numerical 
categorical labels as shorthand for subjective description of specific 
histological features observed within liver biopsy specimens. More recent 
histological scoring systems include the Ishak (23) and METAVIR (24) 
systems, which incorporate a mixture of histological features, but no 
individual score is related specifically to the amount of fibrosis. Ishak score 
(Table 1.5) for example places greater emphasis on the subjective degree 
of nodularity and architectural change – and is therefore prone to intra and 
inter observer variability. The numerical categorical labels have been 
widely misunderstood as continuous measurement quantities, and the lack 
of an arithmetic relationship between stages (ie stage 4 is not twice that of 
stage 2) causes confusion - particularly amongst clinicians. The 
categorical system has also lead to inappropriate use of statistical method 
(other than those appropriate for order categorical assignments) in 
numerous scientific publications. A further issue is that these semi-
descriptive assessments are relatively aetiology specific because of the 
differing histological patterns of disease. This adds additional complexity 
to interpretation of fibrosis score and does not allow non-disease specific 
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evaluation – for example in the assessment of surrogate markers and non-
invasive methods.  
 
Table 1.5 Summary of modified Ishak Soring 
Histopathological characteristics with corresponding modified Ishak Score. 
 
The limitations of these scoring systems have led to the development of 
objective, systematic numerical methods. Routine histological evaluation 
of fibrosis is usually performed with trichrome or reticulin stains, each of 
which identify collagen to some extent but are not specific and the amount 
of staining dose not necessarily correspond quantitatively with the amount 
of hepatic collagen. PicroSirius red has an affinity for most hepatic 
collagens including types I and III, with reliable and reproducible 
correlation between bound stain and collagen determined biochemically 
(25). Computer assisted/ digital image analysis (DIA) of Picrosirius red 
stained sections allows for accurate morphometric assessment of 
collagen, while staining of structures which do not contribute to the 
disease process can be expressly excluded. Segmentation of collagen 
compared with the area of tissue examined produces a fibrosis area ratio 
or ‘Collagen Proportionate Area’. DIA studies have looked at fibrosis in 
many liver conditions, producing overall similar results ranging from 1–4% 
fibrous tissue in normal liver to 15–35% fibrous tissue in cirrhosis. By 
weight comparison: normal human liver is estimated to contain 
approximately 5.5 mg/g of collagen, and cirrhotic liver contains of the order 
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of 30 mg/g (26). CPA has been assessed against both hepatic venous 
pressure gradient (HVPG) (27) and clinical outcomes in recurrent hepatitis 
C (28). Manousou showed CPA to be more predictive of clinical outcome 
than both Ishak stage and HVPG.  
Similar schemes have been applied to diffuse fibrosis within other organs 
– e.g. the heart. In severe aortic stenosis, myocardial fibrosis quantified by 
collagen volume fraction (CVF) after section staining with Picro Sirius Red 
is associated with the degree of ventricular functional improvement and 
mortality after valve replacement (29). CVF is also used widely used in 
drug research, allowing direct assessment of the effect of cardiac anti-
fibrotic therapies (30).  
1.4.2 Pharmacokinetic modelling 
Pharmacokinetic analysis has been used to evaluate the distribution of 
hydrophilic solutes (such as beta-lactam antibiotics), which are limited to 
the extracellular space. Measurement has also helped understand fluid 
changes in the critically ill where for example after surgery, burns or major 
trauma, interstitial oedema can expand the body weight by over 10%. 
Reference methods for measuring whole body ECV are based on dilution 
of indicators such as radiosodium, and bromide that distribute throughout 
the EC space and are slowly excreted by the kidneys as a result of tubular 
reabsorption. ECV (and GFR) can also be measured from mean transit 
time of a marker through its distribution volume (31), but each of these 
methods are technically challenging. 
1.4.3 Plasma biomarkers 
The past decade has seen fibrosis marker research focus on serological 
tests. Direct markers reflect the shedding of peptides involved in the 
accumulation of fibrillar extracellular matrix, its degradation or in tissue 
inflammation into the circulation. These are generally more specific than 
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indirect markers, which are a mixture of biochemical and clinical 
parameters. The predictive ability of these markers can be enhanced by 
their combination into a panel by a mathematical algorithm.  
In the liver, serological markers such as the aspartate 
aminotransferase/platelet ratio index (APRI), FibroTest and the ELF test 
(discussed further in chapter 3) have been shown to provide accurate 
estimate of fibrosis (34). The strength of APRI is that it can be calculated 
using routine laboratory assays at the bedside/clinic: 
APRI = (AST/upper limit of normal) x 100/platelet count].  
Serological markers have been used to provide information on prognosis 
in patients with symptomatic heart failure, idiopathic or ischaemic dilated 
cardiomyopathies, and after acute MI. Natriuretic neuropeptides (ANP; 
BNP) are synthesised by muscle cells primarily in the atria in response to 
high blood volumes. Ventricular NT-proBNP is upregulated in cardiac 
failure and has use for diagnosis and prognosis. NT proBNP has also a 
strong prognostic value of death in acute and chronic heart failure and also 
predicts short and long term mortality in patient with suspected or 
confirmed unstable CVD.  
1.4.4 Positron Electron Tomography 
FDG-PET has been used to probe fibrotic disease. The degree of cellular 
FDG uptake is related to the cellular metabolic rate and the number of 
glucose transporters. FDG is transported into cells by glucose transporters 
and is phosphorylated by hexokinase enzyme to 18F-2-FDG-6 phosphate 
but is not metabolized. Increased numbers of glucose transporters are 
seen in activated inflammatory cells, and there is also increased affinity of 
these glucose transporters for deoxyglucose caused by various cytokines 
and growth factors.  
In 2009 Groves et al. described FDG-PET/CT finding in patients with 
diffuse parenchymal lung disease (35). This is a spectrum of diseases, 
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which includes idiopathic pulmonary fibrosis, with unknown causation. 
Environmental exposure is thought to produce to repetitive injury to the 
alveolar epithelium producing accumulation of transforming growth factor 
beta (TGF ), fibroblast and myofibroblasts, which mediate a cascade that 
leads to lung tissue scarring. Increased FDG uptake was seen in areas of 
lung fibrosis – identified on HRCT by ground glass, reticulation and 
honeycombing. This finding suggested that the morphological changes on 
HRCT did not simply represent burnt out inert disease, but that the 
inflammatory process causing fibrosis was active. FDG-PET may then 
provide useful information on the background inflammatory process driving 
fibrosis in other organs and which could potentially be a target for 
pharmacological manipulation. 
1.4.5 Ultrasound Elastography 
The effect of disease on the mechanical properties of tissues has long 
been appreciated and forms the basis for subjective clinical palpation. 
Diffuse fibrosis, for example in cirrhosis, results in an increase in tissue 
stiffness, causing the liver to feel hard on palpation. Measurement of 
tissue elasticity is called elastography, and assessment techniques include 
transient elastography (FibroScan®), ARFI, Real Time Elastography, 
Shear Wave mode elastography and elasto-MR. 
Uni-dimensional transient ultrasound elastography, as implemented by 
FibroScan uses a mechanical transducer to produce a shear wave, whose 
velocity is measured using a one dimensional ultrasound probe – figure 5. 
The propagation velocity is directly related to the stiffness of the medium, 
defined by the Young modulus. Elasticity is expressed in kPa (kilopascals) 
and is measured at depth ranging from 25 to 65 mm in a 1 × 4 cm area: 
allowing a sample volume many hundreds of times larger than that 
evaluated by biopsy. The obtained values range from 2.5 kPa to 75 kPa – 
a normal value being around 5 kPa. Mean liver elasticity in healthy 
individuals is 5.81 ± 1.54 and 5.23 ± 1.59 kPa respectively for men and 
 52 
women (36). Assessment can be performed at the bedside or clinic using 
a dedicated portable device and approximately 10 measurements are 
taken to achieve a sample success rate of >60%. TE however may also 
suffer sampling error, and of limited valve in patients who are obese, with 
narrow intercostal spaces or ascites. 
 
Figure 1.6 Transient Elastography 
Taken from Frulio et al. Fibroscan equipment, probe, diagram illustrating 
measurement principle and results. 
 
FibroScan offers many of the characteristics of an ideal test; it is quick, 
painless; reproducible (37) and accurate (Figure 1.6). The technique is 
simple and can be learned quickly. The equipment is also portable and 
 53 
results available immediately, which allows clinicians to use in a clinic 
setting. Limitations include thin intercostal spaces, ascites, obesity and 
need for dedicated expensive equipment. The evaluated liver parenchyma 
is also not visualised. Foucher et al in 2006 showed a significant 
association between TE and clinical and biological parameters of liver 
disease – Figure 1.7 (32).  
 
 
Figure 1.7 Box-and-whisker plot of elasticity vs fibrosis stage 
Taken from Foucher et al Gut 2006 (16020491) - Liver stiffness values by TE for 
each fibrosis stage (0–4). The vertical axis is a logarithmic scale. The top and bottom 
of the boxes are the first and third quartiles. The length of the box represents 
interquartile ranges, within which are located 50% of the values. The lines through 
the middle of the boxes represent median values. 
 
Gomez-Dominguez et al. evaluated this technology in 103 patients 
undergoing liver biopsy and compared stiffness values with pathological 
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METAVIR score. The AUROC result to detect F>2 fibrosis was 0.76 with a 
sensitivity of 90% but a specificity of only 34%. In 18.4%, the method 
failed to yield diagnostic data (due to obesity and/or ascites) (38) 
The diagnostic performance of the FibroScan® has been examined in four 
meta-analyses (39, 40, 41, 42, 40). Mean AUROC for diagnosis of 
significant fibrosis and cirrhosis in the meta analysis which included the 
largest number of studies (n = 50) were 0.84 and 0.94, respectively, and 
performance varies little with underlying disease (42).  As with other 
methods, testing is again against liver biopsy – with limitations discussed 
in section 1.4.1. 
More recently, 2 dimensional acoustic radiation force impulse elastography 
(ARFI) has been developed which uses mechanical excitation of tissue 
with short duration acoustic pulses that produce shear waves within 
tissues. The shear wave velocity (in m/s) is then measured in a small 
(6x10mm) area of tissue – with a normal range of 0.5-4.4 m/s. ARFI is 
enabled within a flexible ROI at variable depths and can be incorporated 
into a routine ultrasonographic examination of the abdomen. Results are 
also much less affected by obesity and ascites. Necroinflammatory activity 
– reflected in a raised alanine aminotransferase (ALT) level affects the 
accuracy of both transient elastography, and ARFI (33).  
1.4.6 Magnetic resonance elastography 
MR elastography is new technology that also characterises the 
biomechanical properties (43) of in vivo tissues. Shear waves are 
generated continuously (50-500Hz) by an external mechanical driver 
(figure 1.6), which are imaged using modified phase-contrast MR 
sequences. A motion-encoding gradient (MEG) oscillating at the same 
frequency as the driver is applied and conventional MR imaging is 
performed. The phase of harmonically vibrating tissue is directly 
proportional to its displacement and an MR image containing information 
about the propagating wave in its phase is called a wave image. Typically 
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two such wave images are collected with opposite polarity of the MEG, 
and a phase-difference image calculated to remove non-motion-related 
phase information. From the wave images showing the propagation of 
shear waves in the tissue, mathematical inversion algorithms based on 
equations of motion, with simplifying assumptions like isotropy, 
homogeneity, and incompressibility, allow for the calculation of mechanical 
properties like the shear modulus and production of tissue stiffness maps 
(elastogram) for clinical interpretation - (Figure 1.9. Fibrotic livers produce 
longer wavelengths and higher stiffness valves compared with normal 
tissues.  
 
Figure 1.8 MRI Elastography – mechanical driver 
External mechanical driver used to apply sheer waves to the abdomen for MR 
Elastography. The driver is located away from the magnetic field of the MRI unit and 
usually transmitted via flexible tube to a passive driver placed over the anterior 
abdominal wall (for liver imaging). Example mechanical active driver (Resoundant, 
Rochester, MN). 
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(Figure 1.9 Example MRI Elastogram 
Elastogram in a patient with cirrhosis (F4) (Taken from Ichikawa et al. Magn Reson 
Imaging. 2015 Jan;33(1):26-30) 
Compared with TE, MRE has demonstrated superior discriminative ability 
for hepatic fibrosis stage (44). Shintaro et al. found that even at the 
histopathological METAVIR F1 cutoff, mean (95% confidence interval) 
area under the receiver operating characteristic curve values were 
significantly higher or MRE than TE (0.97 [0.92– 0.99] vs. 0.87 [0.76–
0.93]; P = 0.0126).  
MRE allows capture of a two dimensional section of tissue ((Figure 1.9) 
rather than the one dimensional sample on TE. MRE also does not suffer 
limitations of ascites and narrow intercostal spaces but claustrophobia and 
other typical contraindications to MRI apply. Low liver signal return 
resulting from parenchymal iron deposition can also present a challenge. 
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1.4.7 Dynamic contrast enhanced (DCE-MRI) and diffusion weighted 
MRI (DWI-MRI)  
By analysing the temporal enhancement pattern of a tissue following 
intravenous administration of a paramagnetic contrast agent, dynamic 
contrast enhanced MRI (DCI-MRI) allows a number of physiological tissue 
properties to be derived related to microvascular blood flow – such as 
vessel permeability, surface area and tissue volume fractions. Semi-
quantitative analysis provides a description of the tissue enhancement 
curve characteristics, but values are dependent on signal intensity (SI), 
which in turn are dependent on scanning conditions. These values also 
lack intrinsic physiological meaning and are difficult to interpret.  
Absolute parameters can be deduced by converting SI into gadolinium 
(Gd) concentration using T1 maps; and using appropriate mathematical 
modelling reflecting the two-compartment pharmacokinetics exhibited by 
extracellular contrast agents (intra and extravascular extracellular spaces). 
The most widely used model by Tofts et al. (45) calculates the parameters 
Ktrans (bulk transfer coefficient which governs the leakage of contrast from 
the vascular to the extravascular compartment) and Ve (fractional volume 
of the extravascular extracellular distribution space). Evaluation of these 
parameters within tumours with DCE-MRI has been widely evaluated to 
aid tumour diagnosis (46), staging and assess response to treatment (47).  
Early evaluation of the ability of DCE-MRI to distinguish extracellular 
volume changes secondary to diffuse fibrosis used semi-quantitative 
perfusion parameters and a single compartment model. Zhou et al found 
that the maximum slope of increase (MSI) – reflecting a reduced rate of 
blood flow – could predict mild and moderate stages of fibrosis (S1-3); and 
time to peak (TTP) enhancement, reflecting transit time could predict high 
stage fibrosis (S4) (48) – a result of increased vascular resistance and 
liver capillarization. However, the single compartment model and semi-
quantitative approach did not allow specific consideration of the alteration 
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in compartment permeability and extracellular volume that is known to 
occur in liver fibrosis.  
Li et al. used a dual input extended Tofts model to assess CCl4-induced 
fibrosis in rabbits. Ktrans best predicted fibrosis stage through the range 
from normal, non-advanced to advanced fibrosis (p < 0.001 for all). Ve 
decreased with fibrotic stage, with significant differences between control, 
overall and advanced fibrosis groups (p = 0.009). This negative 
association contradicts previous similar work using DCE-MRI, which the 
authors suggest may be the result of fibrosis related cellular proliferation, 
loss of endothelial fenestration or regenerative architectural distortion.  
Benjaminsen et al. showed that the partition coefficient obtained using 
Kety analysis (1 tissue compartment model) within human melanoma 
xenografts increased with histological extracellular space fraction and with 
radial heterogeneity. No correlation was found with measures of 
microvascular density or perfusion. 
DCE-MRI therefore offers potential as a tool to explore extracellular 
changes related to disease. However, use of this technique presents a 
number of challenges. There is currently no consensus on DCE protocol, 
and practice varies immensely. Depending on the scan timing, T1 
measurement method, pharmacokinetic model, and curve fitting technique 
there can be large variation in measured parameters, limiting 
reproducibility. Movement of tissues over the prolonged acquisition time 
can introduce error and even with use of the high temporal resolution 
imaging sequences, data registration and movement correction is often 
required. Sampling of the tissue arterial input function (AIF) required for 
pharmacokinetic model also demands high spatial, temporal resolution 
and scan coverage to encompass feeding vessels.  (49).  
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1.5 Equilibrium contrast imaging – background 
Soon after Roentgen discovered the X-ray, scientists appreciated the need 
for extraneous agents to improve radiographic soft tissue contrast. In 1896 
Sehrwald compared the properties of in-vitro halogens (e.g. iodine and 
bromide) with other metal salts and organic compounds – Figure 1.10, 
before Haschek and Lindenthal administered a paste of mercury sulphide 
and lime into the blood vessels of an amputated hand to produce the first 
contrast angiogram - Figure 1.11. Todays contrast agents are stable, inert, 
water (but not fat) soluble molecules, with negligible protein binding; 
Iohexol contains organically bound iodine and has been used widely in 
medical imaging for the past 30 years. Both iodinated and gadolinium 
based agents are extracellular tracers which when administered into the 
blood, circulate in the plasma and move passively into the tissue 
interstitium without crossing intact cell membranes, before being excreted 
by the kidneys. Their various vascular and interstitial phases provide 
exquisite soft tissue contrast and markedly enhance diagnostic 
performance when used.  
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Figure 1.10 A selection of X-ray absorbing materials 
From Wilhelm Conrad Röntgen and the Early History of the Roentgen Rays by Otto 
Glasser 1993. 
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Figure 1.11 An early angiogram 
From Wilhelm Conrad Röntgen and the Early History of the Roentgen Rays by Otto 
Glasser 1993. An early angiogram showing opacified blood vessels in an amputated 
hand (Vienna Jan 1806). 
Contract agents have for some time been used to assess myocardial 
diseases which cause alteration in the extracellular space.  Following 
acute ischaemic injury, loss of cell membrane integrity and interstitial 
oedema leads to a local increase in extracellular contrast agent volume of 
distribution (50). Following infarction, myocyte death leads to replacement 
by hydrated collagen matrix into which contrast agent molecules can 
accumulate. Contrast accumulated within this expanded extracellular 
space can be resolved on T1 weighted MRI, forming the basis for the late 
gadolinium enhancement technique (LGE) on cardiac MRI (CMR). Using 
an inversion recovery sequence with an inversion time (TI) set to null 
(blacken) remote normal myocardium, LGE allows direct subjective 
appreciation of the spatial extent of focal scarring and has become the 
reference standard for clinical assessment of focal myocardial fibrosis (51, 
52).  
The LGE method is however less useful in the case of diffuse fibrosis 
where there is no normal adjacent tissue to act a reference and where 
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extracellular volume changes are less marked. Assessment of diffuse 
fibrosis therefore requires more sensitive, absolute extracellular volume 
estimation. However, quantifying EC contrast accumulation is complicated 
by the wash-in and wash-out effects as plasma concentration rises 
following intravenous injection and falls as the contrast agent is 
redistributed and renally cleared.  
Arheden et al. (53) described a method to quantify the myocardial partition 
coefficient (that is the ratio of the myocardial to blood extracellular 
distribution volume) of Gadopentetate Dimeglumine in rats by measuring 
the change in T1 relaxation time within the myocardium compared with the 
left ventricular blood pool after contrast administration. In order to 
compensate for clearance processes causing a constant change 
(reduction) in blood and tissue Gd concentration, imaging was performed 
between 5 and 29 minutes after contrast administration. At this delayed 
time point the rate of change of contrast concentration is reduced; and 
where contrast kinetics are rapid compared with T1 measurement time, 
good estimation of the partition co-efficient can be achieved. 
Tong et al. (54) then showed that a bolus plus infusion method (in a ratio 
of 50:1) could be used to achieve a constant concentration of contrast 
within the plasma. Movement across the capillary wall allows equalisation 
of contrast concentrations between the plasma and interstitium, during 
which time there is no concentration gradient and no net movement 
between the two compartments – a steady state equilibrium. In 2001 
Flacke et al. (50) combined the methods described by Arheden and Tong 
in humans, establishing a technique for measurement of the myocardial 
partition coefficient in vivo using a bolus followed by a 30 to 40 minute 
infusion of Gadopentetate dimeglumine. In this study, the myocardial 
partition coefficient (λ) was measured in healthy volunteers (n=12) and 
compared with a group of patients with acute (n=5) and chronic (n=5) 
myocardial infarction. Although the sample size was small, λ in both the 
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acute and chronically infarcted myocardium was significantly elevated 
compared with healthy tissue (p<0.001). 
1.6 Equilibrium Imaging - theory 
As described in section 1.5, contrast agents commonly used in modern CT 
and MR imaging (Iohexol and Gadolinium) are extracellular tracers that 
passively diffuse between blood and tissue, partitioning in the extracellular 
space (the interstitium) and the equivalent space in blood (the plasma 
volume), without crossing the cell membrane – and can thus be described 
using a two compartment model – Figure 1.12.  
  
 64 
 
 
Figure 1.12 Schematic 2 compartment model 
Schematic diagram showing passage of contrast agent molecules from the 
intravascular to the extravascular extracellular compartments. 
 
Figure 1.13 Schematic contrast equilibrium 
Schematic diagram showing equal net movement of contrast agent molecules 
between the tissue interstitium and blood plasma – a state of equilibrium 
By administering these agents as a primed infusion (bolus followed by an 
infusion to replace renal losses) it is possible to engineer a state where the 
concentration of contrast within the plasma and interstitium are constant 
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and equal, and where there is no net motion of contrast across the 
capillary wall (contrast steady state equilibrium) – Figure 1.13. During this 
state, the relative quantities of contrast within a unit volume of tissue and 
blood are dependent only on the respective fractional extracellular volume 
(ECV) within each. Therefore: 
ECVtissue / ECVblood = (Δtissue / Δblood)  
and 
ECVtissue = (Δtissue / Δblood) x ECVblood 
where Δtissue = tissue signal post contrast – tissue signal pre contrast  
The ECV within the tissue can then be estimated by measuring the 
attenuation or signal before and after contrast equilibrium, and by 
measuring the ECV of blood as 1-haematocrit – Figure 1.14. 
ECVtissue = (Δtissue / Δblood) x (1-haematocrit) 
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Figure 1.14 Tissue and blood extracellular volume 
A magnified histological slide of liver tissue with matrix components in the 
extracellular space stained red, illustrating the extracellular volume; (B) a blood tube 
after centrifugation; with separation of the cellular (blood cell) and extracellular 
(plasma) components. 
Measurement of contrast change is simple using X-ray based techniques 
such as computed tomography, where iodinated contrast agent 
concentration is linearly related to attenuation of the incident X-ray beam. 
The scenario with MRI and Gadolinium chelates is however more 
complex. Gadolinium is a paramagnetic metal whose unpaired electrons 
(55) cause effective shortening of T1 relaxation time of adjacent hydrogen 
protons (resulting in higher signal return on T1 weighted imaging). T1 
relaxation time is then inversely related to contrast concentration – a 
relationship that is however only linear over a certain range of contrast 
concentrations (56).    
In 2010 Flett et al (57) showed that contrast static steady state could be 
achieved within blood and myocardium using a primed infusion (bolus plus 
slow infusion) of Gadolinium-DTPA – Figure 1.15. Repeat measurement of 
T1 signal using an inversion recovery T1 mapping technique during the 
infusion showed variation of < 5% in T1; confirming static equilibrium.  
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Figure 1.15 T1 related signal change after primed infusion 
From Flett et al. T1’ is directly related to T1 relaxation time. After contrast bolus, TI’ 
drops rapidly as contrast concentration rises, but then falls as contrast is redistributed 
and renally cleared. Adding a slow infusion counteracts renal clearance and results in 
a steady state static equilibrium – i.e. constant contrast concentration 
 
This contrast equilibrium cardiac MRI technique (EQ-CMR) was then 
applied in a group of patients with severe aortic stenosis – a disease 
process leading to diffuse myocardial fibrosis. ECV was calculated: 
ECVmyocardium = ( 1 – haematocrit ) x      
∆ R1myocardium 
∆ R1blood 
where: ∆R1 = (1/T1)post contrast – (1/T1)pre contrast 
Myocardial ECV was compared with a collagen quantified from biopsy 
specimens collected at the time of surgical valve replacement (collagen 
volume fraction), with results demonstrating a close association between 
the two (r2 = 0.796 p = 0.001) - Figure 1.16. This work has then introduced 
the possibility of clinical non-invasive evaluation of myocardial fibrosis.  
The importance of the myocardial fibrosis, as measured by EQ-CMR has 
since been demonstrated by its relationship with mortality. Wong et al. 
measured myocardial ECV in 793 patients without amyloidosis or 
hypertrophic cardiomyopathy using EQ-CMR and found a significant 
relationship between ECV and mortality – even after adjusting for 
characteristics such as age and ejection fraction. 
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Figure 1.16 Myocardial ECV vs CVF 
From Flett et al. Association between myocardial contrast volume of distribution 
(ECV) and histological collagen volume fraction (CVF). 
It should be noted that equilibrium contrast imaging does not strictly 
evaluate the whole extracellular volume, but rather the volume of 
extracellular water in which the contrast agent distributes. However, the 
majority of extracellular volume is occupied by the intrafibrillary aqueous 
domains of proteoglycans, into which the relatively small soluble contrast 
agent molecules are free to pass. Expansion of the interstitium occurs with 
concurrent increases in both extracellular protein and water, thus offering 
potential for changes in EC water to closely track the extent of EC disease. 
In order for equilibrium contrast imaging to provide useful assessment of 
extracellular disease we must then assume that: 
• the volume of the collagen is small compared with its associated 
aqueous domain 
• extracellular expansion occurs with concurrent increases in protein 
content and aqueous volume 
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1.7 EQ imaging technique summary 
The Equilibrium Contrast MRI (EQ-CMI) protocol then consists of 3 basic 
elements:  
• administration of a purely extracellular contrast agent such as 
Gadolinium (Gd-DTPA) to achieve equilibrium between blood and 
tissue concentrations, thus eliminating the effect of contrast 
kinetics;  
• imaging before and after contrast equilibrium to measure the 
produced change in signal; 
• and a blood test to measure the extracellular volume fraction within 
blood. Tissue ECV can then be simply calculated using the formula: 
ECV = (1-haematocrit) x (∆ R1tissue ÷ ∆ R1blood) 
where ∆ R1=(1÷T1)post contrast - (1÷T1)pre contrast 
1.8 Development of a new clinical biomarker test 
Quantitative biomarkers which allow objective measurement of a 
biological, pathological or therapeutic process can provide powerful 
prediction of relevant clinical outcomes and end-points. In order to become 
a valid clinical and research tool, diagnostic biomarkers must successfully 
negotiate developmental, validation and implementation phases before 
clinical acceptance.  
Early technical development requires measurement validation with 
demonstration of test performance (accuracy, precision, specificity, and 
sensitivity). This is then followed by clinical validation, where the 
association between the biomarker result and a clinical outcome, is 
assessed. Both analytical and clinical validations precede demonstration 
of clinical utility, which requires evidence of improved, measurable clinical 
outcomes directly related to the use of the test.  
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A example of this development pipeline is summarised below:  
1. Technical development  
2. Comparison against histology 
3. Comparison in disease vs health 
4. Correlation with imaging markers 
5. Correlation with blood biomarkers 
6. Assessment in multiple clinical scenarios 
7. Assessment in early disease or with aging 
8. Ability to track change over time, and after Rx 
9. Predictive/prognostic value 
10. Test standardisation 
11. Define normal reference ranges 
12. Test as Surrogate trial endpoint 
13. Clinical use and regulatory approval 
14. Test improves clinical outcome 
Non invasive evaluation of tissue ECV has undergone initial technical 
development, with comparison against histology and demonstrated early 
potential as a biomarker of interstitial disease. In the following chapters the 
ECV biomarker will be developed further.   
 
 71 
2 AIMS, OBJECTIVES AND HYPOTHESES 
2.1 Thesis Hypothesis 
Tissues in which the interstitium is expanded by diffuse fibrosis or 
amyloidosis will demonstrate an elevated extracellular volume fraction 
(ECV) that can be measured using equilibrium contrast imaging (EQ) 
2.2 Aims and Objectives 
2.2.1 Basic Principles 
Rationale: Extracellular volume estimation by equilibrium contrast imaging 
necessitates a tissue 2-compartment model assumption. Contrast agents 
are assumed to be exclusively extracellular tracers, which do not cross the 
cell membrane. There is no direct experimental evidence proving a 
relationship between changing tissue extracellular volume fraction and 
ECV measured by EQ imaging, as the extracellular volume cannot be 
easily measured directly. 
Hypothesis: Increasing extracellular volume within a 2-compartment 
engineered tissue model will lead to increases in ECV measured using 
EQ-MRI 
Aim: Test the basic assumptions of EQ imaging estimation of ECV using a 
3 dimensional engineered tissue model (tumouroid) 
Objectives:  
i. Multiple engineered tissue models will be constructed with 
known extracellular volume fractions. 
 72 
ii. EQ-MRI will be used to measure the ECV within tumouroids 
and compared with that measured directly during their 
construction. 
2.2.2 EQ-MRI ECV in extra cardiac tissues 
Rationale: EQ-MRI has been successfully developed and applied in the 
heart in systemic amyloidosis (1) – providing potentially useful non-
invasive estimation of cardiac amyloid burden. Although cardiac 
involvement is the major cause of mortality and morbidity in both AL and 
ATTR type, extra cardiac amyloidosis is also important. Hepatic 
amyloidosis for example can cause derangement of liver function and 
rarely hepatic failure (2) and evaluation of extra cardiac involvement could 
aid diagnosis and prognostication.  
Hypothesis: ECV measured within the liver, spleen and skeletal muscle of 
patients with systemic amyloidosis will be higher than that of healthy 
volunteers and that ECV will track disease burden measured by current 
reference techniques  
Aim: develop EQ-MRI for evaluation of ECV within tissues outside of the 
heart 
Objectives:  
i. EQ-MRI will be used to measure ECV within extracardiac 
organs in patients with systemic amyloidosis  
ii. Comparison will be made with a group of healthy volunteers 
iii. ECV will be compared with amyloid organ involvement as 
measured with current reference standard of SAP serum 
amyloid P scintigraphy 
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2.2.3 Translation of EQ imaging to Computed Tomography 
Rationale: MRI based estimation of extracellular volume fraction has been 
established. Although MRI allows for high soft tissue and post contrast 
agent contrast to noise ratio (CNR), computed tomography (CT) is a 
faster, cheaper and more widely available imaging technology. 
Additionally, there are concerns over the effect on signal of water 
exchange between compartments; whereas the relationship between 
iodinated contrast agent concentration and attenuation is linear. 
Translation of the equilibrium contrast technique to a CT platform would 
add further validity, widen the availability of this test and provide an 
alternative modality when MRI is contraindicated. 
Hypothesis: ECV quantified using equilibrium contrast computed 
tomography is equivalent to that measured using EQ-MRI 
Aim: Translate the EQ technique to a computed tomography platform 
using iodinated contrast agents 
Objectives: 
i. An equilibrium iodinated contrast protocol will be devised 
ii. ECV measurements will be made using EQ-CT in patients 
with diffuse tissue fibrosis and amyloidosis involving the 
heart and liver 
2.2.4 EQ-CT in liver fibrosis 
Rationale: Chronic liver disease causing fibrosis and cirrhosis is a growing 
worldwide problem. Non-invasive assessment of liver fibrosis could 
potentially reduce the need for invasive liver biopsy and allow early 
intervention. Several non-invasive methods already exist but these have 
limitations. Equilibrium contrast imaging may allow simple accurate whole 
organ ECV assessment as a surrogate measure of fibrosis. 
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Hypothesis: Increasing diffuse fibrosis within the liver will be associated 
with increasing ECV measured using equilibrium contrast CT 
Aims: Evaluate the ability of EQ-CT to detect and quantify diffuse liver 
fibrosis 
Objectives: 
i. Recruit a group of patients with viral hepatitis and evaluate 
the liver using EQ-CT 
ii. Compare ECV with existing measures of liver fibrosis (serum 
biomarkers and histology) 
2.2.5 Quantitative CT for ECV measurement 
Rationale: Quantitative tissue assessment using computed tomography is 
limited by accuracy and precision of attenuation measurement using 
clinical CT systems. In developing EQ-CT I noted specific instances of 
image artefact induced variation in measured attenuation. 
Hypothesis: Unexpected variations in measured CT Hounsfield number 
are due to system artefacts; and application of corrective methods will 
reduce in this variation. 
Aim: Investigate artefacts leading to error in CT attenuation measurement, 
and evaluate methods to mitigate their effect 
Objectives: 
i. Evaluate attenuation variation within equilibrium phase CT 
image data acquired as part of work within previous chapters  
ii. Quantitative variation within and between scans; and 
investigate the effect of applying different reconstruction 
methods 
iii. Perform a subjective assessment of the artefact type 
underlying the attenuation variation 
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2.2.6 Optimisation of EQ-CT 
Wider use of CT based ECV estimation requires development of accurate, 
rapid and convenient test. 
Hypothesis: ECV can be measured using CT and rapid dynamic contrast 
equilibrium – with values comparable to that measured using the reference 
standard bolus and infusion steady state equilibrium  
Aim: Optimise the EQ-CT contrast and scan acquisition protocol 
Objectives: 
i. determine the feasibility of Dynamic-Equilibrium Computed 
Tomography (DynEQ-CT) to quantify cardiac amyloidosis  
ii. compare DynEQ-CT to clinical parameters and steady state 
equilibrium cardiovascular magnetic resonance (CMR) as 
standards of reference 
2.2.7 Estimation of musculoskeletal amyloid using EQ imaging 
Rationale: The use of 99mTc-DPD scintigraphy has highlighted skeletal 
muscle as a significant target organ in systemic transthyretin (ATTR) 
amyloidosis. The clinical significance of this deposition is unclear, but non-
specific symptoms of weakness and malaise are common in the systemic 
disease.  
Aim: to quantify skeletal muscle tracer uptake on 99mTc-DPD, and evaluate 
this as a measure of amyloid disease burden by comparison with muscle 
extracellular volume fraction, quantified using equilibrium contrast MRI 
(EQ-MRI). 
Objectives: 
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iii. devise a grading system for skeletal muscle 99mTc-DPD 
uptake and grade uptake in a group of patients undergoing 
clinical imaging 
iv. measure skeletal muscle ECV within this group using EQ-
MRI and compare ECV with DPD grade 
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3 METHODS 
3.1 ELF serum biomarker 
Serum biomarkers have been broadly discussed in a chapter 1, however 
the Enhanced Liver Fibrosis (ELF) panel is used in chapter 7 as a 
surrogate measure of liver fibrosis and will be specifically described here. 
The test comprises an algorithm combining quantities of three specific 
ECM matrix components and metabolites. Quantitative serum 
measurements of tissue inhibitor of metallo-proteinases-1 (TIMP-1), 
amino-terminal propeptide of type III procollagen (PIIINP) and hyaluronic 
acid (HA) made using specific immune assays are combined into a single 
valve using the equation:  
ELF score = 2.494+0.846 ln(CHA) + 0.735 ln(CPIIINP) + 0.391 ln(CTIMP-1)  
The ELF assay was evaluated in a large multicentre study carried out by 
the European Liver Fibrosis Group (1). This study included over 1000 
patients and showed high sensitivity and negative predictive value, 
particularly in liver diseases characterised by initial peri-sinusoidal fibrosis 
such as non-alcoholic steatohepatitis (NASH), post-transplant HCV 
hepatitis and haemochromatosis. Subsequent studies have demonstrated 
a close association between ELF and HVPG (widely considered one of the 
strongest independent predictor of clinical outcome (2) in HCV; and the 
ability of the ELF predict liver-related outcomes in primary biliary cirrhosis 
(3). Parkes et al in Gut 2010 (4) found ELF to be at least as accurate as 
liver biopsy in predicting liver-related outcomes, supporting its use as a 
prognostic marker. 
The ELF assay therefore offers a less invasive, and potentially more cost 
effective alternative to liver biopsy and has since been implemented as a 
CE marked quality-controlled test, making it suitable for patient use. 
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However, ELF, as with other serological fibrosis markers is not disease or 
organ specific (5), and may overestimate disease by reflecting 
extrahepatic abnormal extracellular matrix turnover. Evidence also 
suggests an association with inflammatory activity (6).   
3.2 High performance liquid chromatography (HPLC) 
Development of an iohexol steady state equilibrium protocol required 
measurement of the concentration of iodine (carried by iohexol) within the 
plasma, without exposing test volunteers to ionising radiation. Liquid 
chromatography is a technique that allows the separation and 
quantification of components within a liquid sample. High performance 
liquid chromatography (HPLC) can accurately measure plasma iodine 
concentration and has been widely used to estimate Iohexol clearance and 
glomerular filtration rate (7). 
Liquid, or the more recent ‘flash’ chromatography involves placement of a 
small volume of a liquid sample into a tube packed with porous particles of 
3-5μm in diameter. The sample is then forced along the packed tube 
high pressure delivered by a pump, and separation occurs by chemical or 
physical interaction between components of the sample and the packing 
particles. Separated components can then be detected at the exit of the 
column and their amounts measured – Figure 3.1. Thus HPLC offers 
significantly faster, more efficient and sensitive separation compared with 
traditional liquid chromatography. 
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Figure 3.1 Principles of liquid chromatography 
A sample is loaded into top of column of porous particles and forced along using 
pressure or solvent flow. Separation occurs by differential interaction between the 
sample and column material. 
Experimental samples were prepared at the UCLH Clinical Research 
Facility main laboratory within 1 hour of venesection. Whole blood samples 
were centrifuged at 2000rpm for 8 minutes and the plasma separated and 
frozen at -80°C pending transportation to the processing laboratory.  
The Iohexol assay was provided by Dr. Helen Aitkenhead, Principal 
Clinical Scientist, Dept of Chemical Pathology, Great Ormond Street 
Hospital, London, WC1N 3JH. 
3.3 Computed tomography 
CT is a form of photon absorptiometry, where linear attenuation is 
measured in multiple projections and reconstructed into an image map of 
normalised (Hounsfield) units. Values within the reconstructed attenuation 
map reflect the imaged material (density and atomic number). System 
manufacturers have invested heavily in technology to produce consistent, 
reliable and diagnostic images.  
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CT scan data was acquired using 2 scanner platforms:  
Somatom sensation, 64, 2004 model release date (3rd generation); 64 
slice, 40 detector rows, filtered back projection reconstruction 
Toshiba Aquilion one, 2010 model release date (3rd generation); 640 slice; 
320 x 0.5 mm detector rows; Beam hardening correction software; 
Adaptive Iterative Dose Reduction reconstruction 
Patient preparation and scan acquisition were performed by myself, with 
assistance from a collaborating research fellow (T. Treibel) and CT 
radiographers (E. Atkins; P. Patel).  
3.4 Magnetic resonance imaging (MRI) – T1 mapping 
T1 is a parameter that describes the speed with which protons recover Z-
axis (longitudinal) magnetisation after being excited by a radiofrequency 
pulse. This relaxation process is summarised by an exponential time 
constant, T1, which describes the non-linear rate of recovery. 
Reconstructing the longitudinal recovery curve using a magnetic 
resonance experiment with mathematical curve fitting of the data points 
can derive the T1 valve. Several techniques have been proposed using 
different acquisition schemes to sample the T1 recovery signal. Generally 
multiple images with different T1-weighting are acquired and a model used 
to estimate T1.  
The reference method for T1 relaxometry is an inversion recovery (IR) 
experiment (8) where signal intensity is measured at variable time points 
after an inversion pulse. Full recovery of the longitudinal (Z) magnetisation 
is allowed between sequential inversion pulses ensuring that the recovery 
curve is accurately sampled. This method is used in chapters 4, 5 and 10, 
with curve fitting performed using a sum of least squares method (see 
appendix 2 for T1 recovery function derivation). 
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The IR method is however time consuming and not practical for clinical 
use. Acquisition across multiple breath-holds is also prone to motion error. 
The Look-Locker sequence was introduced to measure the relaxation time 
at multiple time points after an initial excitation (8). Further rapid 
relaxometry sequences have been implemented that use sequential 
inversion recovery measurements within a single breath-hold - including 
the modified Look-Locker inversion recovery (MOLLI) Figure 3.2, and 
shortened MOLLI (ShMOLLI). The MOLLI sequence uses multiple single-
shot images, acquired along the recovery curve after an inversion pulse at 
the same phase of the cardiac cycle. Data from 3 inversion-recovery 
experiments over a single breath hold and 17 heart beat acquisition are 
then merged into one. This scheme has the potential for reduced heart 
rate dependence compared with the standard Lock-Locker approach, but it 
requires long breath holds – an issue in the elderly or those with 
cardiopulmonary disease. The shMOLLI sequence also uses sequential 
inversion recovery measurements but in a single shorter breath hold – 
typically 9 seconds. Here the longitudinal magnetisation is not allowed to 
fully recover between inversion pulses, but a conditional data analysis 
algorithm is used to prevent the Z magnetisation being significantly 
affected by the preceding inversion pulse (9). Data from both methods can 
be displayed as a colour pixel-wise T1 map, where each pixel reflects the 
relaxation time with the imaged tissue.  
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Figure 3.2 Example MOLLI T1 map image 
Example axial T1 map acquired through the upper abdomen using a MOLLI 
acquisition (Siemens WIP). T1 relaxation times are measured within regions of 
interest drawn within the liver, spleen, paravertebral skeletal muscle, fat and aortic 
blood. 
Other techniques include the saturation recovery single-shot acquisition 
(SASHA), and saturation pulse prepared heart rate independent inversion 
recovery (SAPPHIRE) sequences, with each implemented differently by 
the various scanner manufacturers.  
T1 measurements are influenced by several factors, such as the 
acquisition protocol, magnetization transfer, blood flow, T2 effect, and 
motion. The T1 relaxation time of a given tissue is dependent on its 
composition with each exhibiting a characteristic range of normal values at 
a certain magnetic field strength. Changes in tissue T1 relaxation time in 
disease have been reported in the heart, with myocardial infarction, heart 
failure valvular heart disease and systemic disease such as amyloidosis 
(10) leading to T1 prolongation (9) Figure 3.3.  
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Figure 3.3 Native T1 vs ECV in disease 
1346-9843 Native T1 value vs extracellular volume in various myocardial processes 
(concept slide from Martin Ugander SCMR 2014). Note the large overlap in T1 
relation times between the various disease states and healthy tissue. 
3.5 Image data processing 
CT and MRI image data acquired at University College London Hospital 
was stored on the hospital Picture Archiving and Communication System 
(PACS) before being exported to a secure research server. All image 
datasets were reviewed by myself for incidental findings and any serious, 
or potential serious findings were reported to the identifying clinical team 
and GP; and a report documented on the hospital Radiology Information 
System (RIS). 
DICOM data were then fully anonymised in accordance with UCL Centre 
for Medical Imaging policy using an open source application 
(DICOMCleaner, PixelMed Publishing Bangor, PA).  
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Region of interest (ROI) analysis was performed using an open source 
image software (OsiriX v4.1.2; OsiriX Foundation, Geneva, Switzerland). 
3.6 DPD scintigraphy 
Bisphosphonate bone scintigraphy agents have long been reported to 
localize to cardiac amyloidosis.  Recent evaluation of this approach 
suggests that two such tracers, 99mTc-labelled 3,3-diphosphono-1,2-
propanodicarboxylic acid (DPD)10–12 and 99mTc-labelled pyrophosphate 
(PYP) may have use for imaging cardiac amyloidosis – with high 
sensitivity for cardiac uptake in ATTR amyloidosis. The low cost and 
availability of bone scintigraphy make use of DPD and PYP imaging of 
cardiac amyloid an attract possibility, although the basis for its localization 
in the heart and its limitations in clinical practice have not been fully 
determined. DPD scans as part of this thesis work were performed at the 
National Amyloidosis Centre, under lead technologist David Hutt. Patients 
were scanned using a GE® Medical Systems hybrid SPECT-CT gamma 
camera (Infinia Hawkeye 4) following administration of 700MBq of 
intravenously injected 99mTc-DPD. Three hour (delayed) whole body 
planar images were acquired followed by a single photon emission 
computed tomography (SPECT) of the heart with a low-dose, non-contrast 
CT scan.  Gated/non-gated cardiac SPECT reconstruction and SPECT-CT 
image fusion was performed on the GE Xeleris workstation. Cardiac 
retention of 99mTc-DPD was visually scored according to the classification 
described by Perugini et al. as follows: Grade 0 - no visible myocardial 
uptake in both the delayed planar or cardiac SPECT-CT scan;  
Grade 1 - cardiac uptake on SPECT-CT only or cardiac uptake of less 
intensity than the accompanying normal bone distribution;  
Grade 2 – moderate cardiac uptake with some attenuation of bone signal; 
Grade 3 – strong cardiac uptake with little or no bone uptake; 
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3.7 SAP scintigraphy 
123I-SAP scintigraphy is the only modality in routine clinical use for the 
assessment of the extent and distribution of visceral amyloid deposition in 
all types of amyloidosis. Serum amyloid P (SAP) is a non-fibrillar 
glycoprotein found in all types of amyloid deposits as well as circulating 
blood plasma. Hawkins et al developed a method using radiolabelled SAP 
as a tracer for a deposits, and 123I-SAP is used routinely at the National 
Amyloidosis centre for in vivo amyloid imaging. Method as follows: 
A weight adjusted dose of purified human SAP component, radiolabelled 
with 200MBq of 123I is injected into the patient. Anterior and posterior 
whole body, planar images are captured on a General Electric (GE)® 
Infinia gamma camera no less than 6 hours after the injection. Total 
amyloid load in the liver and spleen are graded visually (by Prof. Philip 
Hawkins, with over 15 years experience in reporting SAP scans in the UK, 
having co-invented the scan with Prof. Sir Mark Pepys in 1988). Grading 
criteria were as follows:  
None – No tracer uptake into organs. Normal blood pool signal.  
Small – tracer uptake into organs with blood still clearly visible 
Moderate – Tracer uptake into organs with blood pool only just visible 
Large – Tracer uptake into organs with no blood pool visible 
SAP is a very effective method for identifying and measuring amyloid in 
large solid organs, especially the liver and spleen which have a 
fenestrated epithelium that allows efficient localisation of this large 
molecule.  However, this radionucleotide is costly and not commercially 
available, and only two centres in the world, in London, UK, and 
Groningen, the Netherlands currently use this technique routinely.  
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3.8 Collagen Proportionate Area 
Collagen proportionate area has been mentioned in section 1.8.1. This 
histological analysis method employed digital image analysis to quantify 
specific stained elements within a slide image. CPA analysis is used within 
this thesis to quantify fibrosis histologically. Analysis was performed by Mr. 
Andrew Hall, Department of Histopathology, Royal Free Hospital using the 
following method. Tissue is mounted within a paraffin block of at least 
1cm2. Sections cut at 3Am and stained with picro-Sirius red. Image 
capture uses a Canon Powershot A640 digital camera and Zeiss KS3000 
software for digital image analysis. Using image analysis software, a 
greyscale slider is used to select the tissue area that is then calculated as 
a total tissue area in pixels. A red, green, blue (RGB) threshold is used to 
detect areas of stained collagen and the collagen mask area calculated. 
The ratio between the total tissue are and collagen mask (CPA) is 
expressed as a decimal fraction. 
3.9 Statistics 
All statistical analyses were performed by myself using Prism statistical 
package; version 5 (Graphpad Software Inc., San Diego, CA). Normal 
distribution was assessed using the Kolmogorov-Smirnov test, and 
Gaussian variables presented as a mean and standard deviation. Non 
Gaussian variables are presented as median and interquartile range. 
Non Gaussian variables were compared between 2 groups using a Mann-
Whitney U test. Variation between more than 2 groups was assessed 
using a Kruskal-Wallis test, where the dependent variable was continuous 
or ordinal. 
Association between variables was assessed using Pearson correlation 
and linear regression used to evaluate model prediction of a dependent 
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variable. Bland-Altman analysis was used to assess agreement between 
two different measurement techniques. 
A P valve of <0.05 was considered significant.   
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4 INITIAL VALIDATION OF EQUILIBRIUM 
CONTRAST IMAGING FOR 
EXTRACELLULAR VOLUME 
QUANTIFICATION USING A 3D 
ENGINEERED TISSUE MODEL 
4.1 Author Declaration 
The experiments presented in this chapter were performed, and the data 
analysed and written by the author under the supervision of Dr. Shonit 
Punwani and Dr. Umber Cheema. Cell cultures and building of tissue 
models was completed with the assistance of Tarig Magdeldin. This work 
was published in the journal article: Bandula, S., Magdeldin, T., Stevens, 
N., Yeung, J., Moon, J. C., Taylor, S. A., … Punwani, S. (2016). Initial 
validation of equilibrium contrast imaging for extracellular volume 
quantification using a three-dimensional engineered tissue model. Journal 
of Magnetic Resonance Imaging: JMRI, 43(5), 1224–9. 
doi:10.1002/jmri.25066 
4.2 Introduction 
As discussed in chapter 1, diseases in which an altered tissue 
environment precipitates expansion of the extracellular volume are 
common and include myocardial fibrosis and hepatic cirrhosis. Equilibrium 
contrast (EQ) imaging is an emerging technique that allows non-invasive 
interrogation of the tissue extracellular volume fraction (ECV) using 
already widely used contrast agents and has potential as a useful 
biomarker for extracellular disease (1).  
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Contrast agents are purely exclusively extracellular tracers, allowing their 
behaviour to be modelled by assuming a 2-compartment approximation. 
Estimation of ECV is performed by administering contrast agents in such a 
way as to create a state of equilibrium between the intravascular 
extracellular and extravascular extracellular compartments – whereby 
there is no net movement of contrast molecules between the two 
compartments. The tissue partition coefficient can then be calculated by 
using imaging techniques, notably CT and MRI, to measure the relative 
contrast enhancement in the tissue compared with the blood. Correcting 
for the fractional extracellular volume within blood, which is easily 
measured with a complete blood count (1-haematocrit), yields the tissue 
ECV (2,3). 
This thesis seeks to validate the EQ method in disease processes that 
cause expansion of the extracellular space i.e. diffuse fibrosis and 
amyloidosis by comparing ECV with various clinical parameters and 
surrogate markers of the extracellular volume e.g. histological collagen 
fraction and extracellular protein component scintigraphy. However, the 
two-compartment model has limitations as MRI images water rather than 
the tracer (gadolinium) directly, and a number of assumptions are present, 
for example concerning water exchange (5). Confirmation of the 
underlying principles of the EQ technique requires comparison with a 
direct measure of the extracellular space. Several groups have attempted 
to quantify the extracellular volume using microscopy (light, confocal and 
electron) (6–8) but in all methods, sample preparation leads to variable 
distortion of tissue structure and measurement error. An alternative 
method, proposed in this chapter, is to artificially engineer a tissue of a 
specific volume, containing a known quantity of extracellular collagen 
matrix and known volume of cells – thus allowing the true extracellular 
volume to be calculated. Establishing a state of contrast equilibrium within 
this engineered tissue would allow comparative estimation of ECV by EQ 
imaging. 
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Recently three-dimensional engineered tissue constructs have been 
described which more closely model sophisticated cell orientation and 
matrix interactions than existing 2D models. Nyga et al. described 
construction of a three-dimensional in vitro colorectal cancer model or 
‘tumouroid’ with good structural and biomimetic properties (9).  
The experiments presented in this chapter aim to test the underlying 
principles of equilibrium MRI using a 3D engineered tissue model. Models 
are constructed with known cellular and extracellular volumes and ECV 
measured using EQ-MRI.  
4.3 Materials and methods 
4.3.1 Tumouroid construction 
3D tissue models were constructed using HT29 human colon 
adenocarcinoma cells - from the European Collection of Cell Cultures, 
Sigma Aldrich, Dorset, UK - seeded into a collagen hydrogel. Cells were 
cultured in 2D monolayers in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FBS, 100 units/ml penicillin and 
100µg/ml streptomycin (from Invitrogen, Paisley, UK) at 37°C in standard 
cell culture conditions (5% CO2/air and 95% humidity).  Total cell volume 
within a culture was quantified by centrifugation of the culture at 1500rpm 
for 5 minutes and measuring the dimensions of the formed cylinder of 
cells. Total cell number within each culture was counted using a 
haemocytometer. 
Collagen hydrogels containing HT29 cells were prepared as described by 
Nyga et al (9) with a slightly modified protocol. In brief, 3.2ml of type I 
collagen (rat tail collagen type I, 2.04 mg/ml in 0.6% acetic acid, First Link 
UK) was mixed with 0.4ml of 10x concentrated minimum essential Eagle’s 
medium (MEM) (Invitrogen). The solution was neutralized in a drop-wise 
manner, first with 5M and then 1M NaOH, and assessed by a visible 
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colour change from yellow to bright pink, indicating a pH change to 7.3. 
The cell suspension, in 0.4ml medium, was added and mixed gently to 
avoid bubbles. Acellular gels were set using DMEM instead of a cell 
suspension. The volume ratios of collagen type I:MEM:cell suspension 
were: 8:1:1. This cellular collagen solution was thoroughly mixed and 
transferred to a mould, then left to incubate for 30 minutes at room 
temperature, allowing the gel to set. Typically 4ml of HT29 cell–gel 
solution was used. Once set, the volume of the HT29-containing cellular 
collagen gel was reduced by partial plastic compression (10). The mould 
containing the gel was placed on a 165Am steel mesh and a nylon mesh 
on absorbent paper. The gel was compressed under a 175 g load for 30 
seconds. The gel was turned over and the process repeated for a further 
30 seconds. The final dimensions of the collagen gel containing the cells 
was 22mm x 10mm x 8mm. Cellular tumouroids were constructed with 
cultures containing 5, 6, 10, 15 and 31 million cells respectively, and an 
acellular tumouroid was used as a control. Each of the tumouroids were 
then placed into 6 separate specimen pots each containing 20ml DMEM. 
Cell number selection was guided by previous experience (9), and 
although the produced cell density was not representative of biological 
tissue, increasing the density further was not possible. Once constructed, 
tumouroids containing a higher number of cells lacked sufficient integrity to 
allow handling, and would disintegrate before imaging could be completed. 
In this model the tumouroid represented tissue parenchyma and 
surrounding DMEM solution represented the vascular compartment. 
Gadolinium contrast agent added to the DMEM would diffuse passively 
along a concentration gradient into the tumouroids until a state of static 
equilibrium is reached where the extracellular concentration within the 
collagen gel is equal to that within the DMEM. A schematic illustration and 
photograph of the experimental setup for a single tumouroid is given in 
Figure 4.1; Figure 4.2; note the similar hue of the tumouroid and 
surrounding medium made photographic visualization difficult. 
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Figure 4.1 Schematic showing single tumouroid 
Experimental schematic showing a single tumouroid with surrounding medium 
(DMEM) after addition of Gadolinium contrast. The specimen container is held within 
a water bath for thermal stability and to minimise susceptibility artefact arising from 
an air-fluid interface.   
 
 
Figure 4.2 Photograph of Sample tumouroid 
Sample tumouroid within specimen pot containing normal saline – semi-opaque 
culture medium would obscure view of the sample.   
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4.3.2 Tumouroid model EQ-MRI  
Due to a practical limitation on the number of cells that could be 
simultaneously cultured, tumouroids were manufactured and imaged in 2 
groups of 3. Once manufactured, tumouroids were stored at room 
temperature and imaged within 24 hours. Specimen pots containing the 
tumouroids were placed into a temperature monitored water bath within 
the MRI scanner room. After a 2-hour interval to allow temperature 
stabilisation, the water bath was moved onto the scanner table with the 
pots aligned in a line running across the scanner table from right to left. 
The T1 relaxation time within the gels was measured using a 3T clinical 
MRI scanner (Achieva 3T, Philips Healthcare, Best, The Netherlands) as 
follows: 
A single transverse slice was planned through the pots allowing all of the 
tumouroids to be visualised on a single image. T1 relaxometry was 
performed using a reference standard inversion recovery technique (table 
4.1). A turbo spin echo inversion recovery sequence was used to acquire a 
single slice with an inversion time (TI) of 50ms (Table 4.3), and repeated 
with TI of 100, 300, 500, 800, 1000 and 1500ms. Data acquisition for each 
T1 measurement took approximately 20 minutes. Image data was loaded 
into analysis software (OsiriX v4.1.2; OsiriX Foundation, Geneva, 
Switzerland) and regions of interest drawn within the DMEM fluid, and 
centre of the tumouroid. In order to reconstruct the T1 recovery curve 
(Figure 4.4), signal intensity (SI) was plotted against relaxation time and 
points to the left of intersection with the X-axis changed from positive to 
negative. Data was fitted to the recovery function:  
M(t) = M(0)*[1-2exp(-t/T1)]  
using a least squares method to solve for T1 relaxation time.  
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Parameter Value 
Imaging sequence Turbo spin echo 
TSE factor 16 
TE 7.9 
TR 5000 
TI 50 – 1500 
Slice thickness 2mm 
FOV (RL x AP)mm 140 x 72  
Voxel size (RL x AP)mm 1 x 0.926 
 
Table 4.3 EQ-MRI imaging parameters 
Table of EQ-MRI imaging sequence parameters 
Contrast equilibrium was then modelled by replacing a volume of DMEM 
within each specimen pot with gadopentetate dimeglumine (Dotarem; 
Guerbet, Paris, France) to achieve a concentration of 1.4mmol/L Gd 
(approximate blood concentration following clinical intravenous bolus 
administration) whilst giving a final volume of 20ml.  
The T1 relaxation time measurement was then repeated at 45, 170, 260, 
350 and 375 minutes after contrast addition (Figure 4.5). In a preliminary 
experiment, steady state contrast equilibrium (<5% change in T1 over 30 
minutes) was found to occur within the tumouroid and surrounding medium 
between 240 and 300 minutes following contrast addition.  
The ECV within each tumouroid was the calculated using the formula: 
ECVtumouroid = ( R1tumouroid /  R1DMEM)  
where  R1 = (1/T1) at steady state equilibrium - (1/T1) pre- Gd  
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4.3.3 Statistical Analysis 
A statistical package (Prism, version 5; GraphPad Software, San Diego, 
Calif.) was used for all data analysis. Linear regression analysis was 
performed to assess model prediction of directly measured ECV (ECVm) 
by EQ-MRI measured ECV (ECVeq). A P valve of <0.05 was considered 
significant. Bland-Altman comparison assessed agreement between 
ECVm and ECVeq.  
4.4 Results 
Steady state contrast equilibrium between tumouroids and medium was 
confirmed between 350 and 375 minutes after contrast addition, with a 
less than 5% change in T1 (Figure 4.6).  
The fractional extracellular volume by direct volume measurement (ECVm) 
ranged between 0 and 11%. ECVm and corresponding values of ECV 
measured by EQ-MRI (ECVeq) within each collagen gel are given in table 
4.7. ECVeq was shown to be a good predictor of ECVm (R2=0.77, 
P=0.02).  The regression line Y-axis intercept (when X=0) was 0.045 ± 
0.019 with a slope of 1.28 ± 0.35 (Figure 4.8). Bland-Altman comparison of 
ECVm and ECVeq (Figure 4.9) demonstrated 95% limits of agreement 
between -0.002 and 0.114 with a bias (SD) of 0.056 (0.03). 
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Figure 4.4 Fitted T1 relaxation curves 
T1 relaxation curves within a tumouroid before (t=0) and at 4 time points following 
addition of Gadolinium to the surrounding medium. T1 relaxation becomes more 
rapid as gadolinium diffuses into the hydrogel. 
 
 
 
Figure 4.5 Single tumouroid colour scale T1 maps 
Colour scale T1 maps (generated using Jim, version4; Xinapse Systems Ltd, West 
Bergholt, UK) showing tumouroid No.5 containing 15 Million cells held with a medium 
containing specimen pot at: (a) pre contrast, and (b) 45mins, (c) 2hr 50mins, (d) 4hr 
20mins and (e) 5hr 50mins post contrast (WL667; WW1335). Note that following the 
addition of contrast agent there is centripetal reduction in T1 relaxation time as 
gadolinium diffuses into the tumouroid. At equilibrium the concentration of gadolinium 
within the tumouroid is less than that of the surrounding media because of the 
volume occupied by cells. 
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Figure 4.6 T1 relaxation over time in single experiment 
Change in T1 relaxation time with time after administration of Gd within tumouroid 
No.5 and its surrounding medium. There is immediate shortening of T1 measured 
within the DMEM after addition of Gadolinium. T1 within the tumouroid however falls 
more gradually as gadolinium diffuses into the collagen gel, eventually reaching a 
steady state where there is no concentration gradient between DMEM and the 
extracellular compartment of the tumouroid 
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Tumouroid No. Cell no. x106 ECVm ECVeq 
1 0 1 0.963 
2 5 0.982 0.894 
3 6 0.979 0.963 
4 10 0.965 0.926 
5 15 0.95 0.864 
6 31 0.89 0.821 
 
Table 4.7 Tumouroid results summary 
Number of cells contained within each tumouroid with fractional extracellular volume 
quantified by direct volume and equilibrium imaging measurement 
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Figure 4.8 Comparison of extracellular volume measurements 
Plot showing fractional extracellular volume (ECV) derived by cell volume 
measurement and equilibrium contrast imaging, with regression line and line of 
identity (dotted) 
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Figure 4.9 Bland-Altman comparison of ECV measurements 
Bland-Altman comparison of cellular fraction measured directly ECVm and by EQ 
imaging ECVeq showing difference calculated by subtracting ECVeq from ECVm 
against mean ECV. Analysis demonstrates a bias of 0.05 (dashed line) with upper 
(dotted line) and lower (solid line) 95% limited of agreement.  
4.5 Discussion 
In this chapter I demonstrate initial use of a 3D engineered tissue model to 
interrogate estimation of extracellular volume fraction using equilibrium 
contrast imaging. EQ-MRI estimated ECV was strongly related to the 
fractional extracellular volume within tumouroids measured directly during 
their manufacture.  
ECV measured using EQ imaging has promise as a biomarker of 
extracellular disease, and may be able to quantify extracellular expansion 
resulting from diffuse fibrosis (11-15), and amyloid protein deposition (16-
17) within a range of organs. Although ECV has already been validated 
against specific reference standard measures of disease severity, to date 
there has been no specific verification of this volume fraction. By utilising a 
new 3-dimesional engineered tissue model I have been able to control the 
fractional cellular volume within a tissue and demonstrate in 6 collagen 
gels, that EQ-MRI provides good prediction of extracellular fraction.  
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ECV quantified by direct measurement might be expected to be equivalent 
to that by EQ-MRI, and for the regression line to overlie the line of identify. 
However Bland-Altman analysis demonstrated a bias, with ECV estimated 
by direct measurement consistently 5% greater than that by EQ imaging 
(also seen as a Y-axis intercept of 5% on the regression plot). This 
consistent discrepancy may in part reflect the volume occupied by 
collagen protein fibres, but other factors such as magnetization transfer 
(18) or differential relaxivity of the contrast agent in tissue rather than 
solution may contribute. A similar overestimate is suspected clinically 
where ECV in myocardial amyloid may appear very high (e.g. 0.7) (1).  
This initial experiment has a number of limitations. The range of fractional 
extracellular volume across which EQ-MRI was tested was relatively 
small. Previous studies have shown myocardial ECV can increase from 
approximately 25% in healthy individuals to 40% in severe fibrosis (1) and 
up to 60% (4) in Amyloidosis, although the ECV in skeletal muscle may be 
much lower (10%). The tumouroid ECV range of 89-100% tested here was 
limited by the fraction of cells that could be incorporated into the collagen 
gels. At higher cell fractions, failure of preparations to solidify is likely the 
result of an inadequate supporting collagen matrix. Future development of 
these engineered models with more complex extracellular components will 
support cell packing, cell-cell and cell-matrix interactions which better 
represents biological tissue.  
Future 3D engineered tissue models may incorporate higher amounts of 
collagen (19) in a more complex matrix able to support higher, more 
physiological cell fractions. Thus the relationship between ECV(m) and 
ECV(EQ) over a wider range, and the effect of varying extracellular 
collagen quantity may be investigated. Only 6 collagen gels were included 
in this initial proof of concept study and demonstration of the expected 1:1 
relationship between ECV(m) and ECV(EQ) over this wider range will 
require an appropriately powered study.  
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A significant drop in oxygen level has been demonstrated inside tumouroid 
model specimens in the 24 hour period after manufacture (9). This 
reduced oxygen tension is likely to have an effect on cell metabolism, 
membrane permeability and cell volume, although this was not measured 
in this current study. The 2 compartment model assumes that all water 
(intracellular and extracellular) is relaxed by the contrast agent – ie that 
water exchange is in the fast exchange regime (5). However, 
transcytolemmal water exchange is in part an active process, and 
ischaemia (especially if cells are large and contrast agent doses are high) 
may push the model into the slow exchange regime. To minimise this in 
future, studies should be designed to reduce this ‘wait’ time. Some delay is 
however necessary due to the need for cells to equilibrate in the 3D 
environment, and attach to the collagen matrix.  
The reference standard of cell fractional volume estimation involved 
separation of cells from medium supernatant by centrifugation to allow 
direct volume measurement. It is likely that a small volume of medium 
remained around the cells following centrifugation, but this volume is 
unlikely to be significant compared with volume measurement error.  
Several practical issues arose during MRI imaging. Accurate T1 mapping 
necessitated use of the reference standard inversion recovery method, 
which allowed only acquisition of a single slice. Collagen gels were free 
floating within media to allow even, rapid contrast diffusion but this also 
allowed tumouroid motion. Whilst stationary during the 6 hour imaging 
experiment, the pots were subject to vibrations from the MRI scanner likely 
resulting in small through plane movement of tumouroids. 
Repeatability of T1 and ECV measurements was not evaluated due to 
limitations on clinical scanner time (each measurement took approximately 
20 minutes) but future extension of the work should include repeatability 
and reproducibility evaluation across scanner platforms, T1 mapping 
methods and at a 1.5T field strength.  
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MR imaging of this engineered tissue, may also provide a powerful model 
for exploration of imaging biomarker of other tissue properties. By 
incorporating elements such as blood cells, fat and calcium, specifically 
engineered tissue phantoms may allow improved MR microstructural 
tissue assessment. 
In this initial exploratory experiment, I demonstrate use of a 3-dimension 
engineered tissue model as a platform to evaluate non-invasive tissue 
characterisation by equilibrium MRI. The results support the principles 
underpinning extracellular volume fraction estimation but future 
development of this model may allow validation over a wider, more 
physiological ECV range and a greater understanding of the effect of 
tissue extracellular protein burden on ECV. 
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5 EQUILIBRIUM MRI MEASUREMENT OF 
LIVER AND SPLEEN ECV IN SYSTEMIC 
AMYLOIDOSIS 
5.1 Author declaration 
The experiments presented in this chapter were completed, and the data 
analysed and presented by the author under the supervision of Prof. 
James Moon and Prof. Stuart Taylor. Dr. Daniel Sado provided comparator 
healthy volunteer data. This work was published in the journal article: 16. 
Bandula S, Banypersad S, Sado D et al. Measurement of Tissue Interstitial 
Volume in Healthy Patients and Those with Amyloidosis with Equilibrium 
Contrast-enhanced MR Imaging. Radiology. 2013;268(3). 
5.2 Introduction 
Systemic AL Amyloidosis causes multiorgan dysfunction through interstitial 
expansion (1). The presentation is usually non-specific and diagnosis is 
often difficult and delayed (2) – a major reason for this is an inability to 
reliably and accurately quantify interstitial expansion. The reference 
standard of invasive tissue biopsy is limited by its technical difficulty and 
complication rate; and although quantitative estimation of congo red 
birefringence is possible, the large sampling error limits clinical utility (3).  
As discussed in chapter 1, amyloidosis is eminently suited for evaluation 
using equilibrium imaging techniques. Indeed equilibrium contrast imaging 
has been used to explore cardiac interstitial expansion (5-6)(8-9) mainly 
by diffuse fibrosis, but also in cardiac amyloidosis (4) where interstitial 
expansion is caused by the deposition of extracellular amyloid fibrils. 
Interstitial expansion in amyloidosis can be massive and difficult to 
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measure (7) – the only widely used non-invasive quantitative test being 
serum amyloid P (SAP) scintigraphy (10) which is ineffectual in the heart 
(11).  
When the heart is at contrast equilibrium, so too are other tissues in the 
body, excluding privileged sites such as structures behind the blood:brain 
barrier. This raises the possibility of extending the equilibrium imaging 
technique beyond the heart ie EQ-MRI to evaluation of a range of tissues 
and organs. 
The purpose of work within this chapter was too to investigate equilibrium 
contrast MRI (EQ-MRI) measurement of extracellular volume fraction 
(ECV) within healthy abdominal tissues; and test the hypotheses that 
tissue ECV in systemic AL Amyloidosis is greater than in health; and that 
this increase tracks organ amyloid burden. 
5.3 Materials and Methods 
Local ethics committee approval was obtained (see chapter 1) and all 
participants provided informed written consent.  
5.3.1 Preliminary Evaluation of Tissue Equilibrium 
Previous studies described in chapter 1 have confirmed contrast 
equilibrium within the myocardium (8). As static contrast steady state has 
been previously verified only in the heart, before applying the EQ 
technique to other organs I performed a preliminary experiment to test if 
the gadolinium bolus plus infusion (B/I) protocol described would also 
produce contrast equilibrium within the liver, spleen and skeletal muscle.  
2 healthy volunteers (both male; aged 35 and 42 years) were given a 
bolus of 0.1 mmol/kg Gd-DTPA (Dotarem; Guerbet) with a 20ml normal 
saline flush at 3ml/s. After a 15-minute pause, an infusion of Gd at 0.0011 
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mmol/kg/min (equivalent to 0.1 mmol/kg over 90 minutes) was started as 
described by Flett et al. (8).  
For comparison a further healthy volunteer (male; aged 41) received only 
a bolus of 0.1 mmol/kg Gd-DTPA with a 20ml normal saline flush at 3ml/s. 
MRI was then used to measure the change in tissue signal intensity for a 
period of 55 minutes from the point of bolus injection:  
Axial, sagittal and coronal plane localisers were used to plan an axial slice 
through the upper abdomen to include the largest section of liver and 
spleen and a 4 chamber view of the heart. 
For rapid within-subject T1 measurement, a TI (time to inversion) scout 
steady-state free precession sequence was used (TR=1.27; TE=1.27ms; 
slice thickness 8mm, flip angle 30°; TI= 105 to RR interval) to measure TI’ 
(TI prime, the TI without heart rate or readout correction (i.e. a reliable 
reflection of intrasubject T1 variation over time), at the selected slice every 
5 minutes. TI’ signal intensity was measured within regions of interest 
(ROI) drawn in the blood, myocardium, liver and biceps muscle (see EQ-
MRI ECV measurement (section 5.3.3) for ROI drawing method).  Steady 
state was defined within a tissue as a variation in signal intensity of less 
than 5% between 3 consecutive TI’ readings.  
5.3.2 Recruitment 
Healthy volunteers were recruited as part of ongoing studies looking at 
ECV in health and disease at our institution. Amyloid patients were 
recruited specifically for this and a parallel study examining EQ-CMR in 
the heart (work outside of this thesis, results published elsewhere (12)). 
Recruitment took place between November 2010 and January 2012. Forty 
healthy volunteers (18 male; 22 female; median age 43; range 24-88 
years) were recruited through advertising within the hospitals, university 
and general practitioner surgeries. Healthy subjects had no previous 
history of cardiac or liver disease. 
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Consecutive patients with systemic AL amyloidosis (n=90) were identified 
from the National Amyloidosis Centre clinic. Inclusion criterion was biopsy 
proven AL amyloidosis demonstrated by Congo red and immunospecific 
staining. Biopsies were from various sites including kidney, heart, liver and 
soft tissue depending on the individual patient’s clinical presentation. 
Exclusion criteria were renal impairment defined as an estimated 
glomerular filtration rate (eGFR) <30ml/min or a contraindication to 
standard MRI. 18 patients were excluded due to abnormal renal function, 4 
had pacemakers, and 1 suffered with claustrophobia. The remaining 67 
patients (43 male; 24 female; median age 65 years, range 38-81) were 
recruited to the study. Subjects in the amyloidosis group contained a 
greater proportion of men and were on average older (P<0.0001) than the 
healthy volunteer group. 
5.3.3 EQ-MRI ECV Measurement 
EQ-MRI was performed using a 1.5T magnet (Siemens medical solutions, 
Avanto, 16 channel coil). T1 was measured using an inversion recovery 
technique previously used and validated by Flett et al (8). This is a multi–
breath-hold, spoiled gradient echo, fast low angle shot (FLASH) inversion 
recovery (IR) sequence with the following parameters: slice thickness 
8mm, TR 2000ms, TE 3.15ms, flip angle=21°, field of view 400x260mm, 
increasing inversion times (TI) per breath-hold of 140 ms, then 200 to 
1000 ms in 100-ms increments subsequently corrected for repeat time (8) 
– Table 5.1.  
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Sequence FLASH Gradient Echo 
Plane Axial 
Slices 1 
TR 2000ms 
TE 3.15ms 
Flip angle 21° 
FoV read / phase 400 / 260mm 
Slice thickness 8mm 
Inversion times 140, 200-1000ms 
Acquisition time per TI 14s 
Acquisition time for slice T1 map Approx. 6mins 
Image matrix 256 x 168 
Breathing Breath hold 
Saturation bands None 
 
Table 5.1 Sequence parameters for IR T1 measurement 
Sequence parameters for Inversion Recovery FLASH based measurement and 
mapping of T1 relaxation times 
Immediately prior to the EQ-MRI a sample of blood was drawn and sent 
for complete blood count (CBC) analysis, and the subject briefed on 
consistent breath holding. A member of the research team used axial, 
sagittal and coronal plane localisers to plan an axial slice through the 
upper abdomen to include the greatest area of liver and spleen. Pre-
contrast FLASH images were acquired at this location for T1 measurement 
with inversion times increasing from 140 to 200ms and then to 1000ms in 
100ms increments.  
A bolus and infusion of contrast was then administered to achieve 
equilibrium using parameters validated previously (8). A bolus of 0.1 
mmol/kg Gd-DTPA (Dotarem; Guerbet) was used with a 20ml normal 
saline flush at 3ml/s, after which the subject was allowed to leave the 
scanner table to sit in a chair. Following a 15-minute pause, an infusion of 
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Gd at 0.0011 mmol/kg/min (equivalent to 0.1 mmol/kg over 90 minutes) 
was started. At 45 to 55 minutes post bolus, i.e. during contrast equilibrium 
(EQ), the patient was returned to the scanner and a further set of FLASH 
images acquired for T1 measurement (TI 200 to 600ms) at a similar 
location to the pre-contrast images – Figure 5.2. 
 
Figure 5.2 EQ-MRI scan protocol schematic 
EQ-MRI protocol including contrast administration and imaging components  
Matching of slice locations was done visually by the author. Mean tissue 
T1 relaxation time was then measured within the selected tissues at both 
time points as described below. Scan analysis was performed by the 
author, who was blinded to all clinical data. Region of interest (ROI) 
analysis was performed using OsiriX (Pixmeo SARL, Switzerland). 
Beginning with the equilibrium phase data, the image with the greatest soft 
tissue contrast was visually selected. Single ROIs were then drawn in 
each of the 4 tissues of interest. A circular ROI was drawn in the 
abdominal aorta (mean=136mm2, range 81-358mm2) so as to include the 
greatest area of lumen, but not include aortic wall – frequently thickened 
by atheroma. In the liver, a single large peripherally based, wedge shaped 
polygonal ROI was drawn in liver segment 6 and 7 (mean= 2938mm2, 
range 1268-3281mm2) so as to include the maximum area of liver tissue 
but avoid visible hepatic and portal veins. Elliptical ROIs were also drawn 
in the spleen (mean= 672mm2, range 213-842mm2) and paravertebral 
muscle (mean= 92mm2, range 35-104mm2) to include the maximum area 
of tissue and void adjacent vessels and fat – Figure 5.3. The 4 ROIs were 
then copied to the other EQ phase FLASH images and mean signal 
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intensity within each tissue at each inversion time recorded. Mean tissue 
signal intensities were then plotted against inversion time. The inversion 
time producing the lowest signal intensity was identified and the sign of 
signal intensities plotted to the left of this point made negative. This 
allowed reconstruction of the full range of the T1 signal intensity inversion 
recovery curve. A second-order polynomial curve-fitting technique was 
used to find the null point – Figure 5.4. A previously validated (8) algorithm 
was then used to correct for incomplete longitudinal recovery giving a 
corrected T1. 
 
Figure 5.3 Example regions of interest 
Example precontrast axial MR image (inversion time, 800 msec) showing sample 
regions of interest drawn within the abdominal aorta, spleen, liver and paravertebral 
muscle  
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Figure 5.4 Signal intensity vs inversion time curves 
FLASH images acquired at increasing inversion times and tissue signal intensity 
plotted with phase restored. From the inversion recovery curves, change in TI’ can be 
determined, allowing ECV for that tissue to be calculated. 
Following measurement of tissue T1 at the EQ phase, ROIs were copied 
to the pre-contrast images with manual adjustment of the ROI position 
where needed. 
Where an organ was incompletely scanned on either phase, or images 
degraded by breathing or wrap around artefact such that measurement of 
reliable signal intensity was deemed not possible by the observer, data for 
the organ in that individual was excluded. 
Using the pre-contrast and EQ phase mean T1 relaxation times, and 
hematocrit measured from the CBC, ECV fraction within each tissue was 
calculated using the formula: ECV = (1-haematocrit) x (∆ R1tissue ÷ ∆ 
R1blood) 
where ∆ R1=(1÷T1)EQ phase - (1÷T1)pre contrast 
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5.3.4 SAP Scintigraphy 
All patients with amyloidosis underwent amyloid I 123-labelled SAP 
scintigraphy as part of their routine assessment at the National 
Amyloidosis Centre – see chapter 1.20 (13). SAP imaging was performed 
within 8 weeks of the EQ-MRI.  As described in chapter 1.20, weight-
adjusted dose of purified human SAP component, radiolabelled with 
200MBq of 123I is injected into the patient. Anterior and posterior whole 
body images and were acquired using a GE Infinia gamma camera and 
medium energy collimator, 24 hours after administration of 200 MBq 123I-
SAP. 
Total body, liver and splenic amyloid burden were scored by visual 
assessment (14) by a single physician (PH) with over 25 years experience 
in SAP imaging – see chapter 1.20.   
• None – No tracer uptake into organs. Normal blood pool signal.  
• Small – tracer uptake into organs with blood still clearly visible 
• Moderate – organ tracer uptake with blood pool only just visible 
• Large – Tracer uptake into organs with no blood pool visible 
 
5.3.5 Statistical analyses 
The Prism statistical package: version 5 (Graphpad Software Inc., San 
Diego, CA) was used for all data analysis. Normal distribution was 
assessed using the Kolmogorov-Smirnov test.  
Variation in ECV between matched organs was assessed using the 
Friedman test for both the healthy subjects and patients with amyloidosis. 
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Liver, spleen and muscle ECV measurements in healthy volunteers 
followed a non-Gaussian distribution and were compared with those in the 
amyloidosis population using a Mann-Whitney U test. 
Variation in ECV across SAP scores was assessed using a Kruskal-Wallis 
test for both the liver and spleen, with Dunn’s multiple comparison 
between SAP gourps. In order to examine for an association between ECV 
and SAP score in the liver and spleen I performed Spearman correlation 
analysis, computing a one tailed P-value. A P value less than or equal to 
.05 was considered significant. 
5.4 Results 
5.4.1 Confirmation of Tissue Contrast Equilibrium 
In the preliminary experiment, contrast equilibrium was achieved in the 
liver, biceps muscle, blood and myocardium in both volunteers with bolus 
and infusion by 25 minutes. In comparison, the volunteer given only a 
bolus of contrast failed to reach equilibrium within the blood, muscle and 
myocardium. After a steep fall immediately following the contrast bolus 
injection, TI’ rose steadily back towards its pre-contrast value.  A similar 
pattern was seen in the liver but the increase was slow compared to other 
organs, and from 25 minutes the change in TI’ was less than 5% between 
consecutive time points – Figure 5.5. 
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Figure 5.5 Confirming tissue contrast equilibrium 
Blood and tissue TI’ measured following (1) contrast bolus only and (2) bolus plus 
infusion in 2 different healthy subjects. The plot demonstrates the effect of the 
infusion on TI’ – which directly relates to T1 and therefore maps contrast 
concentration change over time. 
5.4.2 Clinical Validation 
EQ-MRI was attempted in all 40 volunteers and 67 amyloidosis patients 
(see section 5.3.2 for patient characteristics). Due to scan time limitations, 
patient discomfort, breathing and wrap around artefacts and previous 
surgical resections, complete imaging was available for the liver, spleen 
and paravertebral muscle in 35, 32 and 34 healthy volunteers; and 56, 48 
and 53 amyloidosis patients respectively. Imaging of all 3 tissues was 
available in 30 healthy volunteers and 46 amyloidosis patients. 
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EQ-MRI demonstrated a significant difference (p<0.0001) in median ECV 
between healthy liver, spleen and paravertebral muscle (median[IQR]= 
0.29[0.27-0.33], 0.34[0.32-.35] and 0.09[0.08-0.14] respectively - Figure 
5.6.  
In amyloidosis the median ECVs also varied significantly (p<0.0001) 
between liver, spleen and paravertebral muscle (median[IQR]= 0.32[0.28-
0.37], 0.39[0.35-0.51] and 0.16[0.13-0.22] respectively).  
There was a statistically significant (Pspleen<0.0001, Pliver=0.0136, 
Pmuscle<0.0001) increase in the ECV of all organs in the amyloidosis 
group compared with health volunteers - Figure 5.7. 
56 patients underwent matched liver EQ-MRI ECV measurement and SAP 
scintigraphy. 16 of these cases were excluded - in 15 cases SAP imaging 
demonstrated a congested liver pattern, i.e. an increased blood-pool signal 
associated with cardiac failure, and in 1 case localization of the tracer was 
equivocal. 29 patients scored 0 on SAP; 5 scored 2 and 6 scored 3.  
48 patients underwent matched splenic ECV measurement and SAP 
scintigraphy. 6 cases were excluded as SAP activity was scored as 
equivocal. 22 patients scored 0 on SAP; 8 scored 1; 7 scored 2 and 5 
scored 3. 
There was a significant difference in ECV between SAP scores in both the 
liver (P=0.0005) and spleen (P=0.0014). ECV increased with SAP score in 
both the liver and spleen. There was a positive correlation between ECV 
and SAP score in both the liver (rs=0.54,) and spleen (rs=0.57) - Figure 
5.8.  
Dunn’s multiple comparison test showed that in the liver, only ECV in the 
SAP 0 vs 3 groups; and in the spleen SAP 0 vs 3 and SAP 1 vs 3 vaired 
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significantly. There was no significant difference between ECV in the 
healthy group and SAP 0 in the amyloid group for each organ. 
 
 
Figure 5.6 Tissue ECV (median and IQR) in healthy volunteers 
Plot showing median and interquartile range of ECV measure with the liver, spleen 
and skeletal muscle of healthy volunteers. ECV varied significant between the 
difference tissues (p<0.0001). 
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Figure 5.7 Comparison of ECV in health and amyloidosis 
Comparison of healthy subjects and amyloidosis patient ECV (median and IQR) 
measured in the liver, spleen and paravertebral muscle. 
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Figure 5.8 Confirming tissue contrast equilibrium 
Blood and tissue TI’ measured following (1) contrast bolus only and (2) bolus plus 
infusion in 2 different healthy subjects. The plot demonstrates the effect of the 
infusion on TI’ – which directly relates to T1 and therefore maps contrast 
concentration change over time. 
5.5 Discussion 
In this chapter I have used EQ-MRI to define ECV in healthy tissues; and 
document variation in ECV between tissues. Such data is vital if ECV is to 
be used to detect pathological processes. I have then shown significant 
differences in a disease process that exemplifies expansion of the 
extracellular space - systemic AL amyloidosis. This provides strong proof 
of concept that the equilibrium techniques can be successfully applied 
outside the heart.  
Although evidence exists that changes in the extracellular space may be a 
useful indicator of disease severity and treatment response (15), few 
existing techniques are able to quantify this space.  
The ideal comparator for this study would have been histological 
assessment of the extracellular space. Histological techniques do exist to 
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quantify extracellular collagen matrix; and when applied to the liver, 
automated collagen proportionate area measurement has shown good 
association with other indices of diffuse liver fibrosis (16). However 
collagen proportionate area measurements in the healthy liver are in the 
order of 2-3% (17) – much lower than our ECV estimate. This difference is 
likely to be due to the fact that the extracellular collagen matrix occupies 
only part of the extracellular space within the liver. Current histological 
techniques are unable to directly measure the ECV as the process of 
tissue sampling and preparation almost certainly alters tissue ECV. 
As many pharmaceutical products distribute exclusively within interstitial 
space, some pharmacokinetic model based ECV estimates exist. Levitt 
(18) collected data from earlier experiments to produce a physiologically 
based pharmacokinetic model; estimating the EC fraction in organs of a 
hypothetical standard human. He estimated the EC fluid fraction with the 
liver and muscle to be 0.23 and 0.15, which is broadly similar to the 
equilibrium imaging data. 
DCE-MRI has been used more recently to quantify the extracellular space 
and evaluate changes in response to treatment using a tumour disease 
model (19). DCE-MRI is however a complex technique, prone to 
substantial measurement error and application is limited to only one tissue 
site (20). A direct comparison of EQ-MRI and DCE-MRI ECV quantification 
has yet to be made, however other authors using DCE-MRI have reported 
ECV in the healthy liver as 0.2-0.3 (15) and skeletal muscle as 0.106-
0.115 (21). The estimates of ECV from pharmacokinetic modelling and 
DCE-MRI are thus broadly consistent with each other, and with our EQ-
MRI results.  
In this chapter, comparison is made with a disease specific in vivo probe 
for extracellular (amyloid) protein deposition.  Serum amyloid P component 
scintigraphy is the current reference standard method for evaluation of 
systemic amyloidosis and has enabled wider assessment of organ amyloid 
 120 
involvement. Unlike histology, it can be used to track changes in whole 
organs over time. These results demonstrate that an increase in tissue 
amyloid burden assessed by SAP scintigraphy is associated with an 
increase in tissue ECV. ECV between SAP groups showed some overlap 
particularly in the lower disease burden range, with ECV unable to 
distinguish between SAP 0 and 2. Improvements in measurement 
precision in this disease range will then be required before EQ-MRI can 
provide a useful non-invasive tool for early amyloid diagnosis, disease 
assessment and therapeutic monitoring. 
Disease evaluation and quantitation using SAP scintigraphy however 
requires specific expertise and is only available in highly specialized 
centres. The high atomic mass of the SAP molecule (125 kDa) also 
favours evaluation in tissues with a fenestrated endothelium (such as the 
liver and spleen), where the large molecule is able to pass into the 
interstitium. Hence SAP scintigraphy provides little information about 
amyloid deposition in tissues such as skeletal muscle and myocardium.  
This experiment had several limitations. The FLASH IR based T1 mapping 
technique used was complicated, time consuming and prone to error. To 
minimise possible variation in slice position during the multi breath hold 
acquisitions, careful subject coaching was necessary. Other sources of 
error were copying of ROIs, which required individual adjustment; and the 
restoration of signal intensity phase around the null inversion time, which 
was subjectively assessed to match the curve fit. Technical improvements 
in T1 mapping, for example the ‘Shortened Modified Look Locker Inversion 
recovery’ sequence (22) allows faster and more robust tissue ECV 
mapping; albeit within a single slice per breath hold. Although the bolus 
plus infusion protocol used in this study provided steady state equilibrium 
in all tissues of interest, prolonged contrast infusions are not practical for 
clinical imaging. Preliminary experimental findings concur with other 
authors (8) in showing steady state equilibration is reached approximately 
15 to 20 minutes after administration of contrast bolus plus infusion. Future 
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protocols may then incorporate equilibrium phase imaging after a shorter 
delay than was used here.  
EQ-MRI evaluation of ECV is also not specific to disease aetiology. As 
well as amyloid deposition and diffuse fibrosis, tissue ECV may be 
elevated by interstitial edema or an inflammatory infiltrate. Although these 
potential confounders could not be specifically excluded in this study, 
cases demonstrating a congested pattern of activity on SAP scintigraphy 
were excluded from the SAP/ECV correlation. 
It is noted that healthy volunteer and amyloidosis patients groups were not 
age and gender matched. Sado et al. (24) showed that mean myocardial 
ECV in healthy females was 4% higher than in healthy men; with no 
change with age. This has not been assessed in other organs. In this 
study, the higher female proportion in the healthy group compared with the 
amyloidosis group (see section 5.3.2) may have reduced the difference in 
mean ECV measured between these groups. In order to minimise such 
bias, future studies should ensure that groups are gender matched. 
Having assessed EQ-MRI in one disease, it is worth noting that 
amyloidosis forms a relatively small part of a larger set of conditions where 
EC disruption and expansion leads to organ dysfunction. Diffuse fibrosis is 
a ubiquitous process of interstitial collagen deposition, occurring in 
response to diffuse tissue injury as well as in senescence. Many of the 
conditions where this process can be identified histologically; for example 
diffuse myocardial fibrosis and liver cirrhosis, have huge population 
significance. The application of EQ imaging in these organs could 
potentially provide a new biomarker for disease evaluation and is the topic 
of subsequent chapters. 
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6 DEVELOPMENT OF EQUILIBRIUM 
CONTRAST COMPUTED TOMOGRAPHY 
(EQ-CT)  
6.1 Author declaration 
The experiments presented in this chapter were performed, and the data 
analysed and presented by the author under the supervision of Dr. Shonit 
Punwani, Prof. James Moon and Prof. Stuart Taylor. This work was 
published in the journal article: 1. Bandula S, White SK, Flett AS, 
Lawrence D, Pugliese F, Ashworth MT, et al. Measurement of myocardial 
extracellular volume fraction by using equilibrium contrast-enhanced CT: 
validation against histologic findings. Radiology. 2013 Nov;269(2):396–
403. 
6.2 Introduction 
We have seen in previous chapters that developments in magnetic 
resonance imaging have permitted non-invasive quantification of tissue 
extracellular volume (ECV)(1), with validation against histological 
measures of diffuse fibrosis in the myocardium.  These “equilibrium” 
techniques rely on three principles laid out in chapter 1: firstly, the 
measurement of global myocardial and blood T1 signal before intravenous 
contrast administration; secondly, re-measurement of T1 signal during 
sufficient contrast equilibrium to negate contrast kinetics as a contributor to 
signal change, (2); and thirdly, a direct measurement of the blood contrast 
volume of distribution (1-hematocrit).  However, there are a number of 
limitations to the EQ-CMR approach.  CMR availability is limited and T1 
mapping as a technique is immature. Contrast agent induced signal 
change in CMR is complex, and potentially non-linear in tissue (3-4). 
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Together, these act as significant barriers to widespread clinical 
implementation 
Iodinated computed tomography (CT) contrast agents are also 
extracellular tracers (5), and so theoretically behave similarly to CMR 
contrast agents. Although CT is associated with exposure to ionising 
radiation, the potential advantages of CT over CMR for measuring the 
interstitium include less complex measurements, faster, more widely 
available and cheaper imaging, and the potential for sub-millimetre 
resolution. Such an approach could allow measurement to be performed in 
almost any organ or tissue in the body (outside the blood-brain barrier) in 
almost any hospital, using conventional equipment and contrast agents.   
The pharmacokinetics of iodinated contrast agents were described some 
time prior to the advent of CT imaging (6). Most recently, Nacif et al. 
described an EQ-CT technique (9) to measure myocardial ECV using a 
bolus only equilibrium contrast protocol (i.e. without contrast agent 
infusion), showing good agreement with ECV measured using 
conventional EQ-CMR.  
In order to quantify extracellular volume using a bolus of contrast agent, a 
dynamic state of equilibrium is assumed, where tissue contrast 
enhancement parallels that of the blood. This dynamic state however 
requires rapid equilibration of contrast between the intra and extravascular 
EC spaces - kinetics which are dependent on tissue blood flow, capillary 
permeability, rate of diffusion and extravascular volume. A bolus only 
protocol has shown good ECV estimation in selected tissues such as 
myocardium, liver and spleen (7-9), although these measurements have 
yet to be validated against a histological standard.  Furthermore, tissue 
perfusion or permeability, or disease states with interstitial expansion, will 
increase disequilibrium between plasma and the interstitium after a bolus 
of contrast. A steady state equilibrium, where a continuous infusion 
replaces renal and other losses produces a period of constant plasma 
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concentration (1)(10), which allows equilisation with the interstitium in all 
tissues (outside of the blood-brain barrier). The plasma and interstitum can 
then be treated as one extracellular compartment allowing measurement 
of ECV without knowledge of tissue perfusion or vascular permeability. For 
the initial validation of EQ-CT, the bolus/ infusion approach was deemed to 
be more robust than a single injection approach.  
The work within this chapter aims to develop and validate steady state 
equilibrium contrast computed tomography (EQ-CT) as a measure of 
myocardial extracellular volume fraction (ECV) using a histological 
reference standard, and to compare with equilibrium contrast MRI (EQ-
MRI).  
6.3 Materials and Methods 
Local ethics committee approval was obtained for each part of the study – 
see chapter 1. All participants provided informed and written consent.  
EQ-CT development was approached in three stages. Firstly, in order to 
remove contrast kinetic effects, a protocol of primed iodinated contrast 
infusion (bolus plus maintenance infusion) that generated steady state 
equilibrium contrast conditions was developed, demonstrating this first in 
blood and later in blood and tissue. Secondly, a CT scanning and analysis 
protocol that could measure cardiac muscle and blood pool attenuation 
with an adequate signal to noise ratio was developed. Thirdly, this EQ-CT 
method was validated against human myocardial tissue obtained by 
surgical biopsy in patients with severe aortic stenosis where diffuse 
fibrosis is known to occur (21). Lastly EQ-CT measurement of ECV was 
compared with measurement using EQ-MRI.  
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6.3.1 Blood Contrast Equilibrium 
A contrast infusion and bolus protocol to achieve equilibrium in the blood 
was developed in 15 individuals (12 healthy volunteers and 3 patient 
volunteers; mean age 44.2, range 27-76). An unpaired t-test demonstrated 
no significant difference in mean age between the 9 males (mean 41.8; 
range 27-76 years) and 6 females (mean age 47.0; range 27-71 years) in 
this group. 
In order to achieve contrast equilibrium rapidly a primed infusion technique 
(bolus followed by slow continuous infusion) was developed to achieve 
steady state equilibrium consistently within 30 minutes. The parameters 
required for to reach contrast equilibrium in this time frame were identified 
using an iterative approach, first in healthy volunteers (n=12) then in 
patient volunteers (n=3), based on those previously validated in EQ-MRI 
(1).   
Volunteers had a intra venous cannula placed in both antecubital fossae 
(one for contrast administration, and the other for blood sampling).  The 
initial contrast protocol consisted of a bolus volume of 1mg/kg of Iohexol 
(Omnipaque 300; Nycomed Amersham, Oslo, Norway; 300 mg of iodine 
per millilitre) administered a rate of 3mls/sec. This initial infusion rate was 
based on similar work using MRI contrast agents (1). 3ml blood samples 
were taken at 0, 1, 3, 7, 10, 15, 20, 30, 45, 60 minutes after bolus injection 
and plasma iodine concentration measured using high performance liquid 
chromatography (HPLC) (11) – see methods Chapter 3.  In the second 
volunteer a 1mg/kg bolus was given at 3ml/s followed after a 15 minutes 
delay by an infusion of Iohexol at 2.4ml/kg/hr (with a maximum contrast 
volume of 200mls). Three parameters: bolus volume; infusion start time 
and infusion rate were then varied iteratively after each experiment based 
on the derived plasma iodine concentration curve. Contrast equilibrium 
was defined as a plasma concentration variation in consecutive 
measurements of < 5% over 10 minutes. At the end of the iterative 
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development, a protocol consisting of 1mg/kg bolus at 3ml/s, followed 
immediately by an infusion of 1.88ml/kg/hr was found to provide the most 
rapid and consistent steady state equilibrium – Figure 6.1. 
 
Figure 6.1 Iodinated contrast concentration curves 
Blood iodine concentration measured using HPLC in 2 normal volunteers following 
(a) 80ml bolus and (b) 80ml bolus followed immediately by an infusion at 2.5ml/min of 
Iohexol (300mgI/ml). 
 
6.3.2 Confirmation of Tissue contrast equilibrium 
Following derivation of the contrast bolus and infusion protocol, blood and 
tissue equilibrium was assessed using CT imaging in consenting patient 
volunteers (n=5; 3 male, 2 female) referred for abdominal imaging for non-
specific symptoms. Imaging examinations were performed using a multi 
detector 64-row CT scanner (SOMATOM Sensation 64, Siemens Medical 
Solutions, Erlangen, Germany). A topogram was used to plan a spiral CT 
volume of the lower chest from the level of the aortopulmonary window to 
just below the inferior aspect of the heart. Scans (tube voltage 120kV, tube 
current-time product 160mAs, slice collimation 64mm×1.2mm, gantry 
rotation time 330ms) were acquired using retrospective ECG gating at 4 
time points (pre contrast, 10, 15 and 25 minutes post-primed infusion) to 
confirm equilibrium was achieved within cardiac tissue. Retrospective 
gating required continuous data acquisition through multiple cardiac cycles 
with simultaneous ECG recording, allowing reorganisation of the 
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reconstruction to the desired phase (65-75% of the RR interval). Heart rate 
was recorded at the beginning of the pre-contrast acquisition. Axial images 
were reconstructed with a slice thickness of 5mm using a B20f kernel.  
Regions of interest (ROI) were drawn using OsiriX v4.1.2 (Pixmeo, 
Switzerland) by the author who was blinded to all other study data. An 
axial slice was selected that visually contained the greatest area of 
myocardial septum. On this slice an elliptical ROI was drawn in the left 
ventricular chamber so as to include the largest area of blood pool but not 
including papillary muscle; and a polygonal ROI was drawn in the 
myocardial septum to include the maximum area of myocardium but 
avoiding the endocardium.  
Initially blood pool attenuation was measured in the descending aorta, 
however ROIs here were affected by streak and beam hardening artefact 
(see chapter 9.4.1) from adjacent dense vertebral endplates and aortic 
wall calcification leading to significant variation in measured attenuation. 
To overcome this, blood attenuation was measured within the left 
ventricular blood pool adjacent to the myocardial septum (the ventricular 
blood pool lies further away from the vertebra, is less affected by artefact, 
and given the proximity of the myocardial septum and ventricular blood 
pool, any artefact present was likely to affect both ROIs in a similar way). 
The mean HU was measured in each ROI and plotted against time. 
Steady state equilibrium was confirmed in all 5 volunteers by a change in 
mean HU attenuation within myocardial and blood ROIs between 
successive time points of < 10% (reflecting the increased noise associated 
with CT attenuation measurement) - Figure 6.2.  
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Figure 6.2 CT confirmation of tissue equilibrium 
Left – pre contrast CT; middle – post contrast at 25 minutes; right - CT attenuation 
plots of blood and myocardial equilibrium. Pre contrast blood and myocardium are 
visually iso-dense; post contrast, both have increased attenuation but now a 
blood:myocardial boundary is visible with blood brighter – therefore blood visually 
has the larger ECV. 
6.3.3 Clinical Validation 
Recruitment took place at UCLH between July 2010 and February 2012.  
Patient inclusion criteria were severe aortic stenosis with elective open 
valve replacement planned within 4 weeks. Exclusion criteria were 
uncontrolled arrhythmia; impaired renal function (estimated glomerular 
filtration rate, eGFR< 60 ml/min) or contraindications to MRI (e.g. 
implanted devices). 2 patients were excluded with atrial fibrillation; 2 with 
impaired renal function and 1 due to severe claustrophobia.  
EQ-CT was performed pre-operatively using the contrast and scan 
parameters defined in the preliminary experiment (bolus 1ml/kg, no delay, 
infusion 1.88ml/kg/hr) and tube current 300-650mAs depending on patient 
body habitus. Prior to the scan, following insertion of an intravenous 
cannula, a 2ml blood sample was collected and sent for complete blood 
count (CBC) analysis. CT images were acquired pre contrast and 25 
minutes post contrast bolus (i.e. during static equilibrium). In order to 
reduce inter-slice dose variation, which would lead to variation in image 
noise and attenuation measurement standard error, the proprietary dose 
modulation function (CARE Dose) was not used. Careful attention was 
paid to ECG gating and breath hold instructions to ensure consistency 
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between scan phases and reduce image misregistration. CT datasets 
were reconstructed into 5mm thick axial slices. The scanner measured 
total Dose Length Product for each examination an effective dose was 
calculated using a conversion factor of 0.014 (12). 
The author who was blinded to the rest of the study data performed the CT 
analysis. The slice with the greatest area of myocardial septum was 
selected for ROI analysis from the images acquired during steady state 
equilibrium (EQ phase images) and the matching pre contrast slice 
identified visually. ROIs were drawn first on to the EQ phase image; as in 
the preliminary experiment within the left ventricular chamber (mean area 
3.1cm2; range 1.7-5.3cm2) and myocardial septum (mean area 4.3cm2; 
range 2.1-8.8cm2). ROIs were then copied to the pre contrast image. 
Mean attenuation in Hounsfield units (HU) at each phase was then 
recorded and myocardial ECV calculated using the formula: 
ECVmyocardium = (1-haematocrit) x (ΔHUmyocardium÷ ΔHUblood)   
;where ΔHU = HU EQ phase- HUpre contrast 
EQ-MRI was performed pre-operatively and within 48 hours of the EQ-CT 
to quantify myocardial ECV. A previously validated protocol (1) consisting 
of 0.1 mmol/kg Gd-DTPA bolus (Dotarem; Guerbet), followed by a 15-
minute pause, then an infusion at a rate of 0.0011 mmol/kg/min was used. 
Tissue T1 relaxation time was measured using a Shortened Modified 
Look-Locker Inversion Recovery (ShMOLLI) (13) sequence – which 
provided a single slice T1 map in a breath hold. Using multi-plane 
localisers to plan, an axial T1 map was acquired through the heart to 
include the largest area of myocardial septum. Images were acquired at 
the same position before and during contrast equilibrium, with position 
matching performed visually by a researcher supervising the scans 
(Steven K. White – Cardiology Fellow UCLH). A standard cardiac MRI late 
Gadolinium enhancement (LGE) technique(2) was included in the protocol 
to exclude focal myocardial fibrosis. 
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MRI data was analysed independent of the CT and histology data by a 
Cardiologist with 3 years experience in cardiac MRI (Steven K. White – 
Cardiology Fellow UCLH). Beginning with the EQ phase T1 map, single 
ROIs were draw within the ventricular blood pool and myocardial septum 
using the method described above for CT and copied to the pre contrast 
T1 map and mean T1 relaxation times recorded as previously 
published(4). Myocardial ECV was then calculated using the formula: 
ECVmyocardium = (1-hematocrit) x (ΔR1myocardium÷ ΔR1blood) 
;where ΔR1 = (1 ÷T1EQ phase) – (1 ÷T1pre contrast) 
Aortic valve surgery took place no more that 7 days after imaging – 
typically within 24 hours. Intra-operative myocardial septal tissue 
specimens (1cm cores) were collected during cardioplegia using a 14-
gauge coaxial needle system at the time of aortic valve replacement by the 
senior attending surgeon who had been briefed by a member of the 
research team. The myocardial septum was agreed as a safe site for 
biopsy by the cardiothoracic surgical team. Samples were immediately 
fixed in 10% buffered formalin, embedded in paraffin, and stained with 
picrosirius red. Collagen volume fraction was measured as previously 
described in chapter 3.  
 
6.3.4 Statistical analysis 
The Prism statistical package: version 5 (Graphpad Software Inc.) was 
used for all data analysis. Normal distribution was assessed using the 
Kolmogorov-Smirnov test. 
EQ-CT derived myocardial ECV was compared with histological CPA 
using Pearson correlation. The EQ-MRI data was similarly compared with 
histology. 
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The relationship between myocardial ECV measured using EQ-CT and 
EQ-MRI was assessed using Pearson correlation. Agreement between 
these measures was assessed using Bland-Altman comparison (14).  
6.4 Results 
6.4.1 Clinical Validation 
23 eligible pre-operative patients (male=16; female=7; mean age=70.8; 
SD=8.3) with severe aortic stenosis were recruited – Table 6.3.  
All 23 patients underwent EQ-CT prior to surgery. The mean heart rate at 
the beginning of the examination was 69 beats/minute. The mean total 
calculated effective radiation dose for the EQ-CTs was 10.7mSv (+\- 
3.4mSv), with a mean total Iohexol volume of 143.2ml (+/- 22.7ml).  
19 of the 23 patients underwent EQ-MRI (including a standard LGE 
technique) prior to surgery. Mean total dose of Gd-DOTA was 10.7mmol 
(+/- 1.8mmol). Of the 4 patients who failed to undergo MRI; one became 
acutely unwell prior to scanning; one was found to have a non-MRI safe 
device in-situ; one had a metallic eye foreign body and 1 scan was 
cancelled after the patients operation was brought forward. None of the 
scanned patients were found to have late gadolinium enhancement. 
All 23 biopsy procedures during aortic valve replacement surgery were 
uneventful. Four biopsies were unsuitable for analysis as they contained 
only superficial endocardium, and two were fragmented. In the remaining 
17 biopsies the mean histological CVF was 18% (intersubject range 5% to 
40%) – Figure 6.4.  
In the 23 patients, the ECV measured by EQ-CT had a mean of 0.31 and 
range of 0.18-0.44. ECV measured by EQ-CT correlated with CVF: r=0.71, 
p<0.001 (Figure 6.5) in the 17 patients with comparative data.  
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In the 19 patients that underwent EQ-CMR, ECV had a mean of 0.30 and 
range of 0.25 to 0.41. There was a good correlation between EQ-CMR 
measured ECV and CVF: r=0.84, p<0.0001 (Figure 6.6) in the 15 patients 
with comparative data. 
In 19 cases, myocardial ECV was measured using both EQ-CT and EQ-
CMR. Pearson correlation demonstrated a good linear relationship 
between these two measures: r=0.73, p=0.0002 (Figure 6.7), Bland-
Altman analysis demonstrated little bias (-1.4% with no slope) but with 
relatively wide confidence limits (95% limits -34.7 and 31.9%) - Figure 6.8. 
  
Volunteer Characteristics for Healthy and Aortic Stenosis Groups 
 Group Male Female P value 
Healthy volunteers     
Number [%] 15 9 [60] 6 [40]  
Age (y) 44.2 
(18.9) 
41.8 
(20.0) 
47.0 
(19.4) 
0.675 
     
Aortic stenosis patients     
Number [%] 23 16 [70] 7 [30]  
Age (y) 70 (8) 70.9 (8.3) 69.9 (7.6) 0.785 
Heart rate (beats/min) 68.9 (9.1)    
Estimate glomerular 
filtration rate 
(ml/min/1.73m2) 
76.9 (13)    
Hematocrit (%) 40.2 (5)    
 
Table 6.3 Volunteer characteristics 
Volunteer characteristics for healthy and aortic stenosis groups. Data are mean 
values (+/- standard deviation) 
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Figure 6.4 Histological stages of fibrosis 
Example histological samples with collagen stained red with picrosirius red. Slides 
show mild, moderate and severe myocardial fibrosis, with digital image analysis 
measurement of collagen proportionate area of 6, 21 and 40% respectively.. 
 
 
Figure 6.5 ECV by EQ-CT vs CVF 
Scatter plot of ECV measured by EQ-CT against histological CVF with regression 
line 
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Figure 6.6 ECV by EQ-MRI vs CVF 
Example histological slides showing mild, moderate and severe myocardial fibrosis. 
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Figure 6.7 ECV by EQ-MRI vs EQ-CT 
Plot of ECV measured by EQ-CT against ECV measured by EQ-CMR 
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Figure 6.8 Bland-Altman evaluation of ECV measures 
Bland-Altman comparison of ECV measurement method shows ECV difference 
expressed as a percentage (calculated by subtracting ECV measured with 
equilibrium CT from ECV measured with equilibrium MR imaging) against mean ECV 
(solid line), with lower (bottom dotted line) and upper (top dotted line) 95% limited of 
agreement 
 
6.5 Discussion 
The work within this chapter supports the use of CT for the non-invasive 
quantification of tissue extracellular space, measured as the Extracellular 
Volume (ECV). Here, diffuse fibrosis quantified histologically from human 
myocardial biopsies in severe aortic stenosis is used as the reference 
standard for validation, with a secondary comparator of ECV measured by 
EQ-MRI.   
Our group and others have used T1 mapping based contrast techniques to 
measure ECV with cardiac MRI(1)(3)(15). An important assumption of the 
equilibrium model is that the extracellular space with tissue consists only 
of a single compartment. In reality, the tissue extracellular space consists 
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of an intravascular extracellular component in addition to the extravascular 
extracellular space we describe as the interstitium. Where the tissue 
vascular volume is large, for example in the liver, this intravascular 
extracellular component may introduce error into ECV measurement using 
the equilibrium technique (see chapter 1.10). 
A steady state contrast equilibrium technique - achieved here using a 
bolus followed by a slow contrast infusion - was chosen in preference to 
the bolus only dynamic equilibrium protocol used by other authors (2) (7) 
as a method to eliminate the effect of contrast kinetics. A steady state 
protocol allows ECV measurement in tissues irrespective of permeability 
or blood flow and has been validated a histological reference (1). It is 
recognised that a steady state infusion method has disadvantages over a 
contrast bolus based method – i.e. is more time consuming, and would be 
additional to standard diagnostic images. However, in this work I sought to 
lay out an optimal method against which future abbreviated estimations of 
ECV could be compared. White et al. (16) recently compared bolus only 
and primed infusion methods for myocardial ECV measurement using 
CMR, demonstrating good agreement between techniques in aortic 
stenosis. This bolus only approach is explored in subsequent chapters. 
Using this EQ-CT methodology to measure tissue ECV, the correlation 
with histological fibrosis obtained in this proof of principle study was 
reasonable (r=0.71) but lower than found with CMR in this study and by 
other authors (r=0.84 and 0.93)(1). There are several possible underlying 
explanations.  
The use of ionising radiation necessitates a dose that is as low as 
reasonably possible – thus CT attenuation SNR was lower than the 
changes found using MRI (17). Additional noise in the CT images 
stemmed from streak and beam hardening artefacts originating from 
dense vertebral endplates and vessel wall calcification – Figure 6.9. To 
minimise these effects, blood attenuation was instead measured within the 
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left ventricular chamber. Applying tailored reconstruction algorithms (18, 
19) may reduce these effects and allow accurate aortic blood pool 
attenuation measurement. I address the subject of CT artefacts in chapter 
9.  
Examination dose for the EQ-CT study was comparable to local Dose 
Reference Levels for a similar multiphasic body CT examination. 
 
Figure 6.9 CT artefacts 
Inter-related artefacts affecting pre contrast blood attenuation measured within the 
descending aorta. Ventricular blood pool suffers less from these. All figures have all 
artefact types – but each has a different predominance: (a) beam hardening; (b) 
brighter aortic vs myocardial blood pool (streak from the adjacent vertebral body); (c) 
streak from focal aortic wall calcification. 
It is noted that myocardial radio-density did not alter post contrast to the 
same degree as T1 weighted signal intensity following gadolinium. Low 
voltage and dual energy techniques may improve this contrast, and while 
the effective radiation dose for this EQ-CT protocol lay with acceptable 
limits, could be included in a dose minimisation strategy. 
Additionally, despite choosing a disease (aortic stenosis) with 
homogeneous diffuse fibrosis and optimal sampling method (surgical 
biopsy), comparison of either EQ-CT or EQ-MRI with a reference standard 
of biopsy is imperfect because of the potential for sampling error. In this 
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study, precise matching of pre-operative CT and MRI ROI placement with 
the site of biopsy was not possible. Surgical specimens were collected 
without image guidance making precise localisation within the myocardial 
septum difficult.  
Further potential technical improvements include additional processing of 
image data with application of automated segmentation methods, which 
may reduce reliance on expert interpretation, and increase the speed of 
image data processing. Co-registration of pre and EQ phase images has 
been used to compute a pixel-by-pixel ECV map (20) showing regional 
tissue ECV variation. This may aid clinical interpretation and comparison 
with assessment other imaging modalities – for example ultrasound / 
echocardiography.  
Although correlation between CT and MRI measures of ECV 
demonstrated a good linear relationship, the Bland-Altman limits of 
agreement between the two techniques were relatively wide. This may 
result from the small sample size used, but may also reflect technical 
differences in the two imaging modalities. Whether the strength of 
correlation between ET-CT derived ECV and histological fibrosis 
demonstrated here translates into a meaningful clinical tool remains 
unknown. Larger cohorts studies are need to test the ability of EQ-CT to 
differentiate between clinically important disease states (e.g. mild vs 
severe fibrosis) and if indeed EQ-CT findings can prognosticate on 
disease outcome and guide therapeutic decision-making. 
This chapter demonstrates proof of principle of EQ-CT measurement of 
ECV against a histological standard in a common cardiac disease. Further 
work will be required to pursue potential technical improvements to the 
method, but the use of conventional CT equipment and contrast agents 
suggests wide potential clinical applicability. This work will provide the 
basis to explore the utility of EQ-CT in other organs and diseases where 
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diffuse interstitial expansion plays a key role, such as the liver, bowel wall, 
bladder, or nerves.  
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7 EQUILIBRIUM CONTRAST CT TO 
EVALUATE HEPATIC FIBROSIS 
7.1 Author declaration 
The experiments presented in this chapter were performed, and the data 
analysed and presented by the author under the supervision of Dr. Shonit 
Punwani, Prof. James Moon, Prof. Stuart Taylor and Prof. William 
Rosenberg. This work was published in the journal article: 14. Bandula S, 
Rosenberg WM, Hall AR, Moon JC, Taylor SA. Equilibrium Contrast-
enhanced CT Imaging to Evaluate Hepatic Fibrosis : Initial Validation by 
Comparison with Histopathologic. 2015;000(0):1–8. 
7.2 Introduction 
Chronic liver disease is a major worldwide public health issue (1), with an 
estimated 1.29 million deaths worldwide in 2010 from viral hepatitis alone 
(2). Regardless of etiology, sustained liver injury eventually leads to diffuse 
interstitial fibrosis and expansion of the extracellular space by collagenous 
scar that distorts the normal architecture, impairs hepatic function and is 
the hallmark of cirrhosis. Evaluation of hepatic fibrosis plays a key role in 
disease management, facilitating prognostication and guiding therapies 
such as antiviral agents, which in some instances may reverse the 
fibrogenic process (3). Staging of liver fibrosis allows clinical risk 
stratification, assessment for treatment eligibility and evaluation of 
treatment effect. Histopathological evaluation of biopsy samples remains 
the reference standard test for assessment of diffuse hepatic fibrosis, but 
has a number of well documented limitations, including its invasive nature 
and associated small but significant risk of complications (4). Furthermore, 
it examines only a tiny fraction of the organ (5) and is therefore prone to 
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sampling error(6). These deficiencies have fueled the development of non-
invasive techniques for fibrosis quantification. As discussed in chapter 1, 
liver stiffness measurement by transient elastography is well validated (7) 
but requires dedicated equipment and is of limited use in obese patients, 
and those with ascites or narrow intercostal spaces (8). Serum biomarkers 
such as the enhanced liver fibrosis (ELF) test are sufficiently related to 
liver fibrosis that they are clinically useful (9), but are not liver specific (10), 
and some have other influences such as renal function that reduce their 
discrimination between mild and moderate fibrosis (11-12). 
Both MRI (15) and CT (see chapter 6) have now been applied successfully 
to quantify myocardial ECV as a surrogate marker for diffuse fibrosis. In 
chapter 5 I also applied the technique in the liver using MRI to quantify 
amyloid deposition. Intuitively the technique may have a role in assessing 
diffuse liver fibrosis and indeed Varenika et al. (17) have recently 
described a strong correlation between hepatic ECV and histological 
fibrosis area in a rodent model of chronic liver disease. Early retrospective 
studies suggest this observation may translate into humans (18). To date 
there has been no validation of EQ imaging assessment of diffuse liver 
fibrosis against a histopathological reference, and in particular a robust 
morphometric quantitation of collagen in an appropriate spectrum of 
patients with a range of disease severity. 
In this chapter, I prospectively evaluate hepatic ECV measurement by 
equilibrium CT (EQ-CT) against fibrosis quantified histologically and 
against the enhanced liver fibrosis panel (ELF) (9) in a cohort of patients 
with chronic hepatitis.  
7.3 Materials and Methods 
Between April 2011 and July 2013, 40 patients with serologically 
confirmed hepatitis B or C undergoing clinically indicated liver biopsy were 
recruited prospectively from outpatient clinics at the Royal Free Hospital - 
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London. Exclusion criteria were: contraindication to contrast enhanced CT 
(iodinated contrast allergy; estimated glomerular filtration rate less than 
60ml/min);, previous liver transplantation or risk factors for other casues of 
liver fibrosis including HIV co-infection and a history of significant alcohol 
consumption (>3-4 units/day for men; >2-3units/day for women).  All 
patients gave fully informed written consent. 
7.3.1 Histology 
Liver biopsies were performed following local guidelines as part of the 
patient’s routine clinical care. Percutaneous biopsy was performed using a 
Menghini technique (19) with a 16-gauge needle from the right lobe. 
Transjugular biopsy samples were collected with up to 4 passes of a 19-
gauge needle through either the right or middle hepatic vein wall (20). 
To ensure reliable histopathological evaluation, only biopsies samples with 
a total length ≥ 12mm were included in the analysis (21). Samples were 
formalin fixed, paraffin embedded and stained with hematoxylin and eosin, 
and Gordon and Sweet staining for reticulin. The reference standard 
fibrosis stage was evaluated by an experienced hepatopathologist (Prof. 
P. Dhillon – Department of Histopathology, Royal Free Hospital) according 
to the Ishak system  - see chapter 1.4.1 (22). A further tissue section was 
stained with picro-Sirius red for collagen proportionate area (CPA) 
quantification by digital image analysis (DIA). CPA as been show to be a 
objective continuous quantitative measure of fibrosis with recognized 
prognostic value, but has not yet been widely adopted for clinical use – 
Germani et al. Histopathology 2010. DIA was performed independent of 
fibrosis staging by a single operator (Andrew Hall – Department of 
Histopathology, Royal Free Hosptial) using the method described in 
chapter 3.8 (23)-. A digital camera (Canon Powershot A640) was used for 
image capture and digital image analysis was performed using Zeiss 
KS300 software. 
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7.3.2 Equilibrium Contrast Computed Tomography 
The principals underpinning equilibrium contrast imaging have been laid 
out in chapter 1 and tested in chapter 2. In this initial exploratory study of 
use in liver fibrosis, as in chapter 6, a steady state contrast equilibrium 
protocol was used based on contrast bolus injection followed by an 
infusion. This method was again chosen to minimize potential error 
resulting from inter subject haemodynamic or contrast kinetics variation 
that could arise from a single bolus technique (13).  
EQ-CT was performed using a 64-detector row CT scanner (Somatom 
Sensation 64; Siemens Medical Solutions, Erlangen, Germany) no more 
than 2 weeks prior to liver biopsy. Prior to CT scanning, two 5ml blood 
samples were collected. The first was sent for complete blood count (CBC) 
to obtain blood hematocrit, and the second for ELF analysis (see below). 
A pre contrast scan was acquired through the upper abdomen to include 
the whole liver using the parameters: effective tube current-time product 
250mAs, pitch 0.8, tube voltage 120 kV, slice collimation 24x1.2mm, 
gantry rotation time 500ms and reconstructed to a slice thickness of 10mm 
using a soft tissue convolution kernel (B20f). The iodinated contrast agent 
iohexol (Omnipaque 300, GE Healthcare) was then administered as a 
bolus dose of 1ml/kg at 3ml/s; followed immediately by an infusion of 
1.88ml/kg/hr based on prior development work demonstrating contrast 
steady state on sequential plasma iohexol measurements and CT scan 
attenuation measurements (see chapter 6). After 30 minutes of infusion, 
the scan volume through the upper abdomen was repeated using the 
same parameters. Scanner generated dose length product (DLP) for each 
examination was used to calculate effective dose using a conversion factor 
of 0.015 (25). 
Image analysis was performed using OsiriX v4.1.2 (Pixmeo, Switzerland) 
by the author, blinded to biopsy findings.  
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On 3 contiguous slices reconstructed to a thickness of 10mm, a 
peripherally based wedge shaped region of interest was drawn in segment 
VII of the liver (mean area 34.5cm2) to include the greatest area of liver 
parenchyma whilst avoiding visible vessels or incidental hepatic lesions 
such as cysts. Because the exact liver segment from which the biopsy 
samples were collected was not known in all cases, imaging-biopsy 
matching was at the level of the right lobe only.  A further elliptical region 
of interest was drawn on the same slice within the abdominal aorta (mean 
area 1.6cm2) avoiding the aortic wall and any atheromatous plaque. ROIs 
were drawn on the post contrast images and then copied to the matching 
slices on the pre contrast images. Mean attenuation (in standard CT 
Hounsfield units [HU]) for liver parenchyma and blood were derived and 
liver ECV calculated using the formula: 
ECVliver = (1-hematocrit) x (ΔHUliver ÷ ΔHUblood)   
;where ΔHU = HUEQ phase- HUpre contrast 
Where visible, mean attenuation within the gallbladder was also measured 
on the pre and post contrast images to assess for vicarious biliary 
excretion of contrast.  
7.3.3 ELF Test Biomarker 
Patient serum was separated from blood collected prior to the CT and 
stored at -80°C before being sent to an independent laboratory (iQur 
Limited, London). Proprietary assays (Siemens Healthcare Diagnostics, 
Tarrytown, USA) were used in conjunction with an Advia Centuar 
automated analyser (Siemens Healthcare Diagnostics, Tarrytown, USA) in 
accordance with the manufacturer’s instructions to determine levels of 
tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), hyaluronic acid 
(HA) and amino-terminal propeptide of type III collagen (PIIINP). Results 
were combined  via an algorithm to generate a fibrosis score (9).   
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7.3.4 Statistical Analysis 
Statistical analyses were performed using Prism 5.0 software (Graphpad, 
San Diego, CA). Kolmogorov-Smirnov analysis was used to test for 
normality. Non-Gaussian distributed data were expressed as a median 
and interquartile range. Correlation between variables was evaluated by 
using Spearman correlation, with one sided significance testing set to <= 
0.05. Linear regression was used to evaluate the ability of ECV, ELF and a 
model combining ECV and ELF score to predict CPA. The R and R2 
values were used to assess the strength of correlation, and P values less 
than 0.05 were considered to indicate a significant difference. 
Histological stage was divided into low (S0-1), moderate (S2-4) and 
severe (S5-6) groups, and ECV, CPA and ELF score were compared with 
fibrosis stage by using the Kruskal-Wallis nonparametric analysis of 
variance test.  
7.4 Results 
Of the 40 patients fulfilling the eligibility criteria, complete sets of data 
(ECV, CPA and ELF score) were collected in 33 cases (4 histology 
samples were fragmented or measured less than 12mm; 2 patients had 
pre-CT eGFRs <60mls/min; and 1 patient withdrew consent – see table 
7.1 for demographic data. Figure 7.2 shows an example patient’s EQ-CT 
imaging with corresponding biopsy specimen. Of the 33 patients, a 
diagnosis of hepatitis C virus infection had been made in 23 cases and 
hepatitis B in 10. 24 tissues samples were collected by ultrasound guided 
biopsy and 9 by transjugular biopsy. Demographic and ELF details are 
summarized in table 7.1.  
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 Total 
Patient number (%) 33 (19M/14F) 
age (y) mean 49.9 (48.8M/51.4F) 
age (y) range 22 – 68 
  
Biopsy method (US / TJ ) 25 / 8 
Hematocrit 0.428 +/- 0.041 
Serum creatinine conc. (μmol/L) 89.5 +/- 22 
International Normalized Ratio  1.22 +/- 0.42 
Bilirubin Amol/L 16.6 +/- 10.6 
 
Table 7.1 Demographic data 
Summary of demographic and clinical data. Values are mean +/- SD 
 
EQ-CT examination SSDE had a mean (+/-SD) of 38.8mGy (+/-8.2). The 
region of interest volume was approximately 500 times that of the each 
biopsy (10.4mls vs 0.02mls) average. The mean (and range) attenuation 
within the liver and aorta pre contrast was 50HU (24-62) and 41HU (32-
51); and at equilibrium phase was 67HU (38-78) and 80HU (71-94). 
The gallbladder was present in 24 of the 33 patients analysed, and mean 
attenuation within the gallbladder lumen was 9HU (range 2-25) pre 
contrast and 11HU (range 2 to 24HU) post contrast. Paired t-test 
confirmed no significant difference (p = 0.08) in gallbladder lumen 
attenuation between the pre contrast and equilibrium phase images (mean 
difference 1.1HU).  
Fractional ECV measured in the liver had a median (IQR) of 0.26 (0.24 – 
0.29) and a range of 0.17 – 0.47; CPA a median (IQR) of 5.0 (3.0 – 15.0) 
and a range of 1.8 – 28.3; and ELF score a median (IQR) of 9.71 (8.14 – 
10.92) and a range of 7.27 – 12.43. 
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Fractional ECV showed good association with CPA (r = 0.64, p < 0.0001) 
and ELF score (r = 0.38, p = 0.0272) – figure 7.3 (a) and (b), with no 
significant difference in the strength of the correlations (p = 0.177). A 
significant association was also found between ELF score and CPA (r = 
0.46, p = 0.0075) – figure 7.3c.  
Multiple regression analysis showed that both ECV (p<0.0001) and ELF 
(p=0.0062) were significant independent predictors of CPA, with a t 
statistic for ECV and ELF of 5.20 and 2.94 respectively. The regression 
model (80 x ECV + 1.8 x ELF -30.4) was a better predictor of CPA (R2 = 
0.67; p<0.0001) (figure 7.3d) than either ECV (R2=0.56; p<0.0001) or ELF 
(R2=0.35; p = 0.0168) alone. 
ECV ELF and CPA demonstrated comparable discrimination between 
Ishak score S0-1 vs S5-6 and S2-4 vs S5-6 (p=0.0126, p=0.0160 and 
p=0.0008 respectively). Neither of the three was able to significantly 
distinguish S0-1 and S2-4 (p>0.05). 
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Figure 7.2 EQ-CT images and corresponding biopsy specimens 
EQ-CT and biopsy specimen (picro-Sirius red stain; macro view) images from a 
patients with (a) no significant fibrosis (ECV=0.21; CPA=3,) and (b) severe fibrosis 
(ECV=0.31; CPA=24). Sampled volumes between EQ-CT and biopsy differ by 
approximately x1500. Note that the IVC and right portal vein branches in (b) are less 
visible than in (a) - as liver ECV approaches that of the blood 
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Figure 7.3 Scatterplots comparing ECV, ELF and CPA 
a, b & c. Scatterplots showing correlation between extracellular volume measured 
using EQ-CT, histological collagen proportionate and ELF score, with lines of best fit. 
2d. Multiple regression model combining EVC and ELF to predict CPA 
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Figure 7.4 Bland-Altman evaluation of ECV measures 
Bland-Altman comparison of ECV measurement method shows ECV difference 
expressed as a percentage (calculated by subtracting ECV measured with 
equilibrium CT from ECV measured with equilibrium MR imaging) against mean ECV 
(solid line), with lower (bottom dotted line) and upper (top dotted line) 95% limited of 
agreement 
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7.5 Discussion 
In this prospective exploratory experiment I measured the hepatic 
extracellular volume fraction (ECV) using equilibrium contrast CT.  The 
ECV was found to track liver fibrosis, measured either by collagen 
proportionate area or by Ishak fibrosis stage. These results are consistent 
with preliminary studies using animal models (17) and tentatively suggest 
that a CT scan using widely available equipment and contrast agents 
could be used to evaluate hepatic fibrosis, reducing the need for invasive 
biopsy.  
Automated morphometric fibrosis quantification was used as the primary 
histologic comparator. As a continuous measurement, this largely 
eliminated limitations of traditional categorical staging. Data suggests CPA 
is a better predictor of future clinical decompensation than Ishak stage (25) 
and shows strong correlation with hepatic venous pressure gradient 
(HVPG) – a good prognostic index in relation to survival and complications 
(27). However CPA suffers the limitations of biopsy, with accuracy 
dependent on aetiology of cirrhosis and biopsy specimen size (21). 
EQ-CT derived ECV was compared with a biochemical marker - the ELF 
test. The ELF score is a well-validated marker of hepatic fibrosis, 
incorporating levels of extracellular matrix components and enzymes 
involved in their regulation, and is a strong predictor of clinical outcome in 
chronic liver disease (28). Previous work has shown association between 
ELF score and histological fibrosis stage - confirmed by our current study. 
ECV correlated with ELF suggesting ECV does reflect underlying damage 
and fibrosis, although the strength of association was lower than with 
CPA. Neither ECV nor ELF suffers the limitations of histological staging 
and CPA, imposed by reliance on liver biopsy. It may be that their ability to 
sample the whole liver volume reduces sampling error and may improve 
repeatability. Although ELF was primarily used to test the ability of EQ-CT 
to assess liver fibrosis, regression analysis showed them to be 
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independent predictors of CPA and indeed when ELF and ECV were 
combined they better predicted CPA than either in isolation. The 
combination of two non-invasive tests to accurately predict liver fibrosis is 
clearly an attractive proposition and validation in a new cohort is now 
required. 
The CT work in chapter 6 and MRI work by other authors (15,13,29) using 
equilibrium imaging has provided evidence for an association between 
elevated ECV and diffuse fibrosis in the heart. There are however 
limitations of EQ imaging for fibrosis assessment. The principle behind its 
use is that accumulation of extracellular collagenous matrix is 
accompanied by expansion in the extracellular water volume into which 
contrast agents distribute. There are however several other processes 
which may affect this volume and confound fibrosis measurement which 
may be more problematic in the liver. Oedema arising from inflammation 
or venous congestion for example may expand ECV, while hepatocellular 
swelling arising from steatosis may compress the extracellular volume. A 
further important point to emphasize is that the ECV measures the 
extracellular volume in the whole tissue; parenchyma and enclosed 
vasculature – i.e. both interstitial fluid and the interstitial (plasma) blood 
compartment. This is small in tissues such as the myocardium but much 
larger and potentially independently varying with disease in the liver. A 
further potential confounder in the liver is the vicarious uptake of contrast 
agents by hepatocytes seen following delayed contrast administration. 
This phenomenon is thought to be associated with impaired renal function, 
but has been described in patients with normal kidneys (31). Contrast 
uptake by hepatocytes and excretion via the biliary tree would lead to 
increased hepatic enhancement relative to blood and an overestimation of 
liver ECV. The lack of a discernible increase in the attenuation of bile in 
the gallbladder suggests that in this small group, significant vicarious 
excretion had not occurred following the 30 minute infusion. It should be 
noted that patients with significant renal impairment were excluded from 
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the study, thus lessening the risk of confounding the fractional hepatic 
ECV estimates by vicarious excretion.  
I used standard CT acquisition and reconstruction techniques, which are 
widely available. Modern multidetector scanners and reconstruction 
techniques may reduce image artefacts and noise leading to more precise 
and accurate ECV quantitation while reducing the dose of ionizing 
radiation (32,33).  Mean SSDE for liver EQ-CT in this study was 
comparable to that of a standard clinical CT examination of the liver and 
equivalent to 4 years of natural background radiation in the UK – 
background radiation dose data from Public Health England, 2011. The 
theoretical risk associated with this exposure (35) needs to be weighed 
against the sampling error and complication risks associated with biopsy 
and operator dependence and patient limiting factors associated with 
transient elastography. 
The reference steady state equilibrium method used in this study involves 
establishing a constant plasma concentration of contrast via a prolonged 
infusion. Although time consuming and somewhat impractical, it was, at 
the time of study design, considered the most robust methodology. A 
further limitation of the infusion technique is the relatively low level of 
enhancement with the aorta and liver during the delayed equilibrium 
phase. Even with large ROIs, the contrast to noise ratio at this level of 
enhancement is relatively low. More recently validated equilibrium MRI 
contrast protocols employ a bolus only method (36), which for tissues with 
rapid kinetics such as the myocardium produces a dynamic equilibrium of 
changing but related plasma/interstitial contrast concentrations. This 
dynamic steady state may allow ECV estimation of sufficient accuracy to 
replace less practicable protocols using prolonged infusions, and is 
explored in chapter 8. By using a bolus/infusion technique I ensured 
contrast equilibrium within the liver. Simple integration of whole liver ECV 
quantitation into clinical CT, supplementing anatomical assessment and 
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focal lesion detection is clearly desirable and a future study is now 
indicated. 
There were additional limitations to this experiment. Patient selection 
resulted in a relatively high proportion of patients with mild fibrosis - 70% 
of our patient cohort had CPA values clustered between 2 and 8.1. Future 
studies should endeavour to recruit a patient cohort equally distributed 
across the range of fibrosis severity. I used a uniform aetiology of viral 
induced hepatitis to ensure homogeneity in our data. However we cannot 
assume the results can be extrapolated to other aetiologies such as 
alcohol or steatosis.  
As noted above, factors thought to affect hepatic extracellular volume 
fraction such as hepatic inflammation, steatosis, hepatic venous 
congestion and portal venous flow were not controlled for in this study, and 
future studies may examine the influence of these confounders on hepatic 
ECV. 
Although comparison is made here with the current reference standard of 
histology, other techniques have shown strong association with clinical 
markers of liver cirrhosis, and were not included. HVPG and transient 
elastography are both well validated against histology and are predictive of 
decompensation and portal-hypertension related complications (37). 
Future studies should include comparison of ECV with liver stiffness 
measurement and HVPG. 
This study provides biopsy-controlled evidence for a relationship between 
extracellular volume and diffuse liver fibrosis in man; and provides basis 
for a larger study to examine the diagnostic performance of EQ imaging for 
non-invasive monitoring of liver disease severity. Combination of two non-
invasive tests (EQ-CT ECV and ELF) to accurately predict liver fibrosis is 
potentially very powerful and validation studies are now indicated.  
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8 DYNAMIC CONTRAST EQUILIBRIUM 
COMPUTED TOMOGRAPHY FOR 
MYOCARDIAL EXTRACELLULAR 
VOLUME MEASUREMENT 
8.1 Author declaration 
The work contained in this chapter was completed by the author (in 
partnership with Dr Thomas Treibel Cardiology Fellow - UCLH) including 
the pseudo-equilibrium protocol design; volunteer recruitment; CT image 
data acquisition; and data analysis. Statistical analysis and graphs were 
prepared by Dr Treibel. Primary supervisors were Prof. Stuart Taylor and 
Prof. James Moon. The intention was for the author to jointly lead 
publication with Dr. Treibel, however this was not allowed by the accepting 
journal: Treibel, T. A., Bandula, S., Fontana, M., White, S. K., Gilbertson, 
J. a., Herrey, A. S.,  Moon, J. C. (2015). Extracellular volume quantification 
by dynamic equilibrium cardiac computed tomography in cardiac 
amyloidosis. Journal of Cardiovascular Computed Tomography, 9(6), 585–
92. doi:10.1016/j.jcct.2015.07.001 
8.2 Introduction 
The experiment in this chapter was designed to simplify the steady state 
equilibrium contrast CT method developed in chapter 6, by using a bolus-
only approach (DynEQ-CT) and apply it to an important clinical problem: 
the non-invasive diagnosis and quantification of cardiac amyloid burden. 
As laid out in chapter 6, the steady state protocol was designed to allow 
sufficient time for equilisation of plasma/interstitial contrast concentrations 
(static equilibrium) – thereby eliminating the effects of contrast kinetics and 
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allowing robust ECV estimation. The required prolonged contrast infusion 
was however time consuming - a hurdle to clinical implementation. 
However in tissues like the myocardium and liver where diffusion kinetics 
are rapid, the concentration of contrast within the plasma and interstitium 
following a contrast bolus are changing, but have a fixed relationship – ie 
are in dynamic equilibrium. The objectives in this chapter were to evaluate 
the feasibility and optimal contrast timing for dynamic equilibrium with 
iodinated contrast; to assess the ability of DynEQ-CT to quantify 
myocardial amyloid against conventional semi-quantitative methods (bone 
scintingraphy) (1) and compare against ECV quantification by EQ-CMR as 
the current imaging standard of reference.  
8.3 Materials and Methods 
All research was carried out at University College London Hospital and the 
Royal Free NHS Trusts, London, UK, between January 2013 and 
December 2013. All subjects gave written informed consent to participate 
in the study. A total of 53 patients were recruited: 26 with systemic 
amyloidosis (ATTR and AL) and 27 comparator controls with aortic 
stenosis (23 of these patients were described in the experiment in chapter 
6) in whom amyloid could be histologically excluded.  
Exclusion criteria were uncontrolled arrhythmia, impaired renal function 
(estimated glomerular filtration rate <60 mL/min), or contraindications to 
MR imaging (e.g., implanted devices). 
ATTR amyloid patients. Eighteen patients had ATTR amyloidosis (16 
male, age 68 +/- 8 years). All patients underwent sequencing of exons 2, 
3, and 4 of the TTR gene: 14 had senile systemic amyloid (SSA) and four 
TTR patients were familial (V122I [n = 1], V30M [n = 1], E54G [n = 2]). 
Cardiac status (cardiac involvement, possible cardiac involvement, no 
cardiac involvement) was determined by myocardial biopsy or DPD 
scintigraphy (see chapter 3.6). Cardiac retention of 99mTc-DPD was 
visually scored as: Grade 0: no myocardial uptake; Grade 1: mild cardiac 
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uptake with no significant attenuation of normal bony uptake; Grade 2: 
moderate cardiac uptake with some attenuation of the bone signal; Grade 
3: strong cardiac uptake with little or no bone uptake. 
AL amyloid patients.  Eight patients (5 male, age 56 +/- 12 years) had 
biopsy proven systemic AL amyloid with biopsies from the myocardium or 
other tissues. Cardiac categorization was performed by Dr. Treibel based 
on modified international consensus criteria (2) defined as:  
1) definite cardiac involvement: LV wall thickness of >12 mm in the 
absence of any other known cause or RV free wall thickening coexisting 
with LV thickening in the absence of systemic or pulmonary hypertension; 
2) possible cardiac involvement: LV wall thickening in the presence of 
hypertension; RV thickening in the presence of pulmonary hypertension or 
normal wall thickness with diastolic dysfunction and raised serum bio- 
markers;  
3) no suspected involvement: normal wall thickness with normal serum 
biomarkers.  
All amyloid patients underwent DynEQ-CT and EQ-MRI as described in 
the following section. The 2:1 recruitment of ATTR s AL patients reflected 
a significant prevalence of eGFR <60 (cut-off point requested by the ethics 
committee for this study) in the AL cohort. 
Comparator group. In twenty-seven patients with severe aortic stenosis 
(19 male, age 68 +/- 8 years) cardiac amyloid was excluded histologically 
on myocardial biopsy taken during aortic valve surgery as part of the study 
described in chapter 6. These patients also then underwent DynEQ-CT 
(n=27) and EQ-CMR  (n=22 due to 7 patients suffering claustrophobia and 
15 with pacemakers).  
DynEQ-CT protocol. Imaging examinations were performed by using a 
64–detector row CT scanner (Somatom Sensation 64; Siemens Medical 
Solutions, Erlangen, Germany). To limit radiation exposure, a topogram 
was used to plan CT volumes of the lower chest from the level of the aortic 
valve to just below the inferior aspect of the heart. Cardiac scans (tube 
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voltage, 120 kV; tube current–time product, 160 mAs; section collimation, 
64 detector rows and 1.2-mm section thickness; gantry rotation time, 330 
msec) were acquired with prospective electrocardiographic gating (65%–
75% of the R-R interval). The proprietary dose modulation function 
(CareDose; Siemens Medical Solutions) was switched off so pre and post 
contrast scans were identical for ECV calculation. CT datasets were 
reconstructed into 3-mm-thick axial sections with a B20f kernel.  
The DynEQ-CT protocol was consisted of three steps: firstly, dynamic 
equilibration achieved by delayed post-bolus measurement to remove the 
effect of contrast kinetics; secondly, measuring the ratio of tissue and 
blood CT attenuation change measured in Hounsfield units (ΔHU); thirdly, 
direct measurement of the blood volume of contrast distribution. CT-ECV 
was calculated as:  ECV  =  (1-Haematocrit) x (ΔHUtissue / ΔHUblood) 
Optimal timing of the post contrast scan was unknown: too early and 
equilibrium may not have occurred; too late and the signal to noise ratio 
may have been poor. Accordingly, imaging was performed at pre- and at 
5- and 15-minutes following a bolus of Iodixanol (652mg/mL) at a dose of 
1mL/kg, in order to establish the best timing of post contrast imaging. An 
additional scan at 1-minute was introduced in the amyloid cohort to aid 
segmentation of blood and myocardium which was not easily visible at the 
later time points. Radiation exposure was derived from the dose-length 
product multiplied by a chest conversion coefficient (κ=0.014mSv/mGy) 
(10). 
EQ-CMR protocol. EQ-CMR was performed either after or at least 24 
hours prior to the CT to allow enough time for gadolinium contrast to be 
cleared and not act as a CT contrast agent. Standard EQ-CMR 
examinations were performed in all patients using a 1.5-T scanner 
(Avanto; Siemens Medical Imaging, Erlangen, Germany) using the 
contrast protocol described in chapter 5, with T1 mapping for CMR ECV 
quantification performed using ShMOLLI (Shortened Modified Look-Locker 
Inversion recovery) (11), providing single-section T1 map in one breath 
hold. Images were acquired at  positions visually matched by the operator 
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(Cardiology Fellow - Dr. Thomas Treibel or Steve White) before and during 
contrast material equilibrium – Figure 8.1. Standard CMR inversion 
recovery late gadolinium enhancement was included in the protocol to 
exclude focal myocardial fibrosis. Signal-to-noise ratios (SNR) was 
measured in ROIs on 3 sequential transverse images in the myocardial 
septum as the ratio of the average signal intensity (SI) to the standard 
deviation of the SI. Background image noise was not measured as this 
was reduced automatically by scanner system. 
The CMR-ECV was calculated by:   
ECV = (1–haematocrit) x  (1/ΔT1tissue) / (1/ΔT1blood). 
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Figure 8.1 Example EQ-MRI and EQ-CT imaging 
Examples of ROIs in ShMOLLI (bottom row) and CT (top row); pre-contrast (left) and 
post-contrast (right) with ROIs drawn in the basal septum and blood pool. 
 
. 
8.4 Results 
8.4.1 DynEQ-CT ECV 
Comparison of the SNR at the individual time points (pre contrast, 5 and 
15 minutes following contrast) showed that the highest SNR was achieved 
at 5 minutes post contrast (p<0.001; paired sample T-Test, Figure 8.2). 
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The mean total calculated effective radiation dose for the complete 
DynEQ-CT protocol (including both post contrast time points) was 1.56 
mSv ± 0.58 mSv, with a mean administered total Iodixanol (Visipaque) 
volume of 78 mL ± 11 mL 
In the systemic amyloid group, ECV at 5min by DynEQ-CT showed a 
strong and significant correlation with that derived using CMR (r2 = 0.73, 
p<0.001), which worsened at 15 minutes (r2 = 0.55 at 15 minutes p<0.001; 
Figure 8.4). 
Bland-Altman comparisons of ECV measurement methods by EQ-CMR 
and DynEQ-CT in the amyloid group demonstrated no bias at 5 minutes 
post contrast, with slight bias at 15 minutes (4% with no slope), but the 
confidence limits were twice as wide at 15 minutes (95% confidence limits: 
-19%, 28%; Figure 8.5). 
8.4.2 Diagnosis of cardiac amyloid by ECV 
Myocardial ECV by CT was significant higher in patients with amyloidosis 
than aortic stenosis (0.48 +/- 0.15 versus 0.28 +/- 0.04, p<0.001; Figure 
8.3). The difference in ECV between AL and TTR amyloid only reached 
significance with DynEQ-CT at 5 minutes (0.42 +/- 0.11 versus 0.53 +/- 
0.13, p<0.04) - Figure 8.4. In ATTR amyloid, all patients had at least 
Grade 1 uptake on DPD. ECV by EQ-CT tracked amyloid burden semi-
quantitatively measured by DPD bone scintigraphy (p<0.001) – see Figure 
8.6. 
. 
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Figure 8.2 Image Signal to Noise Ratio at 4 time points 
Signal-to-Noise ratio pre-contrast, at 5 minutes, 10 minutes and 15 minutes post 
contrast for regions of interest drawn in the myocardium (with standard deviations).  
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Figure 8.3 Myocardial ECV by DynEQ CT 
Myocardial ECV by CT was significant higher in patients with amyloidosis than aortic 
stenosis (0.48 +/- 0.15 versus 0.28 +/- 0.04, p<0.001). 
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Figure 8.4 Correlations CMR ECV vs CT ECV 
Association between myocardial ECV measured using EQ-CMR and EQ-CT in 
systemic amyloidosis. Top uses 5 minute and bottom uses 15 minute post contrast 
EQ-CT phase images for ECV estimation. 
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Figure 8.5 Bland-Altman analysis of EQ-CT at 5 and 15 mins 
Bland-Altman comparisons of myocardial ECV measurement method in systemic 
amyloidosis shows ECV difference expressed as a percentage, calculated by 
subtracting ECV measured with DynEq-CT from ECV measured with EQ-CMR) 
against mean ECV (solid thick line), with lower (bottom thin line) and upper (top thin 
line) 95% limits of agreement. 
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Figure 8.6 ECV vs DPD grade 
ECV vs DPD grade (aortic stenosis cohort used as control – no evidence of cardiac 
involvement on intra-operative myocardial biopsy). 
 
8.5 Discussion 
The work in this chapter has showed that a simple 5-minute, gated three 
phase CT protocol can diagnose cardiac amyloid burden and track 
disease severity. This new more rapid protocol can simply be added to 
routine CT coronary angiography protocols with only a minimal increase in 
radiation (equivalent of repeating the pre-contrast coronary calcium score 
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scan), but offer a new insight into the myocardial interstitium and is 
informative for an under-diagnosed and now treatable cause of LVH and 
heart failure: cardiac amyloidosis. 
The steady state protocol developed in chapter 6 using a primed infusion 
to reach contrast equilibrium was logistically cumbersome and time 
consuming, therefore development of a bolus-only approach brings ECV, 
as a promising novel biomarker, a step closer to routine clinical 
applicability. 
As part of the technical development, I established that acquisition of the 
post contrast images at 5 minutes was superior to acquisition at 15 
minutes, resulting in the better signal-to-noise, contrast-to-noise ratios, 
and higher DynEQ-CT ECV correlation with ECV by CMR. Peculiar to 
cardiac amyloid with an extremely high ECV,  is the lack visible interface 
between myocardium and blood even in post contrast images at 5 
minutes, as the ECV in myocardium equals that of the blood. This 
necessitated the addition of a low dose, early arterial phase scan to 
facilitate blood myocardial segmentation. The overall radiation dose for 
this scan was within acceptable limits and lower than the conventionally 
used DPD scintigraphy. 
From a diagnostic perspective, myocardial ECV by DynEQ-CT was higher 
in patients with cardiac amyloidosis than the comparator group with LVH 
due to AS. Furthermore, ECV by CT tracked established markers of 
cardiac amyloid severity as measured by DPD scintigraphy (ATTR 
patients only).  
In this study, the DynEQ-CT technique was compared to the best, 
currently available non-invasive techniques for the quantification of ECV 
(EQ-CMR) and TTR amyloid burden (DPD scintigraphy), but no invasive 
biopsy data was available for this validation, though with the patchy 
distribution of cardiac amyloid deposits, biopsy data may not be superior.  
The data presented here is from a small study in a single specialised 
centre, aimed to be hypothesis generating, and a larger study is required 
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to test these and develop this test further. The 64-slice-CT-system 
employed may reflect the most commonly available systems available, but 
does not take advantage of the newer systems that offer a variety of 
iterative reconstruction algorithms, dual energy acquisition and larger 
detector arrays that allow acquisition of isotropic volumes of the entire 
heart in one heart beat and at low radiation dose. In conjunction with 3D 
image registration and processing, this allows creation of whole heart ECV 
maps. 
8.6 Conclusion 
A simple 5-minute, gated, contrast-enhanced CT scan can diagnose 
cardiac amyloid burden, track disease severity and distinguish cardiac 
amyloid from aortic stenosis, another cause of LV hypertrophy. DynEQ-CT 
is able to quantify interstitial expansion in the heart, and offers to be a 
simple, technique to diagnose amyloidosis, because it is ubiquitously 
available, cheaper and faster than MRI and an alternative for patients with 
claustrophobia or metallic implants. 
 171 
9 QUANTITATIVE COMPUTED 
TOMOGRAPHY 
9.1 Author declaration 
The experiments presented in this chapter were performed, and the data 
analysed and presented by the author under the supervision of Dr. Shonit 
Punwani and Prof. Stuart Taylor. 
9.2 Introduction 
The EQ-CT technique described in chapters 6, 7 and 8 is reliant on 
accurate and precise attenuation measurement. Computed tomography 
development has however focused on delivering high image quality and 
fast processing, allowing rapid and accurate diagnosis of disease. Other 
clinical quantitative CT techniques have been slow to implementation 
compared with other modalities such as MRI and PET, largely as a result 
of the concerns about radiation dose exposure, but CT HU measurement 
is now routinely used in clinical practice to assess suitability of renal 
stones for extracorporeal treatment (1), to evaluate adrenal nodules (2) 
and to evaluate the composition of body fluids.  
Quantitative tissue characterisation using computed tomography relies on 
accurate representation of tissue properties within the created image. By 
measuring the attenuation of a rotating X-ray beam, CT scanners produce 
an image map of Hounsfield Units (CT number) – a linear transformation 
of the linear attenuation coefficient; in which distilled water at standard 
pressure and temperature is assigned a value of zero Hounsfield units 
(HU), while air a value of 1000HU (3).  
HU = 1000 x (μ- μwater / μwater).  
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The exact relationship between imaged material and CT number is 
complex. Firstly attenuation is dependent on the incident photon energy, 
although CT systems utilise a polychromatic spectrum of X-ray energies 
with operator variable effective energy. Photon energies are subject to 
both photoelectric (pe) and Compton (c) interactions, and the total 
attenuation coefficient (μ) is the sum of these effects i.e. μ = μpe + μc, with 
μpe strongly dependent on atomic number as well as electron density. 
Reconstructed CT number values are also dependent on reconstruction 
kernel and post-processing filters. Failure of the reconstruction process 
leads to image artefacts and error in affected areas of the map. Artefacts 
can also result from a number of physics, geometric, patient and 
processing effects. In addition, the obligation to minimise ionising radiation 
exposure results in a level of noise within the image data known as 
quantum mottle and a degree of uncertainly in CT number that cannot be 
overcome by technological refinement. 
Initial development of equilibrium CT involved quantifying attenuation 
within tissue from scan data. During the analysis, significant unexpected 
variations in CT number were noted which did not correspond to 
anatomical structures or pathological processed. In this chapter, these 
effects are investigated with descriptive and quantitative evaluation (4).  
The hypothesis explored in this chapter is that unexpected variations in 
measured CT number are due to system artefacts; and application of 
advanced methods to reduce artefacts will lead to a reduction in this 
variation. 
9.3 Method 
To understand the artefacts underlying unexpected attenuation variations 
in CT scan data, 25 EQ-CT datasets acquired using scanner A (table 9.2) 
as part of experiments in chapter 8 were analysed. Mean (+SD) 
attenuation was measured within the whole imaged descending thoracic 
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and abdominal aorta at equilibrium contrast phase using the open source 
image analysis tool Osirix (OsiriX v4.1.2; OsiriX Foundation, Geneva, 
Switzerland). Elliptical regions of interest were drawn so as to incorporate 
the maximum area of blood, but avoid aortic wall atherosclerotic plaque or 
calcifications. Intra-slice attenuation statistical variance was compared 
with the variance of attenuation values between slices. Mean attenuation 
was plotted against slice number for each scan (Figure 9.1) and the mean 
and standard deviation (SD) attenuation for the whole segmented blood 
pool volume was calculated (as the ROI area within each slice was equal 
and the same number of slices sampled; a pooled standard deviation 
could be calculated).  
 
Figure 9.1 EQ-CT Blood attenuation measured within sequential slices 
Example of attenuation (mean + SD) drawn within the aorta from thorax to abdomen 
within scan acquired using scanner A. The diaphragm lies between slice 12 and 24. 
 
Instances where slice attenuation varied by greater that 2 standard 
deviations from the scan mean were identified. Individual instances could 
involve multiple slices, as long as affected slices were consecutive. 
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Artefact images were subjectively analysed by the thesis author and the 
type of artefact categorised as beam hardening; metal; motion; or helical 
interpolation (5). These are and listed below and discussed further in later 
sections: 
1. Beam Hardening. Mean beam photon energy increases due to 
absorption of low energy photons as the beam passes through an object. 
This can lead to so-called cupping artefacts as central parts of the beam 
are hardened more that than those passing through the edges; and 
streaks and bands caused by variations in beam hardening occurring with 
CT tube position. 
2. Metal: Metal density is beyond the normal range that can be handled by 
the reconstruction method, resulting in incomplete attenuation profiles, and 
severe streaking.  
3. Motion: Misregistration caused by motion produced shading, streaks 
and image ‘smearing’. 
4. Helical interpolation: This is caused by mutidetector scanners operating 
at higher pitch. Several rows of detectors intersect the plane of 
reconstruction during each rotation. The result is a windmill-like spiral 
artefact, with increasing vanes at higher pitch. 
 
For comparison, equilibrium contrast phase data from a further new cohort 
of 30 EQ-CT patient scans acquired using a more recent CT system 
implementing the latest reconstruction and data correction methods 
(scanner B – Table 9.2) were analysed using the same methodology. As in 
previous chapters, these patients were recruited from the outpatient clinic 
at the national amyloid centre, with a histological or imaging diagnosis of 
either AL or ATTR amyloidosis (see Table 9.3). Exclusion criteria included 
an estimated glomerular filtration rate of less than 45ml/min and allergy to 
iodinate contrast agents. All patients provided written informed consent.  
 175 
 Scanner A Scanner B 
Model release date 2004 2010 
CT generation 3rd 3rd 
No. slices 64 320 
Imaging reconstruction  Filtered back 
projection 
Iterative (AIDR) 
Corrections None Beam hardening 
 
Table 9.2 CT scanner specifications 
Summary of technical specifications of CT scanners used in this chapter 
 
 
 Total 
Patient number (%) 30 (20M/10F) 
age (y) mean 65.6 (63.3M/65.8F) 
age (y) range 43-83 
Amyloid AL/ATTR 20/10 
 
Table 9.3 Demographic data – comparison amyloid cohort 
Summary of amyloid patient demographic and clinical data. Values are mean +/- SD 
 
To investigate the specific effect of improved reconstruction on beam 
hardening artefacts, a beam hardening algorithm and iterative algorithm at 
3 levels (low, medium and high) were separately applied to a sample of 6 
clinical scans of the chest and abdomen; 3 acquired and reconstructed 
using scanner A and 3 using and scanner B; in addition to filtered back 
projection reconstruction. ROI analysis of blood attenuation within the 
aorta was performed as described in the earlier part of this methods 
section. 
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9.4 Results 
Data from Cohort 1 scanned using scanner A contained 25 patients (21 
men, 4 women; median age, 65 years; range, 41-87 years); and Cohort 2 
using scanner B contained 30 patients (11 men, 19 women; median age, 
74 years; range, 49-85 years). The pooled SD for scanner A was 7.50 and 
scanner B was 5.28 [P<0.0001] – see Figure 9.4.  
Evaluation of the 55 equilibrium scans demonstrated 20 instances from 
scanner A and 5 instances from scanner B where EQ phase blood pool 
attenuation varied by greater than 2 standard deviations. These instances 
had a mean magnitude of 32HU (range 22-78HU). Subjective evaluation of 
the causes of the artefacts with frequencies are summarised in Table 9.5.  
 
 
 177 
 
Figure 9.4 Scatter plot of blood attenuation SD  
Scatter plot of scan EQ-CT blood pool standard deviation measured within patient 
cohorts scanned using scanner A and B. Horizontal lines indicate mean and standard 
deviation.  
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Table 9.5 Summary of artefacts  
Summary of the type and frequency of artefacts resulting in attenuation variation of 2 
standard deviations of more from mean aortic blood attenuation. 
 
Beam hardening effects were the most common artefacts seen within both 
datasets; with a total of 13 occurrences. These were caused by areas of 
increased density within the scan volume, related to: aortic wall 
calcification (4); vertebral osteophytes (3); dense vertebral end plates (2) 
and contrast that had pooled within the renal pelvis (2). In 2 cases, an 
underlying anatomical source of the artefact was not identified. The 
resulting bright and dark bands projected over the aorta resulted in 
significant attenuation variation.  
Motion artefacts were seen around the diaphragm in 8 cases, causing 
image blurring and a reduction in CT number in the upper abdominal and 
lower thoracic region – Figure 9.6 Figure 9.7.  
Metal artefact was seen in 4 cases relating to pacemaker wires. 
Artefact Frequency in 
cohort A 
Frequency 
in cohort B 
Total 
Beam hardening artefact 10 3 13 
Motion artefact 7 1 8 
Metal artefact 3 1 4 
Helical interpolation 0 0 0 
Total   25 
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Figure 9.6 Example CT image showing motion artefact  
Motion artefact caused by motion of the diaphragm during the scan acquisition. The 
image has been windowed to allow visualisation of the blurred lung as well as upper 
abdominal structures. A thick artefactual band of decreased attenuation is projected 
across the aorta and liver. 
 
 
 180 
 
Figure 9.7 Variation in attenuation within an example EQ-CT dataset  
Example of variation in CT Hounsfield number. Attenuation measured within 
structures within the thorax, before and after equilibrium contrast. The X-axis 
represents slice number, moving cranially from the level of the diaphragm; and Y-axis 
CT number. Around the diaphragm (slice 1-4), motion artefact results in streaks of 
decreased attenuation on the pre-contrast phase and increased attenuation on the 
post contrast images. Pre contrast aorta and myocardium are given in blue and red; 
and post contrast in green and purple. 
 
9.4.1 Beam Hardening 
Beam hardening is seen with polychromatic X-ray sources such as that 
used in CT and can produce dark streaks around high attenuation objects 
(5) – Figure 9.8Figure 9.9; Figure 9.10Figure 9.11Figure 9.12. As X-rays 
pass through the body, low energy photos are attenuated more easily by 
dense structures, leaving high-energy photos, which are not attenuated as 
easily. Beam transmission then does not follow simple exponential decay 
as seen with monochromatic sources. High-energy attenuation is primarily 
due to Compton scatter, which causes X-ray photons to change direction 
(and energy) and thus end up in at a different detector. High pass filters 
used in FBP also exaggerates difference between adjacent detectors 
producing bright streaks in other directions. Evaluation of the attenuation 
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plot within the aorta within several scans revealed small periodic areas of 
reduced attenuation, which coincided with vertebral endplates (most 
marked when an endplate was also associates with dense osteophytes) 
and with aortic wall calcification.  
 
Figure 9.8 Example CT images showing beam hardening effects  
An example of beam hardening caused by dense vertebral osteophytes causing a 
bright streak through axial image (a) and a dark streak through the image (b)  
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Figure 9.9 Example CT images showing beam hardening effects (II) 
Dense contrast pooling in the renal collecting system causes beam hardening with 
bright bands through the affected slices – upper 2 white arrows.. A further dense 
band is seen at the level of the inferior abdominal aorta caused by dense aortic wall 
calcification – lower white arrow 
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Figure 9.10 Example CT images showing metal artefact 
Metal seen as severe streaking caused by pacemaker wires and (e) heavy 
circumferential calcification involving the aortic wall 
 
 
Figure 9.11 Example CT images showing artefactual hypo-attenuation 
Coronal and axial images through an area of artefactual reduced density with ROI 
data caused by a series of large vertebral osteophytes. 
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Figure 9.12 Magnified view of artefact 
Magnified view of this area. Bands of low density coincide with beam hardening 
artefact arising from dense vertebral osteophytes immediately posterior to the aorta 
 
9.4.2 Reducing beam hardening 
Beam hardening correction methods can roughly be subdivided into four 
classes: hardware filtering, dual energy, statistical polychromatic 
reconstruction, and linearization. Various correction schemes have been 
implemented by vendors, including high effective kV scanning, filtration, 
calibration correction and beam hardening correction. Filtration produces 
‘pre hardening’ of the xray beam before it enters the patient and a ‘bowtie’ 
filter can be used to further harden the edges of the beam that will pass 
through the thinner tissues at the edges of the patient. Manufacturer 
calibration is performed with patient area specific phantoms, which allow 
specific elimination of ‘cupping’ artefacts. Modern scanners employ a 
software-based beam hardening correction that assumes an average 
degree of hardening for the given measured attenuation. Application of 
beam hardening correction to the sample of 6 clinical CT scans however 
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produced no significant effect on the noted attenuation variation – Figure 
9.13. 
 
 
 
Figure 9.13 Example CT urogram showing effect of beam hardening algorithm 
Effect of using a beam hardening correction algorithm. Example showing depression 
in aortic attenuation (position 115-120) corresponding to significant beam hardening 
artefact arising from a vertebral osteophyte. Images were reconstructed with the 
standard algorithm and with the addition of a beam hardening correction algorithm 
(FC08 – Toshiba Medical Systems). 
 
Iterative reconstruction can also include custom correction into forward 
projected data – Figure 9.14; Figure 9.15; Figure 9.16; Figure 9.17; Figure 
9.18. Iterative algorithms use multiple reconstruction repetitions to 
converge on an improved representation. Schemes can incorporate 
physical models that allow more intuitive and natural image reconstruction 
- resulting in fewer artefacts. Dual energy CT can be used to derive virtual 
monochromatic images, which do not suffer from beam hardening, 
however this reconstruction assumes an idealised X-ray absorption curve 
without k-edges and is therefore only an approximation. 
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Figure 9.14 Plot of attenuation vs slice number with an example dataset 
Plot illustrating the effect of focal dense vertebral osteophytes on aortic blood pool 
attenuation on a standard clinical scan. Attenuation measured within regions of 
interest draw within the aorta on serial slices though a scan (pre and post contrast) 
from the aortic arch caudally to the aortic bifurcation. Note the marked drop in 
attenuation seen within the centre of the scan data, which coincides with the 
thoracolumbar junction and an area of marked bridging osteophytes. 
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Figure 9.15 Plot showing effect of iterative reconstruction 
Plot showing the same scan data as figure 9.12 but with superimposed data 
reconstructed using increasing degrees of iterative reconstruction (SAFIRE - 
Siemens). There remains a dip in measured attenuation at the level of the 
osteophytes with no change in mean attenuation. However with increasing levels of 
SAFIRE, the standard deviation (noise) within attenuation measurements falls – ie 
error bars become narrower. 
 
 
Aorta
10 20 30 40 50 60 70 80 90 100
-50
0
50
100
150
200
Aorta_Pre_FBP
Aorta_Pre_IR1
Aorta_Pre_IR3
Aorta_Pre_IR5
Aorta_60s_FBP
Aorta_60s_IR1
Aorta_60s_IR3
Aorta_60s_IR5
Aortic Arch Aortic Bifurcation
At
te
nu
at
io
n
 188 
 
Figure 9.16 Example CT urogram attenuation plot with iterative reconstruction 
Plots of attenuation measured on axial section within the abdominal aorta measured 
on a CT urogram, from the diaphragm moving inferiorly to the bifurcation. There are 
two artefactual peaks of increased density within the centre of the plot which are 
unaffected by increasing amounts of iterative reconstruction. Blue plot shows filtered 
back projection data; purple low, red medium and green high level of iterative 
reconstruction. 
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Figure 9.17 Example CT urogram coronal image  
Bands of high and low density affected a transverse area of the scan – seen on 
coronal reconstruction, correspond to areas of densely calcified aortic wall. 
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Figure 9.18 Example CT urogram images with iterative reconstruction 
Images of the beam-hardening artefact, with increasing levels of iterative 
reconstruction applied. The artefact is still clearly visible, but there is progressively 
less noise within the images. Top left – filtered back projection reconstruction; top 
right – low; bottom left- medium; bottom right – high level of iterative reconstruction. 
 
Iterative reconstruction applied to the sample of 3 clinical scans produced 
an overall reduction in image noise (lower noise with increasing amount of 
iterative reconstruction) however the variations caused by beam hardening 
artefact did not change – Figure 9.16.  
9.4.3 Helical Interpolation Error 
Helical interpolation errors create streaks of both increased and decreased 
attenuation, with an element of rotation. In helical mode, as the patient is 
advanced through the scanner the reconstruction alternates between 
measurements from adjacent detector rows, with interpolation between 
rows. Windmill or helical interpolation artefact occurs when a high contrast 
edge (e.g. diaphragm) falls between two detector rows and the 
interpolated values become inaccurate. The effect is most marked when 
there is movement, such as around the diaphragm. This is essentially an 
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aliasing effect that arises as a result of under sampling in the patient 
longitudinal direction (6). The effect is not seen in step-and-shoot or 
‘volume’ modes but these are significantly slower to acquire and impart a 
higher dose. 
9.4.4 Reducing measurement errors from artefacts 
Simple methodological steps can be implemented to reduce attenuation 
error caused by artefacts. Visual evaluation of the image data and 
attenuation plot allows identification of significant artefacts. A more 
systematic and reproducible approach to identifying artefacts would be to 
assign an arbitrary threshold for the attenuation range within an 
anatomically homogenous tissue. For example, within a tissue spanning 
multiple slices (e.g. blood within the aorta), the range of mean HU should 
be less than the HU standard deviation within the tissue volume (from the 
law of total variance, assuming equal sized ROI samples throughout 
structure, the Σ(σ) 
1. Exclusion of affected slices. Artefacts are often difficult to visually 
identify and can affect slices adjacent to the causative structure. In order 
to exclude these areas, graphically plotted attenuation data should be 
evaluated 
2. The effect of artefacts can be ‘smoothed’ by calculating the average 
attenuation measured over multiple slices  
9.5 Conclusion 
As CT technology develops, quantitative methods are emerging which 
augment subjective visual image assessment. Attenuation measurement 
for characterisation of renal stones, adrenal nodules and fluid 
collections/cysts is well established, but newer quantitative techniques 
such as perfusion CT; equilibrium CT, and dual energy material 
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decomposition are emerging which required accurate and reliable 
measurement of attenuation. Modern scanners and reconstruction are not 
however geared towards quantitative evaluation and development up to 
now has been focused on delivering subjective image quality, with good 
contrast between healthy tissue and disease.  
In this chapter I have identified significant variation in measured 
attenuation within homogenous tissue structures with no intrinsic 
anatomical explanation. These variations have a magnitude of up to 78HU 
from the adjacent tissue mean attenuation and if included in any 
quantitative analysis would have a marked deleterious effect. Evaluation of 
these abnormalities was performed subjectively, and in several the 
underlying cause was not clear, but either beam hardening or interpolation 
artefacts were responsible in the majority of cases. 
Manufacturers have worked hard to improve the quality of reconstructed 
images and many schemes exist to reduce image artefact. Beam 
hardening, the result of preferential attenuation of high-energy photons 
and scatter is thought to improve with the use of iterative (6,7) and tailored 
beam hardening correction reconstruction algorithms, but this was not 
observed in our small test sample.   
With the development of quantitative CT biomarkers such as perfusion 
and equilibrium CT, the issue of attenuation measurement precision, and 
parameter repeatability and reproducibility needs to be specifically 
addressed by system vendors. This may require specific acquisition 
modes and reconstruction kernels that prioritise absolute attenuation 
number over image spatial and contrast resolution. These developments 
may improve measurement precision and allow biomarkers like ECV to 
distinguish earlier stages of disease. In the meantime, data analysis, 
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interpretation of results, and clinical application should also be cognisant 
of these limitations.  
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10 QUANTIFICATION OF SKELETAL 
MUSCLE INVOLVEMENT IN SYSTEMIC 
AMYLOIDOSIS USING 99MTC-DPD 
SCINTIGRAPHY AND EQUILIBRIUM 
CONTRAST MRI 
10.1 Author declaration 
The work contained in this chapter was completed by the author, including 
experimental design, MRI data analysis, statistical analysis and 
manuscript preparation. David Hutt of the National Amyloidosis Centre 
(NAC) designed the DPD scoring system and analysed the DPD data. The 
work was additionally supervised by Dr. Ashutosh Wechlekar and Prof. 
Philip Hawkins of the National Amyloidosis Centre. 
10.2 Introduction 
As discussed in previous chapters, amyloidosis is a disease characterised 
by extracellular accumulation of abnormally folded insoluble proteins within 
a range of organs including the heart, kidneys, liver, and muscle (1-3). 
Amyloid myopathy, in which abnormal protein accumulates around muscle 
fibers and small blood vessels leading to progressive proximal weakness, 
muscle pseudohypertrophy and elevated creatine kinase levels is well 
described but is rarely the sole or dominant presentation (3). Weakness is 
however a common symptom in systemic amyloidosis. Current methods 
do not allow assessment of skeletal muscle involvement without invasive 
biopsy - hence its frequency and clinical significance has not been studied, 
and is poorly understood. With the development of new therapies that may 
halt and potentially reverse the deposition process (4), assessment of 
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skeletal muscle involvement and its association with symptoms is 
required. 
Technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid (99mTc-
DPD) scintigraphy is a sensitive method for imaging cardiac muscle 
involvement in transthyretin (ATTR) amyloid – with visual scoring based 
on cardiac uptake and an apparent parallel reduction in bone uptake. 
Recently Hutt et al. however found that rather than a competitive reduction 
in bone uptake, localization to bone was being masked by a consistent 
specific pattern of tracer uptake within skeletal muscles of patients with 
ATTR amyloidosis . This pattern was most pronounced and characteristic 
in wild-type non-hereditary TTR amyloidosis (ATTRwt, senile systemic 
amyloidosis) and the V122I variant of TTR (5). Blinded assessment of soft 
tissue uptake pattern in 150 patients demonstrated a sensitivity of 99% 
and specificity of 100% for ATTR amyloidosis with a cardiac uptake of at 
least grade 2 or 3. These findings suggest skeletal muscle is a significant 
target organ in ATTR amyloidosis, and post mortem of a single patient 
from this cohort indeed confirmed widespread muscle involvement.  
Further elucidation of this phenotypic extension is needed.  
In previous chapters I have established equilibrium contrast (EQ) imaging 
as a technique that allows non-invasive interrogation of tissue extracellular 
volume fraction (ECV) in the heart and the liver. Specifically in chapters 5 
and 8 I demonstrate that EQ-MRI and EQ-CT are able to track the degree 
of amyloid involvement, measured used conventional means (P<0.001). 
ECV can then act as a surrogate measure of amyloid tissue burden 
without the need for invasive biopsy.  
In this chapter I move beyond validating EQ-MR as a tool to quantify the 
burden of tissue amyloid deposition to using it as a standard of reference 
for another technique. Specially I propose a method for quantifying 
skeletal muscle uptake on 99mTc-DPD in ATTR amyloidosis, and test the 
hypotheses that muscle tracer uptake reflects the degree of diffuse muscle 
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amyloid infiltration, quantified non-invasively using equilibrium contrast 
imaging; and that skeletal muscle uptake score follows the grade of 
cardiac involvement. 
10.3 Materials and methods 
All participants provided informed written consent. 
57 patients (51 men, 6 women; median age 78 years; age range, 40–88 
years) with either clinically suspected or proven wild type TTR (ATTRwt) or 
familial amyloid polyneuropathy (ATTRFAP) amyloidosis attending the 
outpatient clinic at the National Amyloidosis Centre (NAC) were recruited. 
Included patients had undergone both 99mTc-DPD and cardiac EQ-MRI to 
assess cardiac amyloid burden with an interval of less than 12 months as 
part of their standard clinical workup at the NAC. Where possible, a 
diagnosis of ATTR amyloidosis was confirmed by the presence of 
characteristic histological staining with Congo red under polarized light or 
by immunohistochemical staining. 
10.3.1 Skeletal muscle ECV measurement 
In order to measure skeletal muscle ECV, the EQ-MRI with a steady state 
equilibrium contrast method via the contrast agent Gadoterate meglumine 
(gadolinium-DOTA, marketed as Dotarem, Guerbet S.A., Paris, France) as 
described in chapter 5.3.3 was analysed. The equilibrium steady state 
contrast protocol comprised a bolus dose of 0.1 mmol/kg followed after a 
15 minutes delay by an infusion at 0.0011 mmol/kg/min for a minimum of 
30 minutes, to achieve a constant blood and tissue contrast (7,9). 
As part of the cardiac-EQ-CMR protocol, single slice transverse section T1 
maps were acquired through the thorax at the level of the mid cardiac 
septum, using a shortened look locker inversion recovery (ShMOLLI) 
sequence on a 1.5T MR scanner (Avanto, Siemens Medical Solutions, 
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Ehrlangen, Germany).  T1 maps (table 10.1) were made before and after 
contrast equilibrium at an equivalent slice location.  
Sequence	 FLASH	Gradient	Echo	Plane	 Axial	Slices	 1	TR	 2000ms	TE	 3.15ms	Flip	angle	 21°	FoV	read	/	phase	 400	/	260mm	Slice	thickness	 8mm	Inversion	times	 140,	200-1000ms	Acquisition	time	per	TI	 14s	Acquisition	time	for	slice	T1	map	 Approx.	6mins	Image	matrix	 256	x	168	Breathing	 Breath	hold	Saturation	bands	 None	
 
Table 10.1 ShMOLLI MRI sequence parameters 
Summary of sequence parameters for Shortened Modified Look-Locker Inversion 
recovery T! mapping 
 
Skeletal muscle was assessed with elliptical regions of interest (ROI) 
drawn within the left biceps muscle (as this comprised the largest muscle 
included within the imaged volume) (mean;range area 63mm2; 28-94mm2) 
and within the left ventricular blood pool (mean;range area 417mm2; 342-
683mm2) by the author. ROIs were drawn to include the maximum areas 
of muscle and blood, but avoid adjacent fat and myocardium with a margin 
of at least 2mm. ROIs were drawn first on the pre-contrast T1 maps and 
copied to the post contrast T1 image.  
A hematocrit was taken in all subjects immediately before the MRI study. 
The ECV was calculated as:  
ECVmuscle = (1-hematocrit) x ( R1muscle/ R1blood), where R1 = 1/T1 
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ECV within the biceps muscle was then compared with comparable data 
(already described in chapter 5 section 4.2) in 67 patients with AL 
amyloidosis and in a group of 40 healthy volunteers (6). Patients were 
scanned using an identical steady state contrast equilibrium and T1 
mapping technique, and ROI analysis was performed as described above. 
Of the 40 healthy volunteers and 67 patients with AL amyloidosis who 
underwent EQ-CMR, limited field of view, and wrap-around artefact limited 
assessment of the biceps muscle to 34 healthy volunteers and 42 AL 
amyloidosis patients. A summary of patient characteristics is given in 
Table 10.2.  
Group ATTR AL Healthy 
Recruited 57 67 40 
Cases in which biceps 
ECV successfully 
measured 
46 42 34 
Age mean (range) 75 (40-88) 67(40-81) 45 (27-88) 
Male / female 42/4 29/13 14/20 
 
Table 10.2 Patient characteristics 
Summary of patient characteristics for ATTR and AL amyloid groups, and healthy 
volunteers 
 
10.3.2 99mTc-DPD scintigraphy 
DPD scintigraphy was performed as part of the routine clinical 
investigation for patients with suspected or confirmed ATTR amyloidosis. 
Scanning was performed on one of two General Electric (GE) Medical 
Systems hybrid SPECT-CT gamma cameras (Infinia Hawkeye 4 and 
Discovery 670) after intravenous injection of 700 MBq of 99mTc-DPD. 
Whole body planar images were acquired 3 hours post-injection followed 
by cardiac SPECT-CT (single photon emission computed tomography with 
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a low-dose, non-contrast CT scan). The soft-tissue reconstruction was 
loaded into the Myovation programme on the Xeleris workstation to 
perform the attenuation correction on the SPECT data. The SPECT data 
were reconstructed using filtered back projection. Data were prefiltered 
using a Butterworth filter with a critical frequency of 0.4 cycles/cm and a 
power of 10. It was then reconstructed with a quantitative ramp filter. 
10.3.3 Quantification of tissue tracer uptake 
The data by Hutt el al. showed that across the range of ATTR disease 
severities, the intensity of the peak uptake seen within bone on Tc-DPD 
remained relatively stable, despite variation in soft tissue uptake. Apparent 
loss of bone signal in higher-grade disease occured due to a progressive 
increase in the adjacent muscle uptake. This pattern was most clearly 
demonstrated in the thigh where large muscle groups surround the femur. 
Signal to noise ratio within the smaller biceps muscle (corresponding to 
the area imaged with MRI) was significant lower, but as tracer uptake was 
diffuse, muscle involvement was assumed to be uniform and uptake 
quantified in the lower limb where signal was strongest.  In order to 
quantify muscle uptake, line count profiles were created by drawing a 
4.5cm wide region of interest (ROI) across the mid thigh on the anterior 
whole body planar image – figure 10.3. The femoral peak and adjacent 
soft tissue uptake were identified visually. The maximum (peak) uptake 
within the femur and the mid-range (mean of the largest and the smallest 
values) of uptake within the soft tissue on either side of the femur were 
recorded for each leg, and the average of each calculated. The femoral 
uptake was used as reference, and relative soft tissue uptake (ST score) 
was then derived using the formula: 
DPDmuscle ST score =  Fmax / STavg 
where Fmax is the mean of the maximum femoral uptake measured within 
both legs; and  STavg is the mean of the midrange uptake within the 4 soft 
tissue compartments sampled (bilateral medial and lateral).  
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Cardiac retention of 99mTc-DPD was visually scored using a modification 
of the grading devised by Perugini et al., with cardiac uptake visualized on 
SPECT-CT but not on planar imaging additionally classified as Grade 1: 
score 0, absent cardiac uptake and normal bone uptake 
score 1, mild cardiac uptake, inferior to bone uptake or cardiac uptake on 
SPECT-CT but not on planar imaging 
score 2, moderate cardiac uptake accompanied by attenuated bone 
uptake  
score 3, strong cardiac uptake with mild/absent bone up- take 
 
10.3.4 Statistical analyses 
Data analyses were performed by using statistical software (prism version 
5; Graphpad Software, San Diego, Calif). Normal distribution was 
assessed using the Kolmogorov-Smirnov test.  
Differences in biceps ECV between the current ATTR group, the group of 
patients with AL amyloidosis and the group of healthy volunteers was 
assessed by using the Kruskal-Wallis test; with Dunn’s post test 
comparison of groups.  
The Kruskal-Wallis test was also used to compare DPD and ECV between 
cardiac DPD grade groups 
Variation in ST score and ECV across cardiac DPD scores was tested by 
using a Kruskal-Wallis test. Spearman correlation analysis was performed 
to establish an association between ST score and ECV; and cardiac DPD 
grade using a one-tailed P value. A P value less than or equal to .05 
indicated statistical significance.  
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Figure 10.3 EQ-MRI Sh-MOLLI colour T1 maps 
Images from EQ-MRI showing T1 colour maps before and after equilibrium contrast.  
Regions of interest have been drawn in the left ventricular blood pool and within the 
biceps muscle 
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Figure 10.4 99mTc-DPD images with line count profiles 
Anterior projection SPECT 99mTc-DPD images in ATTR patients with (a) grade 0 
and (b) grade 3 cardiac involvement; with ROI drawn through the upper thigh and 
corresponding line count profiles. In case (a) clear high count femoral peaks (Fmax – 
maximum femoral uptake) are seen with adjacent shouldering in the profile 
corresponding to soft tissue uptake (STavg – mean soft tissue uptake). Case (b) 
demonstrates increased diffuse soft tissue uptake with activity approaching that of 
the femora. 
 
10.4 Results 
Of the 57 patients recruited, paired cardiac and skeletal muscle DPD 
grade and biceps muscle ECV measurement were available in 46 cases. 
In 11 cases EQ-MRI did not allow adequate assessment of the biceps 
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muscle ECV due to artefact within T1 maps or incomplete coverage of the 
upper arm. 
Of the 46 included cases, the diagnosis was wild-type non-hereditary TTR 
amyloidosis (ATTRwt) in 36 cases; familial amyloid polyneuropathy 
(ATTRmt amyloidosis) in 8 cases and 2 included patients were eventually 
found not to have systemic amyloidosis. 
The mean (range) interval between 99mTc-DPD and EQ-MRI was 0.4 
months (range -10 to +11 months).  
The median (and IQR) soft tissue DPD score was 0.51 (0.41 – 0.69) and 
biceps muscle ECV was 0.21 (0.18 – 0.32).   
When compared with ECV data in a cohort of healthy volunteers and a 
group of patients with AL amyloidosis described in chapter 5 – 
summarised again in table 10.2, ECV with the biceps muscle in the ATTR 
group was not significantly different to that in the AL group, but biceps 
ECV in both the AL and ATTR group were elevated compare with the 
healthy volunteers (P < 0.0001) - see figure 10.5. 
There was a statistically significant differences in both 99mTc-DPD soft 
tissue activity quantified by our soft tissue score (p < 0.0001), and biceps 
ECV (p = 0.026) according to cardiac DPD grade. There was a positive 
correlation between ST_DPD score (rs = 0.64, p < 0.0001) and biceps 
ECV (rs = 0.43, p = 0.0013); and cardiac DPD grade - figure 10.6. 
Regression analysis revealed ST_DPD score to be a predictor of biceps 
ECV (R2=0.34) – figure 10.7. 
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Figure 10.5 Box plot of skeletal muscle ECV 
Box-and-whisker plot of median and IQR of biceps ECV measured within the current 
ATTR cohort, and similar measurements made in a patient group with AL 
amyloidosis and a group of healthy volunteers from chapter 5. 
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Figure 10.6 99mTc-DPD images with line count profiles 
Box-and-whisker plot of median and IQR 99mTc-DPD soft tissue score (ST) showing 
(a) increasing ST and (b) biceps muscle ECV with greater cardiac DPD grade 
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Figure 10.7 Scatter plot of soft tissue score vs ECV with regression line 
Scatter plot of 99mTc-DPD soft tissue score versus ECV measured within the biceps 
on EQ-MRI – with regression line. 
 
10.5 Discussion 
Myopathy is rarely the principle sign of systemic amyloidosis, but non-
specific complaints such as weakness and malaise are common. Biopsy 
evidence exists which suggests diffuse skeletal muscle amyloid infiltration 
(3), and this has recently been postulated as the cause of diffuse soft 
tissue uptake seen on 99mTc-DPD in ATTR amyloidosis (5). In this 
chapter I propose a method for quantifying this soft tissue uptake, and 
demonstrate an association with grade of cardiac involvement. 
Extracellular volume fraction measured within skeletal muscle by 
equilibrium contrast MRI was used as an independent reference technique 
to corroborate these findings. In this cohort of ATTR patients, biceps 
muscle ECV increased with both 99mTc-DPD soft tissue score and 
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cardiac grade, suggesting that diffuse infiltration of skeletal muscle occurs 
in addition to the myocardium with worsening disease.  
I use two imaging techniques to explore skeletal muscle involvement in 
ATTR amyloidosis, showing that with worsening disease, skeletal muscle 
involvement is diffuse.  This study makes no assessment of the possible 
clinical manifestation of this amyloid deposition. Symptoms of muscle 
weakness and malaise may be the result of skeletal muscle infiltration, 
cardiac dysfunction and a peripheral neuropathy. Non-invasive methods 
such as 99mTc-DPD scintigraphy and EQ-MRI; as well as blood markers 
like creatinine kinase and electrophysiological assessment with objective 
assessment of symptoms may allow us to evaluate the various 
contributions – and this should be the subject of future investigation.  
This study had several further limitations. Although variations were 
subjectively apparent, quantification of 99mTc-DPD tracer activity within 
soft tissue was difficult. Absolute tissue uptake is influenced by multiple 
non-disease dependent variables, including tracer clearance, patient 
habitus and gamma camera setup. As a femoral activity peak is a constant 
finding (5), this was used as an internal control. However differences in 
femoral mineralization between individuals will lead to variations in tracer 
binding, and size of the femoral peak. Additionally, with extensive 
infiltration, surrounding soft tissue activity may conceal femoral uptake, 
leading to inaccurate scoring and an artificial plateau in scores at an upper 
threshold where soft tissues and femoral uptake are equivalent. Thirdly, 
the soft tissue and femoral parts of the line count profile were identified 
visually. However noise could make separately distinguishing these parts 
of the trace difficult, particularly when the two were similar.  
In developing a soft tissue scoring system, I initially aimed to quantify 
uptake within the upper limb, matching the area assessed on MRI. The 
smaller size of the upper limb however produced uptake line profiles with 
significantly lower signal to noise, and visual separation of soft tissue and 
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bone was imprecise compared with the lower limb.  Using soft tissue DPD 
scoring data from the lower limb and ECV data from the upper limb 
reduced the usefulness of technique comparison, but the modest 
association between the two (figure 10.7), highlights the diffuse nature of 
amyloid deposition.  
This study provides initial evidence that skeletal muscle is a significant 
target organ in ATTR amyloidosis, with disease burden paralleling that of 
the myocardium. With the advent of therapies able to halt and even 
reverse tissue amyloid deposition (4), techniques to accurately assess 
overall and specific tissue involvement are required, to evaluate efficacy 
and monitor treatment response. 99m-Tc-DPD and EQ-MRI are tools that 
may be used to quantify diffuse amyloid deposition and the associated 
changes in ECV, but in future, pathological and clinic markers will be 
required to fully understand the clinical significance.  
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11 DISCUSSION 
11.1 Summary of conclusions 
This chapter concludes the thesis with a discussion of the main results 
and conclusions, and sets out the areas that require development in the 
future. 
Non-invasive diagnosis has for the most part focussed on tissue 
morphological changes, with the latest techniques now beginning to probe 
tissue function and microstructural changes. Until recently the importance 
of cellular supporting elements and their role in disease was overlooked, 
largely as a result of our inability to probe these changes. 
Histopathologists have for centuries recognised that in several important 
disease processes, tissue volume is replaced by a protein matrix. This 
was however seen as a passive response to disease, rather than an 
intrinsic dynamic process within the pathophysiological pathway. Our 
understand of the interplay between cellular and extracellular tissue 
components in health and disease has been hindered by the lack of robust 
methods for evaluation. Despite advances in tissue collection and 
preparation, histological evaluation is still critically limited by sample 
artefacts which prevent accurate extracellular quantification. It is then the 
development of new non-invasive methods which has allowed improved 
understanding. Equilibrium contrast imaging is one such technique, that 
promises accurate whole organ extracellular volume assessment using 
existing technology and techniques. My aim throughout this work has been 
to initiate the process of development towards producing a robust, 
validated clinical test (figure 11.1), allowing ECV to become a clinically 
useful marker of extracellular disease. 
This thesis provides stepwise development of the Equilibrium Imaging 
method for extracellular volume fraction measurement. After exploring the 
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structure, function and properties of the extracellular space, and its role in 
disease, I began by laying out the basic principles and assumptions of the 
EQ method. Due to the limitations discussed earlier, testing these 
principles against direct tissue measurements has not been possible. In 
chapter 4 I was however able to use engineered tissues with 
predetermined extracellular volume fractions to demonstrate for the first 
time an association with ECV measured by EQ-MRI. Since this 
experiment, three-dimensional engineered tissue models have continued 
to progress towards the complexity of the in vivo environment. Newer 
models now incorporate higher cell densities with rolled cylindrical 
structures, immune cells and vascular elements (1). These improvements 
will allow evaluation of EQ imaging at physiological cell densities with 
more complex cell-cell interactions and allow us to examine the effect of 
higher concentrations of tissue matrix proteins and tissue vascular volume, 
thereby testing the limits of the assumptions necessary for EQ imaging. 
After initial development of EQ-CMR and early validation in aortic stenosis 
I was keen to explore the huge potential application of this technique in 
other organs. The liver, another important organ commonly affected by 
diffuse fibrosis, was an obvious target - although the sinusoidal blood 
volume is higher than in the heart. Before evaluating hepatic cirrhosis, to 
provide the best chance of proof of principle, I applied the EQ-MRI 
technique in systemic light chain amyloidosis, where hepatic extracellular 
expansion by amyloid protein deposition can be massive. The results 
presenting in chapter 5 showed a significant elevation of hepatic ECV 
which tracked disease burden measured by SAP. Identifying the interstitial 
expansion associated with amyloid deposition was then the first 
demonstration of the potential application of EQ imaging in the liver. EQ-
MRI measured liver ECV was subsequently used as an endpoint in a first 
in man, phase 1 clinical trial evaluating a new drug, (R)-1-[6-[(R)-2-
carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid 
(CPHPC). CPHPC acts to deplete plasma SAP, allowing specific targeting 
of SAP within amyloid deposits by therapeutic IgG anti-SAP antibodies. 
 212 
The results of this study showed that in the group of patients who received 
sufficient therapy in relation to disease load, liver function improved with a 
significant reduction in liver ECV and tracer uptake on SAP scintigraphy 
(2). 
Early development of EQ imaging used MRI, an imaging modality able to 
deliver high signal and contrast-to-noise. Although increasing in 
availability, the long imaging times and cost could limit potential use of this 
test. As discussed in chapter 4, the non-linear relationship between signal 
and contrast concentration, and effects of fast transcytolemmic water 
exchanged adds additional complexity to the MRI technique. Computed 
tomography offers faster, cheaper and more widely available imaging, 
albeit with of the use of ionising radiation. Translation to this platform 
required development of a new iodinated contrast administration protocol, 
which I was able to do in chapter 6 with the help of 15 volunteers, before 
evaluating myocardial ECV against histological collagen proportionate 
area, in an experiment mimicking the earlier EQ-CMR validation study by 
Flett et al (3). Although the association was not as strong as that shown 
with EQ-CMR, maintaining dose at an acceptable level meant that CT 
image noise was higher. This initial proof of concept experiment used a 
standard mid-3rd generation scanner, which lacked newer detector and 
reconstruction technologies. Some of these issues and possible solutions 
are explored in chapter 9, with a broad application to quantitative CT 
techniques. Although I was able to make observations and suggestions 
based on a subjective analysis of a small cohort, specific development of 
attenuation measurement by CT, in combination with scanner vendors, 
engineers and ionising radiation physicists is required in the future to allow 
quantitative CT techniques to achieve the necessary accuracy and 
precision. Subsequent work by our group in collaboration with a scanner 
vendor (Toshiba Medical Systems Europe, and Toshiba Medical 
Visualisation Systems), to be published in the future has already taken 
advantage of recent commercially available improvements to develop 
acquisition protocols with improved artefact correction and noise reduction. 
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In chapter 7 I applied development of EQ image to one of the modern 
worlds most prevalent diseases – hepatic cirrhosis. Until the development 
of Transient Elastography (EchoSens 2009) hepatic fibrosis had been 
exclusively managed using invasive biopsy, with sampling done either via 
a percutaneous or transjugular route. Transient Elastography provides a 
convenient bedside test with good sensitivity (90%) but fails in up to 18% 
of cases (4) and suffers from similar sampling error issues to  biopsy. The 
proposed use of Equilibrium contrast CT in chapter 7 could potentially 
provide whole liver ECV assessment at the same time as morphological 
assessment of the liver and assessment of potential complications of the 
disease – such as varices and hepatocellular carcinoma. My initial proof of 
concept study described in chapter 7 showed modest diagnostic accuracy 
in a cohort of 33 patients (r=0.64, p<0.0001). This potentially exciting 
finding should be built upon in the future with refinement of the CT 
acquisition and contrast protocols. The diagnostic performance of EQ-CT 
at discriminating early stages of fibrosis, and crucially its ability to predict 
negative clinical outcomes in liver disease patients can then be explored in 
a larger cohort. Since completing this work, other techniques which utilise 
multiparametric MRI assessment of the liver, including T2* and native T1 
mapping have developed. Pavlides et al. used one such implementation 
(LiverMultiScan, Perspectum Diagnostics, Oxford, UK) and showed a 
composite liver inflammation and fibrosis score generated by a proprietary 
algorithm was predictive of clinical outcome in patients with chronic liver 
disease (3). In the future, performance of EQ-CT, in addition to cost and 
clinical applicability should be compared with these emerging techniques. 
In the final chapter 10, EQ-MRI is used a reference standard for interstitial 
expansion in systemic amyloidosis, probing changes in skeletal muscle 
hypothesised after diffuse soft tissue uptake was noted on 99mTc-DPD 
scintigraphy. The increase in skeletal muscle ECV has added to evidence 
that the soft tissues are a significant target for amyloid deposition in ATTR 
amyloidosis. Although an interesting application of the EQ technique, until 
corroborative clinical and biochemical markers are examined, the 
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significance of this deposition will remain unclear. In the meantime, EQ 
assessment of ECV remains available to those developing new anti ATTR 
amyloid agents.  
This thesis has largely focused on technical development of the 
equilibrium technique with early comparison of ECV against histology and 
other markers of disease. Some limitations of this work have been the 
retrospective use of cohorts for additional analyses, introducing 
experimental constraints. For example, in chapter 10 we relied on muscles 
visible on EQ-CMR for comparison against a scintigraphic marker 
measured in the thigh.  Within this development, importantly evaluation of 
ECV measurement precision has been omitted, with no incorporation of 
repeatability or reproducibility assessment steps. Before proposing use of 
ECV as a diagnostic tool, these attributes, including intra and inter user 
variation, and variation between scanners, vendors and locations must be 
evaluated. Biomarker reference ranges, test sensitivity and specificity, and 
linkage to clinical outcomes can then be defined. This work will form the 
basis of the next phase of EQ imaging development.   
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1. Technical development  
2. Comparison against histology 
3. Comparison in disease vs health 
4. Correlation with imaging markers 
5. Correlation with blood biomarkers 
6. Assessment in multiple clinical scenarios 
7. Assessment in early disease or with aging 
8. Ability to track change over time, and after Rx 
9. Predictive/prognostic value 
10. Test standardisation 
11. Define normal reference ranges 
12. Test as Surrogate trial endpoint 
13. Clinical use and regulatory approval 
14. Test improves clinical outcome 
 
Figure 11.1 Stages of development of a clinical test 
Development stages through which a test such as EQ imaging must pass before it 
can be adopted in clinical practice. 
 
 
11.2 Conclusions 
Finally, in conclusion, this thesis has made stepwise methodological 
development of the Equilibrium Imaging technique, demonstrating early 
proof of the underlying principles, translation to a new imaging platform 
and utility in diffuse fibrosis and amyloidosis of the heart and liver. It is my 
hope that future work will continue development of this technique towards 
a robust non-invasive test, with real clinical utility. 
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